System and methods for optimized drug delivery and progression of diseased and normal cells

ABSTRACT

Systems for recommending an optimal treatment protocol for a specific individual are disclosed. The systems comprise generally a system model, a plurality of treatment protocols, a system model modifier, wherein said system model is modified by the system model modifier based on parameters specific to the individual; and a selector to select an optimal treatment protocol from said plurality of treatment protocols based on the modified system model. Systems embodying the above techniques but for a general patient are also disclosed. Systems for a general patient and an individual for various specific diseases are disclosed. Methods and computer program products embodying the above techniques are also disclosed.

I. DESCRIPTION OF THE INVENTION

[0001] I.A. Field of the Invention

[0002] The present invention relates generally to prediction of aprogression of healthy and diseased cells in patients with/withouttreatment effect incorporated therein. The present invention is embodiedin systems, methods and computer program products for predicting theprogression of a biological system, and for prediction and optimizationof treatment of disease. These systems, methods and computer programproducts can be used to simulate a general patient for the use incertain stages in drug development and trials as well as for anindividual patient.

[0003] I.B. Background of the Invention

[0004] It is well known that when drugs are administered to combatdiseases, they do not differentiate between healthy and diseased cells.The drugs are often toxic to healthy cells as well. Therefore, inprescribing a specific treatment protocol, it is necessary to considerthe effect of the treatment protocol on both healthy cells as well asdiseased cells.

[0005] Mathematical models that model biological systems are well knownin the art. A wide variety of models are known including those that useordinary differential equations, partial differential equations and thelike. More specifically, these mathematical models can simulate celllines, tumor growth, etc. Conventionally, these models have been usedfor prediction of treatment results. However, such conventionalpredictive models generally employ an analytical approach, in whichgeneralizations about the effect of the treatment protocols on a diseasemust be made. This approach, while providing useful general information,cannot be used to predict results of treatment in realisticcircumstances. Thus, techniques that include more complex and detailedscenarios are needed.

II. SUMMARY OF THE INVENTION

[0006] It is an objective of the present invention to provide techniquesfor recommending optimal treatments for a general patient and a specificindividual patient.

[0007] It is another objective of the invention to provide techniquesfor predicting the progress of biological processes in a general patientand a specific individual patient under a variety of treatment protocolsas well as under no treatment.

[0008] It is yet another objective of the present invention to providetechniques for modelling various specific biological processes for ageneral patient and a specific individual patient under a plurality oftreatment protocols including no treatment.

[0009] To meet the objectives of the present invention, there isprovided a system for recommending an optimal treatment protocol for anindividual comprising a system model, a plurality of treatmentprotocols, a system model modifier. The system model is modified by thesystem model modifier based on parameters specific to the individual.The system further comprises a selector to select an optimal treatmentprotocol from the plurality of treatment protocols based on the modifiedsystem model.

[0010] Preferably the system model further comprises a realisticbiological process model and a realistic treatment model that models theeffects of a treatment on the biological process.

[0011] Still preferably, the biological process model comprisesmathematical models for biological processes affecting healthy cellpopulations and biological processes affecting cell populations with atleast one disease.

[0012] Still preferably the healthy cell populations include bone-marrowcells and host tissue cells that are affected by the treatment model.

[0013] Still preferably the cell populations with at least one diseaseis one of cancer cells, and diseased bone-marrow cells includingdiseased Neutrophil cells and diseased Thrompocyte cells.

[0014] Preferably, the treatment models comprise treatment specificprocesses that affect cell population.

[0015] Still preferably the treatment specific process is interactionsinvolving one of a group comprising pharmacokinetic, pharmacodynamic,cytostatic, cytotoxic, and methods of affecting cell biology and causingcell death, with associated biological processes.

[0016] Preferably the parameters specific to the individual include oneor more selected from a group consisting of parameters related to thebiological process' dynamics, patient specific drug PK, PD and dynamicsof dose-limiting host tissues.

[0017] Still preferably the parameters related to biological process'dynamics comprise age, weight, gender, blood picture, desired length oftreatment protocol, previous reaction to treatment, molecular markers,genetic markers, pathologic specifics and cytologic specifics.

[0018] Preferably the selector incorporates user-specific parameters inperforming selection.

[0019] Still preferably the incorporation is done by using a fitnessfunction.

[0020] Still preferably the fitness function incorporates at least oneparameter selected from a group comprising patient survival, time todeath, time to reach a specified disease stage (including cure), tumorload, pathogen load, cytotoxicity, side effects, quality of life, costof treatment, and pain.

[0021] Still preferably a user can input specific coefficients for saidat least one parameter to adjust the fitness function to satisfy theuser's goals.

[0022] Still preferably the user-specific parameters are based on auser, said user being a medical doctor.

[0023] Still preferably the user-specific parameters are based on auser, said user being a scientist.

[0024] Still preferably the user-specific parameters are based on auser, said user being a drug developer.

[0025] Preferably the selection of treatment protocols incorporatecytotoxic effects.

[0026] Preferably the selection of treatment protocols incorporate drugefficacy.

[0027] Preferably the selector performs the selection using operationresearch methods.

[0028] Preferably the selector further comprises heuristics, saidheuristics being used to perform searching and selection.

[0029] Still preferably said heuristics comprise computationalfeasibility.

[0030] Preferably, the recommendation is a combination of disease andtreatment strategy, including types of treatment, e.g. chemotherapy,radiotherapy, surgery, immunotherapy, etc, device, drug or drugcombination and treatment schedule and dosage.

[0031] Preferably the system is implemented over a distributed computingsystem.

[0032] Still preferably the distributed computing system is theInternet.

[0033] Still preferably a user uses the system remotely.

[0034] Another aspect of the present invention is a system forrecommending an optimal treatment protocol for a general patientcomprising a system model, a plurality of treatment protocols and aselector to select an optimal treatment protocol from said plurality oftreatment protocols based on the system model.

[0035] Preferably the system model further comprises a realisticbiological process model and a realistic treatment model that models theeffects of a treatment on said biological process.

[0036] Still preferably, the biological process model comprisesmathematical models for biological processes affecting healthy cellpopulations and biological processes affecting cell populations with atleast one disease.

[0037] Still preferably, the healthy cell populations includebone-marrow cells and host tissue cells that are affected by saidtreatment model.

[0038] Still preferably, the cell populations with at least one diseaseis one of cancer cells, and diseased bone-marrow cells includingdiseased Neutrophil cells and diseased Thrompocyte cells.

[0039] Still preferably, the treatment models comprise treatmentspecific processes that affect cell populations.

[0040] Still preferably, the treatment specific process is interactionsinvolving one of a group comprising pharmacokinetic, pharmacodynamic,cytostatic, cytotoxic, and methods of affecting cell biology and causingcell death, with associated biological processes.

[0041] Preferably the selector incorporates user-specific parameters inperforming selection.

[0042] Still preferably, the incorporation is done by using a fitnessfunction.

[0043] Still preferably, the fitness function incorporates at least oneparameter selected from a group comprising patient survival, time todeath, time to reach a specified disease stage and cure, tumor load,pathogen load, cytotoxicity, side effects, quality of life, cost oftreatment and pain.

[0044] Still preferably, a user can input specific coefficients for saidat least one parameter to adjust the fitness function to satisfy theuser's goals.

[0045] Still preferably, the user-specific parameters are based on auser, said user being a medical doctor.

[0046] Still preferably, the user-specific parameters are based on auser, said user being a scientist.

[0047] Still preferably, the user-specific parameters are based on auser, said user being a drug developer.

[0048] Preferably, the selection of treatment protocols incorporatecytotoxic effects.

[0049] Preferably, the selection of treatment protocols incorporate drugefficacy.

[0050] Preferably, the selector performs the selection using operationresearch methods.

[0051] Preferably, the selector further comprises heuristics, saidheuristics being used to perform searching and selection.

[0052] Still preferably, the heuristics comprise computationalfeasibility.

[0053] Preferably, the recommendation is a combination of disease andtreatment strategy, including types of treatment, e.g. chemotherapy,radiotherapy, surgery, immunotherapy, etc, device, drug or drugcombination and treatment schedule and dosage.

[0054] Preferably, the system is implemented over a distributedcomputing system.

[0055] Still preferably, the distributed computing system is theInternet.

[0056] Still preferably, a user uses the system remotely.

[0057] Still preferably, the remote system is a telephone.

[0058] Yet another aspect of the present invention is a system forpredicting progression of a biological process in an individual patientunder a plurality of treatment protocols, wherein said biologicalprocess could be related to healthy or diseased processes, saidplurality of protocols including no treatment. The system comprises asystem model, a plurality of treatment protocols and a system modelmodifier. The system model is modified by the system model modifierbased on parameters specific to the individual. The system furthercomprises a predictor to predict the progression of at least one of thedisease and the natural biological process under said plurality oftreatment protocols based on the modified system model.

[0059] Preferably, the system model further comprises a realisticbiological process model and a realistic treatment model that models theeffects of a treatment on said biological process.

[0060] Still preferably, the biological process model comprisesmathematical models for biological processes affecting healthy cellpopulations and biological processes affecting cell populations with atleast one disease.

[0061] Still preferably, the healthy cell populations includebone-marrow cells and host tissue cells that are affected by saidtreatment model. Still preferably, the cell populations with at leastone disease is one of cancer cells, and diseased bone-marrow cellsincluding diseased at least one of Neutrophil cells and diseasedThrombocyte cells.

[0062] Still preferably, the treatment models comprise treatmentspecific processes that affect cell population.

[0063] Still preferably the treatment specific process is interactionsinvolving one of a group comprising PK, PD, cytostatic, cytotoxic, andmethods of affecting cell biology and causing cell death, withassociated biological processes.

[0064] Preferably the parameters specific to the individual include oneor more selected from a group consisting of parameters related to thebiological process' dynamics, patient specific drug PK, PD and dynamicsof dose-limiting host tissues.

[0065] Still preferably, the parameters related to biological process'dynamics comprise age, weight, gender, blood picture, desired length oftreatment protocol, previous reaction to treatment, molecular markers,genetic markers, pathologic specifics and cytologic specifics.

[0066] Yet another aspect of the present invention is a system forpredicting progression of a biological process in a general patientunder a plurality of treatment protocols, wherein said biologicalprocess could be healthy or diseased processes, said plurality ofprotocols including no treatment. The system comprises a system model, aplurality of treatment protocols and a predictor to predict theprogression of the disease or the natural biological process under saidplurality of treatment protocols.

[0067] Preferably, the system model further comprises a realisticbiological process model and a realistic treatment model that models theeffects of a treatment on said biological process.

[0068] Still preferably, the biological process model comprisesmathematical models for biological processes affecting healthy cellpopulations and biological processes affecting cell populations with atleast one disease.

[0069] Still preferably, the healthy cell populations includebone-marrow cells as well as other host tissue cells that are affectedby said treatment model.

[0070] Still preferably, the cell populations with at least one diseaseis one of cancer cells, and diseased bone-marrow cells includingdiseased Neutrophil cells and diseased Thrombocyte cells.

[0071] Still preferably, the treatment models comprise treatmentspecific processes that affect cell population.

[0072] Still preferably, the treatment specific process is interactionsinvolving one of a group comprising PK, PD, drug cytostatics, drugcytotoxics, and methods of affecting cell biology and causing celldeath, with associated biological processes.

[0073] Yet another aspect of the present invention is a system formodelling Thrombopietic lineage in an individual, said system comprisinga Thrombopoiesis system model including a realistic process progressionmodel, for cells involved in Thrombopoiesis, said progression modelincluding multiplication and differentiation and a system modelmodifier, wherein said Thrombopoiesis system model is modified by thesystem model modifier based on parameters specific to the individual.

[0074] Preferably, the system model incorporates a realistic progressionof cells involved in diseased Thrombopoiesis.

[0075] Still preferably, the diseased Thrombopoiesis includesThrombocytopenia.

[0076] Still preferably, the system model incorporates effects of atleast one drug in the realistic progression of cells involved inThrombopoiesis.

[0077] Still preferably, said at least one drug is Thrombopoietin (TPO).

[0078] Still preferably, the process model imitates a course of theindividual's bone marrow progression, peripheral platelet counts and TPOconcentration changes.

[0079] Still preferably, said process model incorporatescell-suppressive treatment effects and administration of TPO to thepatient.

[0080] Still preferably, said cell-suppressive treatment can bechemotherapy.

[0081] Still preferably, the process model further comprises a pluralityof compartments.

[0082] Still preferably, the compartments include:

[0083] a stem cell (SC) compartment that comprises bone marrowhaemopoietic progenitors that have an ability to differentiate into morethan one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte;

[0084] a colony forming units—megakaryocytes (CFU-Meg) compartment,wherein the megakaryocyte progenitors get committed as a megakaryocyteline and spend some time multiplying and maturing;

[0085] a megakaryoblast (MKB) compartment, which receives the cells fromCFU-Meg, wherein the cells in the MKB compartment have lost theirability to proliferate but are not mature to release platelets;

[0086] a MK16 compartment, which receives cell from the MKB compartment,wherein a subset of cells in the MK16 compartment release platelets at aconstant rate until they exhaust their capacity and are disintegratedand a second subset of cells do not release platelets but continue withendomitosis;

[0087] a MK32 compartment that receives cells from the MK16 compartment,wherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0088] a MK64 compartment that receives cells from the MK32 compartmentwherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0089] a MK128 compartment that receives cells from the MK64 compartmentwherein a subset of cells in this compartment release platelets; and

[0090] a platelets (PL) compartment.

[0091] Still preferably, an effect of apoptosis is included with anoverall effect of cell proliferation in giving rise to an amplificationof cell numbers in a corresponding compartment.

[0092] Still preferably, the process model further incorporates theeffects of TPO on the SC, CFU-Meg and MKB compartments.

[0093] Still preferably, the effects are expressed in terms of effectsof TPO concentration on amplification rate, rate of cell maturation anda fraction of cells that undergo endomitosis.

[0094] Still preferably, when the TPO concentration is above apredetermined threshold level, the amplification rate of cells in the SCcompartment are affected and below the threshold the amplification rateis dependent only on a current number of cells.

[0095] Still preferably, in the CFU-Meg compartment the cells aresensitive to TPO concentration regardless of the concentration of TPO.

[0096] Still preferably the transit time is same in all plateletreleasing compartments and the transit time of the SC, CFU-Meg and MKBcompartments are functions of micro-environmental conditions.

[0097] Still preferably, the SC compartment when the TPO concentrationis above the threshold, the transit time is shortened based the dose.

[0098] Still preferably, in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.

[0099] Still preferably, a fraction of cells in the SC compartment thatcommits to megakaryocytic lineage is constant and dependent on TPO.

[0100] Still preferably in the CFU-Meg and MKB compartments, everymature cell passes on to the next compartment.

[0101] Still preferably, in the MK16, MK32 and MK64 compartments, afraction of cells pass on to the next compartment, said fraction beingdependent on the TPO concentration.

[0102] Still preferably, cells from MK128 compartment do not flow intoany other compartment.

[0103] Still preferably, each of said compartments is further dividedinto sub-compartments, each of said sub-compartments containing cells ofa specific age in hours.

[0104] Still preferably, cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.

[0105] Still preferably, the platelet releasing cells contributeplatelets to the first sub-compartment of the PL compartment.

[0106] Preferably the model is used for recommending an optimaltreatment protocol, wherein said system further comprises a plurality oftreatment protocols and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on themodified system model.

[0107] Yet another aspect of the present invention is a system formodelling Thrombopietic lineage in a general patient, said systemcomprising a Thrombopoiesis system model including a realistic processmodel for cells involved in Thrombopoiesis.

[0108] Preferably, the system model incoporates a realistic progressionof cells involved in diseased Thrombopoiesis.

[0109] Still preferably, the diseased Thrombopoiesis includesThrombocytopenia.

[0110] Still preferably, the system model incorporates effects of atleast one drug in the realistic progression of cells involved inThrombopoiesis.

[0111] Still preferably, said at least one drug is Thrombopoietin (TPO).

[0112] Still preferably, the process model imitates a course of thepatient's bone marrow progression, peripheral platelet counts and TPOconcentration changes.

[0113] Still preferably, the process model incorporates cell-suppressivetreatment effects and administration of TPO to the patient.

[0114] Still preferably, the cell-suppressive treatment is chemotherapy.

[0115] Still preferably, the process model further comprises a pluralityof compartments.

[0116] Still preferably, the compartments include:

[0117] a stem cell (SC) compartment that comprises bone marrowhaemopoietic progenitors that have an ability to differentiate into morethan one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte;

[0118] a colony forming units—megakaryocytes (CFU-Meg) compartment,wherein the megakaryocyte progenitors get committed as a megakaryocyteline and spend some time multiplying and maturing;

[0119] a megakaryoblast (MKB) compartment, which receives the cells fromCFU-Meg, wherein the cells in the MKB compartment have lost theirability to proliferate but are not mature to release platelets;

[0120] a MK16 compartment, which receives cell from the MKB compartment,wherein a subset of cells in the MK16 compartment release platelets at aconstant rate until they exhaust their capacity and are disintegratedand a second subset of cells do not release platelets but continue withendomitosis;

[0121] a MK32 compartment that receives cells from the MK16 compartment,wherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0122] a MK64 compartment that receives cells from the MK32 compartmentwherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0123] a MK128 compartment that receives cells from the MK64 compartmentwherein a subset of cells in this compartment release platelets; and

[0124] a platelets (PL) compartment.

[0125] Still preferably, an effect of apoptosis are included with anoverall effect of cell proliferation in giving rise to an amplificationof cell numbers in a corresponding compartment.

[0126] Still preferably, the process model further incorporates theeffects of TPO on the SC, CFU-Meg and MKB compartments.

[0127] Still preferably, the effects are expressed in terms of effectsof TPO concentration on amplification rate, rate of cell maturation anda fraction of cells that undergo endomitosis.

[0128] Still preferably, when the TPO concentration is above apredetermined threshold level, the amplification rate of cells in the SCcompartment are affected and below the threshold the amplification rateis dependent only on a current number of cells.

[0129] Still preferably, the CFU-Meg compartment the cells are sensitiveto TPO concentration regardless of the concentration of TPO.

[0130] Still preferably, the transit time is same in all plateletreleasing compartments and the transit time of the SC, CFU-Meg and MKBcompartments are functions of micro-environmental conditions.

[0131] Still preferably, in the SC compartment when the TPOconcentration is above the threshold, the transit time is shortenedbased the dose.

[0132] Still preferably, in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.

[0133] Still preferably, a fraction of cells in the SC compartment thatcommits to megakaryocytic lineage is constant and dependent on TPO.

[0134] Still preferably, in the CFU-Meg and MKB compartments, everymature cell passes on to the next compartment.

[0135] Still preferably, in the MK16, MK32 and MK64 compartments, afraction of cells pass on to the next compartment, said fraction beingdependent on the TPO concentration.

[0136] Still preferably, cells from MK128 compartment do not flow intoany other compartment.

[0137] Still preferably, each of said compartments is further dividedinto sub-compartments, each of said sub-compartments containing cells ofa specific age in hours.

[0138] Still preferably, cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.

[0139] Still preferably, the platelet releasing cells contributeplatelets to the first sub-compartment of the PL compartment.

[0140] Preferably, said model is used for recommending an optimaltreatment protocol, wherein said system further comprises a plurality oftreatment protocols; and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on themodified system model.

[0141] Yet another aspect of the present invention is a system forpredicting progression of Thrombopoiesis and a model of Thrombocytopeniafor an individual under a plurality of treatment protocols, saidplurality of protocols including no treatment, said system comprising aThrombopoiesis and a Thrombocytopenia system model, a plurality oftreatment protocols for affecting Thrombopoiesis and treatingThrombocytopenia using at least one drug, a system model modifier. TheThrombopoiesis and Thrombocytopenia system models are modified by thesystem model modifier based on parameters specific to the individual.The system further comprises a predictor to predict the progression ofthe disease or the natural biological process under said plurality oftreatment protocols based on the modified system model.

[0142] Preferably, the system model incoporates a realistic progressionof cells involved in diseased Thrombopoisis.

[0143] Still preferably, diseased Thrombopoiesis includesThrombocytopenia.

[0144] Still preferably, the system model incorporates effects of atleast one drug on the realistic progression of cells involved inThrombocytopenia.

[0145] Still preferably, said at least one drug is Thrombopoietin (TPO).

[0146] Still preferably, said process model imitates a course of theindividual's bone marrow progression, peripheral platelet counts and TPOconcentration changes.

[0147] Still preferably, said process model incorporatescell-suppressive treatment effects and administration of TPO to thepatient.

[0148] Still preferably, said cell-suppressive treatment ischemotherapy.

[0149] Still preferably, said process model further comprises aplurality of compartments.

[0150] Still preferably, said compartments include:

[0151] a stem cell (SC) compartment that comprises bone marrowhaemopoietic progenitors that have an ability to differentiate into morethan one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte;

[0152] a colony forming units—megakaryocytes (CFU-Meg) compartment,wherein the megakaryocyte progenitors get committed as a megakaryocyteline and spend some time multiplying and maturing;

[0153] a megakaryoblast (MKB) compartment, which receives the cells fromCFU-Meg, wherein the cells in the MKB compartment have lost theirability to proliferate but are not mature to release platelets;

[0154] a MK16 compartment, which receives cell from the MKB compartment,wherein a subset of cells in the MK16 compartment release platelets at aconstant rate until they exhaust their capacity and are disintegratedand a second subset of cells do not release platelets but continue withendomitosis;

[0155] a MK32 compartment that receives cells from the MK16 compartment,wherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0156] a MK64 compartment that receives cells from the MK32 compartmentwherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0157] a MK128 compartment that receives cells from the MK64 compartmentwherein a subset of cells in this compartment release platelets; and

[0158] a platelets (PL) compartment.

[0159] Still preferably, an effect of apoptosis are included with anoverall effect of cell proliferation in giving rise to an amplificationof cell numbers in a corresponding compartment.

[0160] Still preferably, the process model further incorporates theeffects of TPO on the SC, CFU-Meg and MKB compartments.

[0161] Still preferably, the effects are expressed in terms of effectsof TPO concentration on amplification rate, rate of cell maturation anda fraction of cells that undergo endomotisis.

[0162] Still preferably, the TPO concentration is above a predeterminedthreshold level, the amplification rate of cells in the SC compartmentare affected and below the threshold the amplification rate is dependentonly on a current number of cells.

[0163] Still preferably, in the CFU-Meg compartment the cells aresensitive to TPO concentration regardless of the concentration of TPO.

[0164] Still preferably, the transit time is same in all plateletreleasing compartments and the transit time of the SC, CFU-Meg and MKBcompartments are functions of micro-environmental conditions.

[0165] Still preferably, in the SC compartment when the TPOconcentration is above the threshold, the transit time is shortenedbased the dose.

[0166] Still preferably, in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.

[0167] Still preferably, a fraction of cells in the SC compartment thatcommits to megakaryocytic lineage is constant and dependent on TPO.

[0168] Still preferably, in the CFU-Meg and MKB compartments, everymature cell passes on to the next compartment.

[0169] Still preferably, in the MK16, MK32 and MK64 compartments, afraction of cells pass on to the next compartment, said fraction beingdependent on the TPO concentration.

[0170] Still preferably, cells from MK128 compartment do not flow intoany other compartment.

[0171] Still preferably, each of said compartments is further dividedinto sub-compartments, each of said sub-compartments containing cells ofa specific age in hours.

[0172] Still preferably, cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.

[0173] Still preferably, the platelet releasing cells contributeplatelets to the first sub-compartment of the PL compartment.

[0174] Yet another aspect of the present invention is a system forpredicting progression of Thrombopoiesis and a model of Thrombocytopeniafor a general patient under a plurality of treatment protocols, saidplurality of protocols including no treatment. The system comprises aThrombopoiesis and a Thrombocytopenia system model, a plurality oftreatment protocols for affecting Thrombopoiesis and treatingThrombocytopenia using at least one drug; and a predictor to predict theprogression of the disease or the natural biological process under saidplurality of treatment protocols based on the modified system model.

[0175] Preferably the system model incorporates a realistic progressionof cells involved in diseased Thrombopoiesis

[0176] Still preferably, diseased Thrombopoiesis includesThrombocytopenia.

[0177] Still preferably, the system model incorporates effects of atleast one drug in the realistic progression of cells involved inThrombocytopenia.

[0178] Still preferably, said at least one drug is Thrombopoietin (TPO).

[0179] Still preferably, said process model imitates a course of theindividual's bone marrow progression, peripheral platelet counts and TPOconcentration changes.

[0180] Still preferably, said process model incorporatescell-suppressive treatment effects and administration of TPO to thepatient.

[0181] Still preferably, said cell-suppressive treatment ischemotherapy.

[0182] Still preferably, said process model further comprises aplurality of compartments.

[0183] Still preferably, said compartments include:

[0184] a stem cell (SC) compartment that comprises bone marrowhaemopoietic progenitors that have an ability to differentiate into morethan one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte;

[0185] a colony forming units—megakaryocytes (CFU-Meg) compartment,wherein the megakaryocyte progenitors get committed as a megakaryocyteline and spend some time multiplying and maturing;

[0186] a megakaryoblast (MKB) compartment, which receives the cells fromCFU-Meg, wherein the cells in the MKB compartment have lost theirability to proliferate but are not mature to release platelets;

[0187] a MK16 compartment, which receives cell from the MKB compartment,wherein a subset of cells in the MK16 compartment release platelets at aconstant rate until they exhaust their capacity and are disintegratedand a second subset of cells do not release platelets but continue withendomitosis;

[0188] a MK32 compartment that receives cells from the MK16 compartment,wherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0189] a MK64 compartment that receives cells from the MK32 compartmentwherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0190] a MK128 compartment that receives cells from the MK64 compartmentwherein a subset of cells in this compartment release platelets; and

[0191] a platelets (PL) compartment.

[0192] Still preferably, an effect of apoptosis are included with anoverall effect of cell proliferation in giving rise to an amplificationof cell numbers in a corresponding compartment.

[0193] Still preferably, the process model further incorporates theeffects of TPO on the SC, CFU-Meg and MKB compartments.

[0194] Still preferably, the effects are expressed in terms of effectsof TPO concentration on amplification rate, rate of cell maturation anda fraction of cells that undergo endomotisis.

[0195] Still preferably, when the TPO concentration is above apredetermined threshold level, the amplification rate of cells in the SCcompartment are affected and below the threshold the amplification rateis dependent only on a current number of cells.

[0196] Still preferably, in the CFU-Meg compartment the cells aresensitive to TPO concentration regardless of the concentration of TPO.

[0197] Still preferably, the transit time is same in all plateletreleasing compartments and the transit time of the SC, CFU-Meg and MKBcompartments are functions of micro-environmental conditions.

[0198] Still preferably, in the SC compartment when the TPOconcentration is above the threshold, the transit time is shortenedbased the dose.

[0199] Still preferably, in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.

[0200] Still preferably, a fraction of cells in the SC compartment thatcommits to megakaryocytic lineage is constant and dependent on TPO.

[0201] Still preferably, in the CFU-Meg and MKB compartments, everymature cell passes on to the next compartment.

[0202] Still preferably, in the MK16, MK32 and MK64 compartments, afraction of cells pass on to the next compartment, said fraction beingdependent on the TPO concentration.

[0203] Still preferably, cells from MK128 compartment do not flow intoany other compartment.

[0204] Still preferably, each of said compartments is further dividedinto sub-compartments, each of said sub-compartments containing cells ofa specific age in hours.

[0205] Still preferably, cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.

[0206] Still preferably, wherein the platelet releasing cells contributeplatelets to the first sub-compartment of the PL compartment.

[0207] Another aspect of the present invention is a system for modellingNeutrophil lineage for an individual, said system comprising aNeutrophil system model including a realistic process model for cellsinvolved in Granulopoiesis and a system model modifier. The Neutrophilsystem model is modified by the system model modifier based onparameters specific to the individual.

[0208] Preferably, the system model incorporates a realistic progressionof cells involved in Granulopoietic disorders, including Neutropenia.

[0209] Still preferably, the system incorporates effects of at least onedrug in the realistic progression of cells involved in Granulopoiesisand Neutropenia.

[0210] Still preferably, said at least one drug is Granulocyte ColonyStimulating Factor (G-CSF);

[0211] Still preferably, said model comprises at least three stages,

[0212] a first stage related to an administered amount of cytokine;

[0213] a second stage representing a pharmacokinetic behavior of G-CSF;and

[0214] a third stage representing a phrmacodynamic effect of G-CSF onkinetic parameters of the system.

[0215] Still preferably, said model comprises a mitotic compartment, anda post mitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.

[0216] Still preferably, effects of toxic drugs, including chemotherapyare incorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.

[0217] Still preferably, the effects of G-CSF on the mitotic compartmentare modeled as an increase in a rate of cells entering the myeloblastscompartment from an uncommitted stem cell pool.

[0218] Still preferably, the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters the matureNeutrophil pool every hour.

[0219] Still preferably, effects of G-CSF on the Neutrophil lineage aremodeled as a decrease in the cells in the post-mitotic compartment whichis subsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in Neutrophilcount.

[0220] Still preferably, an elimination of Neutrophils in thepost-mitotic compartment is represented by a Poisson distribution.

[0221] Still preferably, the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.

[0222] Still preferably, kinetic of G-CSF is modeled as an exponentialdistribution.

[0223] Still preferably, a selection of an optimal treatment uses anobjective function that aims at minimizing G-CSF administration andreturning Neutrophil lineage to normal levels.

[0224] Still preferably, said selection is performed using linearprogramming.

[0225] Still preferably, pharmacokinetics and pharmacodynamics of G-CSFare defined using piecewise linear functions.

[0226] Preferably, said model is used for recommending an optimaltreatment protocol, wherein said system further comprises a plurality oftreatment protocols; and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on themodified system model.

[0227] Yet another aspect of the present invention is system formodelling Neutrophil lineage for a general patient, said systemcomprising a Granulopoiesis system model including a realistic processmodel for cells involved in Neutrophil production.

[0228] Preferably, the system model incorporates a realistic progressionof cells involved in Granulopoiesis disorders including Neutropenia.

[0229] Still preferably, the system incorporates effects of at least onedrug in the realistic progression of cells involved in Granulopoiesisdisorders including Neutropenia.

[0230] Still preferably, said at least one drug is Granulocyte ColonyStimulating Factor (G-CSF);

[0231] Still preferably, said model comprises at least three stages,

[0232] a first stage related to an administered amount of cytokine;

[0233] a second stage representing a pharmacokinetic behavior of G-CSF;and

[0234] a third stage representing a phrmacodynamic effect of G-CSF onkinetic parameters.

[0235] Preferably, said model comprises a mitotic compartment, and apost mitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.

[0236] Still preferably, effects of toxic drugs, including chemotherapyare incorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.

[0237] Still preferably, the effects of G-CSF on the mitotic compartmentare modeled as an increase in a rate of cells entering the myeloblastscompartment from an uncommitted stem cell pool.

[0238] Still preferably, the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters the matureNeutrophil pool every hour.

[0239] Still preferably, effects of G-CSF on the Neutrophil lineage aremodeled as a decrease in the cells in the post-mitotic compartment whichis subsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in Neutrophilcount.

[0240] Still preferably, an elimination of Neutrophils in thepost-mitotic compartment is represented by a Poisson distribution.

[0241] Still preferably, the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.

[0242] Still preferably, kinetic of G-CSF is modeled as an exponentialdistribution.

[0243] Preferably, a selection of an optimal treatment uses an objectivefunction that aims at minimizing G-CSF administration and returningNeutrophil lineage to normal levels.

[0244] Still preferably, said selection is performed using linearprogramming.

[0245] Still preferably, phrmacokinetics and pharmacodynamics of G-CSFare defined using piecewise linear functions.

[0246] Preferably, said model is used for recommending an optimaltreatment protocol, wherein said system further comprises: a pluralityof treatment protocols; and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on themodified system model.

[0247] Yet another aspect of the present invention is a system forpredicting progression of Granulopoiesis for an individual under aplurality of treatment protocols, said plurality of protocols includingno treatment, said system comprising a Granulopoiesis system modelincluding a realistic process model for cells involved in Neutrophilproduction; a plurality of treatment protocols; and

[0248] a system model modifier. The Neutrophil production system modelis modified by the system model modifier based on parameters specific tothe individual. The system further comprises a predictor that predictsthe progression under the plurality of treatment protocols based on themodified system model.

[0249] Preferably, the system model incorporates a realistic progressionof cells involoved in Granulopoietic disorders, including Neutropenia.

[0250] Still preferably, the system incorporates effects of at least onedrug in the realistic progression of cells involved in Granulopoiesisand Neutropenia.

[0251] Still preferably, said at least one drug is Granulocyte ColonyStimulating Factor (G-CSF).

[0252] Still preferably, said model comprises at least three stages,

[0253] a first stage related to an administered amount of cytokine;

[0254] a second stage representing a pharmacokinetic behavior of G-CSF;and

[0255] a third stage representing a phrmacodynamic effect of G-CSF onkinetic parameters.

[0256] Still preferably, said model comprises a mitotic compartment, anda post mitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.

[0257] Still preferably, effects of toxic drugs, including chemotherapyare incorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.

[0258] Still preferably, the effects of G-CSF on the mitotic compartmentare modeled as an increase in a rate of cells entering the myeloblastscompartment from an uncommitted stem cell pool.

[0259] Still preferably, the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters the matureNeutrophil pool every hour.

[0260] Still preferably, effects of G-CSF on the Neutrophil lineage aremodeled as a decrease in the cells in the post-mitotic compartment whichis subsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in Neutrophilcount.

[0261] Still preferably, an elimination of Neutrophils in thepost-mitotic compartment is represented by a Poisson distribution.

[0262] Still preferably, the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.

[0263] Still preferably, kinetic of G-CSF is modeled as an exponentialdistribution.

[0264] Still preferably, a selection of an optimal treatment uses anobjective function that aims at minimizing G-CSF administration andreturning Neutrophil lineage to normal levels.

[0265] Still preferably, said selection is performed using linearprogramming.

[0266] Still preferably, phrmacokinetics and pharmacodynamics of G-CSFare defined using piecewise linear functions.

[0267] Yet another aspect of the present invention is a system forpredicting progression of Granulopoiesis for a general patient under aplurality of treatment protocols, said plurality of protocols includingno treatment, said system comprising a Neutrophil system model includinga realistic process model for cells involved in Neutrophil production aplurality of treatment protocols; and a predictor that predicts theprogression under the plurality of treatment protocols based on themodified system model.

[0268] Still preferably, the system model incorporates a realisticprogression of cells involved in Granulopoietic disorders, includingNeutropenia.

[0269] Still preferably, the system incorporates effects of at least onedrug in the realistic progression of cells involved in Granulopoiesisand Neutropenia.

[0270] Still preferably, said at least one drug is Granulocyte ColonyStimulating Factor (G-CSF).

[0271] Still preferably, said model comprises at least three stages,

[0272] a first stage related to an administered amount of cytokine;

[0273] a second stage representing a pharmacokinetic behavior of G-CSF;and

[0274] a third stage representing a phrmacodynamic effect of G-CSF onkinetic parameters.

[0275] Still preferably, said model comprises a mitotic compartment, anda post mitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.

[0276] Still preferably, effects of toxic drugs, including chemotherapyare incorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.

[0277] Still preferably, the effects of G-CSF on the mitotic compartmentare modeled as an increase in a rate of cells entering the myeloblastscompartment from an uncommitted stem cell pool.

[0278] Still preferably, the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters the matureNeutrophil pool every hour.

[0279] Still preferably, effects of G-CSF on the Neutrophil lineage aremodeled as a decrease in the cells in the post-mitotic compartment whichis subsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in Neutrophilcount.

[0280] Still preferably, an elimination of Neutrophils in thepost-mitotic compartment is represented by a Poisson distribution.

[0281] Still preferably, the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.

[0282] Still preferably, kinetic of G-CSF is modeled as an exponentialdistribution.

[0283] Still preferably, a selection of an optimal treatment uses anobjective function that aims at minimizing G-CSF administration andreturning Neutrophil lineage to normal levels.

[0284] Still preferably, said selection is performed using linearprogramming.

[0285] Still preferably, phrmacokinetics and pharmacodynamics of G-CSFare defined using piecewise linear functions.

[0286] Yet another aspect of the present invention is a system forrecommending an optimal treatment protocol for treating cancer usingdrugs, including chemotherapy, for an individual, said system comprisinga cancer system modela plurality of treatment protocols for treatingcancer using chemotherapy, a system model modifier. The cancer systemmodel is modified by the system model modifier based on parametersspecific to the individual. The system further comprises a selector toselect an optimal treatment protocol from said plurality of treatmentprotocols based on the modified system model.

[0287] Preferably, the system model further comprises a realisticprocess model of cancer development; and a realistic treatment modelthat models the effects of treating cancer with drugs, includingchemotherapy.

[0288] Still preferably, said process model incorporates a distributionof cycling cells and quiescent cells.

[0289] Still preferably, a tumor cell cycle is divided into at leastfour compartments G1, S, G2 and M and a quiescent stage is denoted byG0, wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age Iin the corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.

[0290] Still preferably, the model traces development of cancer cellsusing a predetermined set of parameters by calculating a number of cellsin each subcompartment using stepwise equations.

[0291] Still preferably, a probability vector is used to determine afraction of cells that leaves any subcompartment in a compartment tomove to a first subcompartment of the next compartment.

[0292] Still preferably, a set control functions uniquely determine anoutcome of every single step, wherein said control functions depend onage of cells, state of a current population and associated environment.

[0293] Still preferably, a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.

[0294] Still preferably, in each step, a number of cells in eachsub-compartment of each compartment of each group is calculatedaccording to factors including a previous state, parameters of tumor,tumor current microenvironment and drug concentration.

[0295] Still preferably, spatial structure of the tumor is included inthe model.

[0296] Still preferably, PK and PD, cytostatic effects, cytotoxiceffects, and other effects on cell disintegration of anticancer drugsare incorporated into the model.

[0297] Still preferably, a dose-limiting toxicity is incorporated intothe model.

[0298] Still preferably, said parameters specific to the individualcomprise parameters related to tumor dynamics, patient specific drug PK,and dynamics of dose-limiting host tissues.

[0299] Still preferably, said parameters related to tumor dynamicscomprise age, weight, gender, percentage of limiting healthy cells,desired length of treatment protocol, previous reaction to treatment,molecular markers, genetic markers, pathologic specifics and cytologicspecifics.

[0300] Yet another aspect of the present invention is a system forpredicting the a progression of cancer in individual patients comprisina cancer system model, a plurality of treatment protocols for treatingcancer using drugs, including chemotherapy a system model modifier. Thecancer system model is modified by the system model modifier based onparameters specific to the individual. The system further comprises apredictor to predict the progression of cancer under the plurality oftreatment protocols based on the modified system model. Stillpreferably, the system model further comprises:

[0301] a realistic process model of cancer development; and

[0302] a realistic treatment model that models the effects of treatingcancer with drugs, including chemotherapy.

[0303] Still preferably, said process model incorporates a distributionof cycling cells and quiescent cells.

[0304] Still preferably, a tumor cell cycle is divided into at leastfour compartments G1, S, G2 and M and a quiescent stage is denoted byG0, wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age iin the corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.

[0305] Still preferably, the model traces development of cancer cellsusing a predetermined set of parameters by calculating a number of cellsin each subcompartment using stepwise equations.

[0306] Still preferably, a probability vector is used to determine afraction of cells that leaves any subcompartment in a compartment tomove to a first subcompartment of the next compartment.

[0307] Still preferably, where a set control functions uniquelydetermine an outcome of every single step, wherein said controlfunctions depend on age of cells, state of a current population andassociated environment.

[0308] Still preferably, a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.

[0309] Still preferably, in each step, a number of cells in eachsub-compartment of each compartment of each group is calculatedaccording to factors including a previous state, parameters of tumor,tumor current microenvironment and drug concentration.

[0310] Still preferably, spatial structure of the tumor is included inthe model.

[0311] Still preferably, PK and PD, cytotoxic effects and cytostaticeffects of anticancer drugs are incorporated into the model.

[0312] Still preferably, a dose-limiting toxicity is incorporated intothe model.

[0313] Still preferably, said parameters specific to the individualcomprise parameters related to tumor dynamics, patient specific drug PK,and dynamics of dose-limiting host tissues.

[0314] Still preferably, said parameters related to tumor dynamicscomprise age, weight, gender, percentage of limiting healthy cells,desired length of treatment protocol, previous reaction to treatment,molecular markers, genetic markers, pathologic specifics and cytologicspecifics.

[0315] Yet another aspect of the present invention is a system forpredicting the a progression of cancer in a general patients comprisinga cancer system model, a plurality of treatment protocols for treatingcancer using drugs, including chemotherapy; and a predictor to predictthe progression of cancer under the plurality of treatment protocolsbased on the modified system model.

[0316] Preferably, the system model further comprises a realisticprocess model of cancer development; and a realistic treatment modelthat models the effects of treating cancer with drugs, includingchemotherapy.

[0317] Still preferably, said process model incorporates a distributionof cycling cells and quiescent cells.

[0318] Still preferably, where a tumor cell cycle is divided into atleast four compartments G1, S, G2 and M and a quiescent stage is denotedby G0, wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age Iin the corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.

[0319] Still preferably, the model traces development of cancer cellsusing a predetermined set of parameters by calculating a number of cellsin each subcompartment using stepwise equations.

[0320] Still preferably, a probability vector is used to determine afraction of cells that leaves any subcompartment in a compartment tomove to a first subcompartment of the next compartment.

[0321] Still preferably, a set control functions uniquely determine anoutcome of every single step, wherein said control functions depend onage of cells, state of a current population and associated environment.

[0322] Still preferably, a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.

[0323] Still preferably, in each step, a number of cells in eachsub-compartment of each compartment of each group is calculatedaccording to factors including a previous state, parameters of tumor,tumor current microenvironment and drug concentration.

[0324] Still preferably, spatial structure of the tumor is included inthe model.

[0325] Still preferably, PK and PD, cytotoxic effects and cytostaticeffects of anticancer drugs are incorporated into the model.

[0326] Still preferably, a dose-limiting toxicity is incorporated intothe model.

[0327] Yet another aspect of the present invention is a method ofrecommending an optimal treatment protocol for an individual comprising:creating a system model; enumerating a plurality of treatment protocols;modifying the system model based on parameters specific to theindividual; and selecting an optimal treatment protocol from saidplurality of treatment protocols based on the modified system model.

[0328] Preferably, the step of creating the system model furthercomprises: modelling a biological process; and realistically modellingeffects of a treatment on said biological process.

[0329] Still preferably, said modelling of biological processes is doneby mathematical modelling biological processes affecting healthy cellpopulations and mathematically modelling biological processes affectingcell populations with at least one disease.

[0330] Still preferably, said healthy cell populations includebone-marrow cells and host tissue cells that are affected by saidtreatment model.

[0331] Still preferably, said cell populations with at least one diseaseis one of cancer cells, and diseased bone-marrow cells includingdiseased Neutrophil cells and diseased Thrompocyte cells.

[0332] Still preferably, said treatment models comprise treatmentspecific processes that affect cell population.

[0333] Still preferably, said treatment specific process is interactionsinvolving at least one of a group comprising pharmacokinetic (PK),pharmacodynamic (PD), cytostatic, cytotoxic, and methods of affectingcell biology and causing cell death, with associated biologicalprocesses.

[0334] Still preferably, said parameters specific to the individualinclude one or more selected from a group consisting of parametersrelated to the biological process' dynamics, patient specific drug PK,PD and dynamics of dose-limiting host tissues

[0335] Still preferably, said parameters related to biological process'dynamics comprise age, weight, gender, blood picture, desired length oftreatment protocol, previous reaction to treatment, molecular markers,genetic markers, pathologic specifics and cytologic specifics.

[0336] Still preferably, user-specific parameters are used in selectingthe optimal treatment.

[0337] Still preferably, a fitness function is used to perform theselection.

[0338] Still preferably, said fitness function incorporates at least oneparameter selected from a group consisting patient survival, time todeath, time to reach a specified disease stage and cure, tumor load,pathogen load, cytotoxicity, side effects, quality of life, cost oftreatment and pain.

[0339] Still preferably, a user can input specific coefficients for saidat least one parameter to adjust the fitness function to satisfy theuser's goals.

[0340] Still preferably, the user-specific parameters are based on auser, said user being a medical doctor.

[0341] Still preferably, the user-specific parameters are based on auser, said user being a scientist.

[0342] Still preferably, the user-specific parameters are based on auser, said user being a drug developer.

[0343] Preferably, said selection of treatment protocols incorporatecytotoxic effects.

[0344] Still preferably, said selection of treatment protocolsincorporate drug efficacy.

[0345] Still preferably, operation research techniques are used inperforming the selection.

[0346] Still preferably, heuristics are used to perform searching andselection.

[0347] Still preferably, said heuristics comprise computationalfeasibility.

[0348] Still preferably, said recommendation is a combination of diseaseand treatment strategy, including type of treatment, device, drug ordrug combination, raditherapy, surgery and treatment schedule anddosage.

[0349] Yet another aspect of the present invention is a method ofrecommending an optimal treatment protocol for a general patientcomprising: creating a system model; enumerating a plurality oftreatment protocols; and selecting an optimal treatment protocol fromsaid plurality of treatment protocols based on the modified systemmodel.

[0350] Still preferably, the step of creating the system model furthercomprises: modelling a biological process; and realistically modellingeffects of a treatment on said biological process;

[0351] Still preferably, said modelling of biological processes is doneby mathematical modelling biological processes affecting healthy cellpopulations and mathematically modelling biological processes affectingcell populations with at least one disease.

[0352] Still preferably, said healthy cell populations includebone-marrow cells and host tissue cells that are affected by saidtreatment model.

[0353] Still preferably, said cell populations with at least one diseaseis one of cancer cells, and diseased bone-marrow cells includingdiseased Neutrophil cells and diseased Thrompocyte cells.

[0354] Still preferably, said treatment models comprise treatmentspecific processes that affect cell population.

[0355] Still preferably, said treatment specific process is interactionsinvolving one of a group comprising pharmacokinetic, pharmacodynamic,cytostatic, cytotoxic, or any other method of affecting cell biology andcausing cell death, with associated biological processes.

[0356] Still preferably, user-specific parameters are used in selectingthe optimal treatment.

[0357] Still preferably, a fitness function is used to perform theselection.

[0358] Still preferably, said fitness function incorporates at least oneparameter selected from a group comprising patient survival, time todeath, time to reach a is specified disease stage (including cure)e,tumor load, pathogen load, cytotoxicity, side effects, quality of life,cost of treatment and pain.

[0359] Still preferably, a user can input specific coefficients for saidat least one parameter to adjust the fitness function to satisfy theuser's goals.

[0360] Still preferably, the user-specific parameters are based on auser, said user being a medical doctor.

[0361] Still preferably, the user-specific parameters are based on auser, said user being a scientist.

[0362] Still preferably, the user-specific parameters are based on auser, said user being a drug developer.

[0363] Still preferably, said selection of treatment protocolsincorporate cytotoxic effects.

[0364] Still preferably, said selection of treatment protocolsincorporate drug efficacy.

[0365] Still preferably, operation research techniques are used inperforming the selection.

[0366] Still preferably, heuristics are used to perform searching andselection.

[0367] Still preferably, said heuristics comprise computationalfeasibility.

[0368] Still preferably, said recommendation is a combination of diseaseand treatment strategy, including type of treatment, device, drug, drugcombination, radiotherapy, surgery and treatment schedule and dosage.

[0369] Yet another aspect of the present invention is a method ofpredicting progression of a biological process in an individual patientunder a plurality of treatment protocols, wherein said biologicalprocess could be related to healthy or diseased processes, saidplurality of protocols including no treatment, said method comprisingcreating a system model, enumerating a plurality of treatment protocols;modifying the system model based on parameters specific to theindividual, and selecting an optimal treatment protocol from saidplurality of treatment protocols based on the modified system model.

[0370] Preferably, the step of creating a system model furthercomprises: realistically modelling a biological process; andrealistically modelling the effects of the treatment on said biologicalprocess.

[0371] Still preferably, said step of modelling a biological processcomprises creating a mathematical model for biological processesaffecting healthy cell populations and creating a biological processesaffecting cell populations with at least one disease.

[0372] Still preferably, said healthy cell populations includebone-marrow cells and host tissue cells that are affected by saidtreatment model.

[0373] Still preferably, said cell populations with at least one diseaseis one of cancer cells, and diseased bone-marrow cells includingdiseased Neutrophil cells and diseased Thrombocyte cells.

[0374] Still preferably, said treatment models comprise treatmentspecific processes that affect cell population.

[0375] Still preferably, said treatment specific process is interactionsinvolving one of a group comprising PK, PD, cytostatic, cytotoxic, orany other method of affecting cell biology and causing cell death, withassociated biological processes.

[0376] Still preferably, said parameters specific to the individualinclude one or more selected from a group consisting of parametersrelated to the biological process' dynamics, patient specific drug PK,PD and dynamics of dose-limiting host tissues.

[0377] Still preferably, said parameters related to biological process'dynamics comprise age, weight, gender, blood picture, desired length oftreatment protocol, previous reaction to treatment, molecular markers,genetic markers, pathologic specifics and cytologic specifics.

[0378] Yet another aspect of the present invention is a method ofpredicting progression of a biological process in a general patientunder a plurality of treatment protocols, wherein said biologicalprocess could be related to healthy or diseased, said plurality ofprotocols including no treatment, said method comprising creating asystem model; enumerating a plurality of treatment protocols; andselecting an optimal treatment protocol from said plurality of treatmentprotocols based on the modified system model.

[0379] Preferably, the step of creating a system model further comprisesrealistically modelling a biological process; and realisticallymodelling the and the effects of the treatment on said biologicalprocess.

[0380] Still preferably, said step of modelling a biological processcomprises creating a mathematical model for biological processesaffecting healthy cell populations and creating a biological processesaffecting cell populations with at least one disease.

[0381] Still preferably, said healthy cell populations includebone-marrow cells and host tissue cells that are affected by saidtreatment model.

[0382] Still preferably, said cell populations with at least one diseaseis one of cancer cells, and diseased bone-marrow cells including atleast one of diseased Neutrophil cells and diseased Thrombocyte cells.

[0383] Still preferably, said treatment models comprise treatmentspecific processes that affect cell population.

[0384] Still preferably, said treatment specific process is interactionsinvolving one of a group comprising PK, PD, drug cytostatics, drugcytotoxics, and methods of affecting cell biology and causing celldeath, with associated biological processes.

[0385] Yet another aspect of the present invention is a method formodelling Thrombopietic lineage in an individual, said methodcomprising: realistically modelling a process to create a process modelfor cells involved in Thrombopoiesis; and modifying the process modelbased on parameters specific to the individual.

[0386] Preferably, a realistic progression of cells involved in diseasedThrombopoiesis is incorporated in the process model.

[0387] Still preferably, diseased Thrombopoiesis includesThrombocytopenia.

[0388] Still preferably, effects of at least one drug in the realisticprogression of cells involved in Thrombopoiesis is incorporated.

[0389] Still preferably, said at least one drug is Thrombopoietin (TPO).

[0390] Still preferably, said process model imitates a course of theindividual's bone marrow progression, peripheral platelet counts and TPOconcentration changes.

[0391] Still preferably, said process model incorporatescell-suppressive treatment effects and administration of TPO to thepatient.

[0392] Still preferably, said cell-suppressive treatment ischemotherapy.

[0393] Preferably, said method is used for recommending an optimumtreatment protocol, and wherein said method further comprises:enumerating a plurality of treatment protocols; and selecting an optimaltreatment protocol from said plurality of treatment protocols based onthe modified system model.

[0394] Yet another aspect of the present invention is a method formodelling Thrombopietic lineage in a general patient, said methodcomprising: realistically modelling a process to create a process modelfor cells involved in Thrombopoiesis.

[0395] Preferably, a realistic progression of cells involved in diseasedthrombopoiesis is incorporated in the process model.

[0396] Still preferably, diseased Thrombopoiesis includesThrombocytopenia.

[0397] Still preferably, effects of at least one drug in the realisticprogression of cells involved in Thrombopoiesis is incorporated.

[0398] Still preferably, said at least one drug is Thrombopoietin (TPO).

[0399] Still preferably, said process model imitates a course of theindividual's bone marrow progression, peripheral platelet counts and TPOconcentration changes.

[0400] Still preferably, said process model incorporatescell-suppressive treatment effects and administration of TPO to thepatient.

[0401] Still preferably, said cell-suppressive treatment ischemotherapy.

[0402] Preferably, said method is used for recommending an optimumtreatment protocol, and wherein said method further comprises:enumerating a plurality of treatment protocols; and selecting an optimaltreatment protocol from said plurality of treatment protocols based onthe modified system model.

[0403] Yet another aspect of the present invention is a method forpredicting progression of Thrombopoiesis and Thrombocytopenia for anindividual under a plurality of treatment protocols, said plurality ofprotocols including no treatment, said method comprising: creating arealistic model of Thrombopoiesis and Thrombocytopenia; generating aplurality of treatment protocols for affecting Thrombopoiesis andtreating Thrombocytopenia using at least one drug;

[0404] modifying the model based on parameters specific to theindividual; and

[0405] predicting the progression of the disease or the naturalbiological process under said plurality of treatment protocols based onthe modified system model.

[0406] Preferably, the model incorporates a realistic progression ofcells involved in diseased Thrombopoiesis.

[0407] Still preferably, diseased Thrombopoiesis includesThrombocytopenia.

[0408] Still preferably, the model incorporates effects of at least onedrug in the realistic progression of cells involved in Thrombocytopenia.

[0409] Still preferably, said at least one drug is Thrombopoietin (TPO).

[0410] Still preferably, the model imitates a course of the individual'sbone marrow progression, peripheral platelet counts and TPOconcentration changes.

[0411] Still preferably, the model incorporates cell-suppressivetreatment effects and administration of TPO to the patient.

[0412] Still preferably, said cell-suppressive treatment ischemotherapy.

[0413] Still preferably, said process model further comprises aplurality of compartments.

[0414] Still preferably, said compartments include:

[0415] a stem cell (SC) compartment that comprises bone marrowhaemopoietic progenitors that have an ability to differentiate into morethan one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte;

[0416] a colony forming units—megakaryocytes (CFU-Meg) compartment,wherein the megakaryocyte progenitors get committed as a megakaryocyteline and spend some time multiplying and maturing;

[0417] a megakaryoblast (MKB) compartment, which receives the cells fromCFU-Meg, wherein the cells in the MKB compartment have lost theirability to proliferate but are not mature to release platelets;

[0418] a MK16 compartment, which receives cell from the MKB compartment,wherein a subset of cells in the MK16 compartment release platelets at aconstant rate until they exhaust their capacity and are disintegratedand a second subset of cells do not release platelets but continue withendomitosis;

[0419] a MK32 compartment that receives cells from the MK16 compartment,wherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0420] a MK64 compartment that receives cells from the MK32 compartmentwherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0421] a MK128 compartment that receives cells from the MK64 compartmentwherein a subset of cells in this compartment release platelets; and

[0422] a platelets (PL) compartment.

[0423] Still preferably, an effect of apoptosis are included with anoverall effect of cell proliferation in giving rise to an amplificationof cell numbers in a corresponding compartment.

[0424] Still preferably, the model further incorporates the effects ofTPO on the SC, CFU-Meg and MKB compartments.

[0425] Still preferably, the effects are expressed in terms of effectsof TPO concentration on amplification rate, rate of cell maturation anda fraction of cells that undergo endomotisis.

[0426] Still preferably, when the TPO concentration is above apredetermined threshold level, the amplification rate of cells in the SCcompartment are affected and below the threshold the amplification rateis dependent only on a current number of cells.

[0427] Still preferably, in the CFU-Meg compartment the cells aresensitive to TPO concentration regardless of the concentration of TPO.

[0428] Still preferably, the transit time is same in all plateletreleasing compartments and the transit time of the SC, CFU-Meg and MKBcompartments are functions of micro-environmental conditions.

[0429] Still preferably, in the SC compartment when the TPOconcentration is above the threshold, the transit time is shortenedbased the dose.

[0430] Still preferably, in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.

[0431] Still preferably, a fraction of cells in the SC compartment thatcommits to megakaryocytic lineage is constant and dependent on TPO.

[0432] Still preferably, in the CFU-Meg and MKB compartments, everymature cell passes on to the next compartment.

[0433] Still preferably, in the MK16, MK32 and MK64 compartments, afraction of cells pass on to the next compartment, said fraction beingdependent on the TPO concentration.

[0434] Still preferably, cells from MK128 compartment do not flow intoany other compartment.

[0435] Still preferably, each of said compartments is further dividedinto sub-compartments, each of said sub-compartments containing cells ofa specific age in hours.

[0436] Still preferably, cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.

[0437] Still preferably, the platelet releasing cells contributeplatelets to the first sub-compartment of the PL compartment.

[0438] Yet another aspect of the present invention is a method forpredicting progression of Thrombopoiesis and Thrombocytopenia for ageneral patient under a plurality of treatment protocols, said pluralityof protocols including no treatment, said method comprising: creating arealistic model Thrombopoiesis and Thrombocytopenia; generating aplurality of treatment protocols for affecting Thrombopoiesis andtreating Thrombocytopenia using at least one drug; and predicting theprogression of the disease or the natural biological process under saidplurality of treatment protocols based on the modified system model.

[0439] Preferably, the model incorporates a realistic progression ofcells involved in diseased Thrombopoiesis.

[0440] Still preferably, diseased Thrombopoiesis includesThrombocytopenia.

[0441] Still preferably, the model incorporates effects of at least onedrug in the realistic progression of cells involved in Thrombocytopenia.

[0442] Still preferably, said at least one drug is Thrombopoietin (TPO).

[0443] Still preferably, the model imitates a course of the individual'sbone marrow progression, peripheral platelet counts and TPOconcentration changes.

[0444] Still preferably, the model incorporates cell-suppressivetreatment effects and administration of TPO to the patient.

[0445] Still preferably, said cell-suppressive treatment ischemotherapy.

[0446] Still preferably, said process model further comprises aplurality of compartments.

[0447] Still preferably, said compartments include:

[0448] a stem cell (SC) compartment that comprises bone marrowhaemopoietic progenitors that have an ability to differentiate into morethan one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte;

[0449] a colony forming units—megakaryocytes (CFU-Meg) compartment,wherein the megakaryocyte progenitors get committed as a megakaryocyteline and spend some time multiplying and maturing;

[0450] a megakaryoblast (MKB) compartment, which receives the cells fromCFU-Meg, wherein the cells in the MKB compartment have lost theirability to proliferate but are not mature to release platelets;

[0451] a MK16 compartment, which receives cell from the MKB compartment,wherein a subset of cells in the MK16 compartment release platelets at aconstant rate until they exhaust their capacity and are disintegratedand a second subset of cells do not release platelets but continue withendomitosis;

[0452] a MK32 compartment that receives cells from the MK16 compartment,wherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0453] a MK64 compartment that receives cells from the MK32 compartmentwherein a subset of cells in this compartment release platelets and asecond subset of cells do not release platelets but continue withendomitosis;

[0454] a MK128 compartment that receives cells from the MK64 compartmentwherein a subset of cells in this compartment release platelets; and

[0455] a platelets (PL) compartment.

[0456] Still preferably, an effect of apoptosis are included with anoverall effect of cell proliferation in giving rise to an amplificationof cell numbers in a corresponding compartment.

[0457] Still preferably, the model further incorporates the effects ofTPO on the SC, CFU-Meg and MKB compartments.

[0458] Still preferably, the effects are expressed in terms of effectsof TPO concentration on amplification rate, rate of cell maturation anda fraction of cells that undergo endomotisis.

[0459] Still preferably, when the TPO concentration is above apredetermined threshold level, the amplification rate of cells in the SCcompartment are affected and below the threshold the amplification rateis dependent only on a current number of cells.

[0460] Still preferably, in the CFU-Meg compartment the cells aresensitive to TPO concentration regardless of the concentration of TPO.

[0461] Still preferably, the transit time is same in all plateletreleasing compartments and the transit time of the SC, CFU-Meg and MKBcompartments are functions of micro-environmental conditions.

[0462] Still preferably, in the SC compartment when the TPOconcentration is above the threshold, the transit time is shortenedbased the dose.

[0463] Still preferably, in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.

[0464] Still preferably, a fraction of cells in the SC compartment thatcommits to megakaryocytic lineage is constant and dependent on TPO.

[0465] Still preferably, in the CFU-Meg and MKB compartments, everymature cell passes on to the next compartment.

[0466] Still preferably, in the MK16, MK32 and MK64 compartments, afraction of cells pass on to the next compartment, said fraction beingdependent on the TPO concentration.

[0467] Still preferably, cells from MK128 compartment do not flow intoany other compartment.

[0468] Still preferably, each of said compartments is further dividedinto sub-compartments, each of said sub-compartments containing cells ofa specific age in hours.

[0469] Still preferably, cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.

[0470] Still preferably, the platelet releasing cells contributeplatelets to the first sub-compartment of the PL compartment.

[0471] Yet another aspect of the present invention is a method formodelling Neutrophil lineage for an individual, said method comprising:creating a realistic a Neutrophil system model including a realisticprocess model for cells involved in Neutrophil lineage; and modifyingthe system model based on parameters specific to the individual.

[0472] Preferably, the system model incorporates a realistic progressionof cells involved in Granulopoietic disorders, including Neutropenia.

[0473] Still preferably, the system model incorporates effects of atleast one drug in the realistic progression of cells involved inGranulopoiesis and Neutropenia.

[0474] Still preferably, said at least one drug is Granulocyte ColonyStimulating Factor (G-CSF).

[0475] Still preferably, said system model comprises at least threestages,

[0476] a first stage related to an administered amount of cytokine;

[0477] a second stage representing a pharmacokinetic behavior of G-CSF;and

[0478] a third stage representing a phrmacodynamic effect of G-CSF onkinetic parameters of the system.

[0479] Still preferably, said model comprises a mitotic compartment, anda post mitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.

[0480] Still preferably, effects of toxic drugs, including chemotherapyare incorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.

[0481] Still preferably, the effects of G-CSF on the mitotic compartmentare modeled as an increase in a rate of cells entering the myeloblastscompartment from an uncommitted stem cell pool.

[0482] Still preferably, the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters the matureNeutrophil pool every hour.

[0483] Still preferably, effects of G-CSF on the Neutrophil lineage aremodeled as a decrease in the cells in the post-mitotic compartment whichis subsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in Neutrophilcount.

[0484] Still preferably, an elimination of Neutrophils in thepost-mitotic compartment is represented by a Poisson distribution.

[0485] Still preferably, the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.

[0486] Still preferably, kinetic of G-CSF is modeled as an exponentialdistribution.

[0487] Still preferably, a selection of an optimal treatment uses anobjective function that aims at minimizing G-CSF administration andreturning Neutrophil lineage to normal levels.

[0488] Still preferably, selection is performed using linearprogramming.

[0489] Still preferably, phrmacokinetics and pharmacodynamics of G-CSFare defined using piecewise linear functions.

[0490] Preferably, said method is used for recommending an optimumtreatment protocol, and wherein said method further comprises:enumerating a plurality of treatment protocols; and selecting an optimaltreatment protocol from said plurality of treatment protocols based onthe modified system model.

[0491] Yet another aspect of the present invention is a method formodelling Neutrophil lineage for a general patient, said methodcomprising: creating a realistic a Granulopoiesis system model includinga realistic process model for cells involved in Granulopoiesis lineage.Preferably the system model incorporates a realistic progression ofcells involved in Granulopoietic disorders, including Neutropenia.

[0492] Still preferably, the system model incorporates effects of atleast one drug in the realistic progression of cells involvedGranulopoiesis and in Neutropenia.

[0493] Still preferably, said at least one drug is Granulocyte ColonyStimulating Factor (G-CSF).

[0494] Still preferably, said system model comprises at least threestages,

[0495] a first stage related to an administered amount of cytokine;

[0496] a second stage representing a pharmacokinetic behavior of G-CSF;and

[0497] a third stage representing a phrmacodynamic effect of G-CSF onkinetic parameters.

[0498] Preferably, wherein said model comprises a mitotic compartment,and a post mitotic compartment, said mitotic compartment being dividedinto subcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.

[0499] Still preferably, effects of toxic drugs, including chemotherapyare incorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.

[0500] Still preferably, the effects of G-CSF on the mitotic compartmentare modeled as an increase in a rate of cells entering the myeloblastscompartment from an uncommitted stem cell pool.

[0501] Still preferably, the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters the matureNeutrophil pool every hour.

[0502] Still preferably, effects of G-CSF on the Neutrophil lineage aremodeled as a decrease in the cells in the post-mitotic compartment whichis subsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in Neutrophilcount.

[0503] Still preferably, an elimination of Neutrophils in thepost-mitotic compartment is represented by a Poisson distribution.

[0504] Still preferably, the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.

[0505] Still preferably, kinetic of G-CSF is modeled as an exponentialdistribution.

[0506] Still preferably, a selection of an optimal treatment uses anobjective function that aims at minimizing G-CSF administration andreturning Neutrophil lineage to normal levels.

[0507] Still preferably, said selection is performed using linearprogramming.

[0508] Still preferably, phrmacokinetics and pharmacodynamics of G-CSFare defined using piecewise linear functions.

[0509] Still preferably, said method is used for recommending an optimumtreatment protocol, and wherein said method further comprises:enumerating a plurality of treatment protocols; and selecting an optimaltreatment protocol from said plurality of treatment protocols based onthe modified system model.

[0510] Yet another aspect of the present invention is a method forpredicting progression of Granulopoiesis for an individual under aplurality of treatment protocols, said plurality of protocols includingno treatment, said system comprising: creating a Neutrophil system modelincluding a realistic process model for cells involved in Neutrophilproduction; generating a plurality of treatment protocols; modifying thesystem model modifier, wherein said Neutrophil system model is modifiedby the system model modifier based on parameters specific to theindividual; and predicting the progression under the plurality oftreatment protocols based on the modified system model.

[0511] Preferably, the system model incorporates a realistic progressionof cells involved in Granulopoietic disorders, including Neutropenia.

[0512] Still preferably, the system incorporates effects of at least onedrug in the realistic progression of cells involved in Granulopoiesisand Neutropenia.

[0513] Still preferably, said at least one drug is Granulocyte ColonyStimulating Factor (G-CSF).

[0514] Still preferably, said model comprises at least three stages,

[0515] a first stage related to an administered amount of cytokine;

[0516] a second stage representing a pharmacokinetic behavior of G-CSF;and

[0517] a third stage representing a phrmacodynamic effect of G-CSF onkinetic parameters.

[0518] Still preferably, said model comprises a mitotic compartment, anda post mitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.

[0519] Still preferably, effects of toxic drugs, including chemotherapyare incorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.

[0520] Still preferably, the effects of G-CSF on the mitotic compartmentare modeled as an increase in a rate of cells entering the myeloblastscompartment from an uncommitted stem cell pool.

[0521] Still preferably, the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters the matureNeutrophil pool every hour.

[0522] Still preferably, effects of G-CSF on the Neutrophil lineage aremodeled as a decrease in the cells in the post-mitotic compartment whichis subsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in Neutrophilcount.

[0523] Still preferably, an elimination of Neutrophils in thepost-mitotic compartment is represented by a Poisson distribution.

[0524] Still preferably, the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.

[0525] Still preferably, kinetic of G-CSF is modeled as an exponentialdistribution.

[0526] Preferably, a selection of an optimal treatment uses an objectivefunction that aims at minimizing G-CSF administration and returningNeutrophil lineage to normal levels.

[0527] Still preferably, said selection is performed using linearprogramming.

[0528] Still preferably, phrmacokinetics and pharmacodynamics of G-CSFare defined using piecewise linear functions.

[0529] Yet another aspect of the present invention is a method forpredicting progression of Granulopoiesis for a general patient under aplurality of treatment protocols, said plurality of protocols includingno treatment, said system comprising: creating a Neutrophil system modelincluding a realistic process model for cells involved in Neutrophilproduction; generating a plurality of treatment protocols; andpredicting the progression under the plurality of treatment protocolsbased on the modified system model.

[0530] Still preferably, the system model incorporates a realisticprogression of cells involved in Granulopoietic disorders, includingNeutropenia.

[0531] Still preferably, the system incorporates effects of at least onedrug in the realistic progression of cells involved in Granulopoiesisand Neutropenia.

[0532] Still preferably, said at least one drug is Granulocyte ColonyStimulating Factor (G-CSF).

[0533] Still preferably, said model comprises at least three stages,

[0534] a first stage related to an administered amount of cytokine;

[0535] a second stage representing a pharmacokinetic behavior of G-CSF;and

[0536] a third stage representing a phrmacodynamic effect of G-CSF onkinetic parameters.

[0537] Still preferably, said model comprises a mitotic compartment, anda post mitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.

[0538] Still preferably, effects of toxic drugs, including chemotherapyare incorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.

[0539] Still preferably, the effects of G-CSF on the mitotic compartmentare modeled as an increase in a rate of cells entering the myeloblastscompartment from an uncommitted stem cell pool.

[0540] Still preferably, the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters the matureNeutrophil pool every hour.

[0541] Still preferably, effects of G-CSF on the Neutrophil lineage aremodeled as a decrease in the cells in the post-mitotic compartment whichis subsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in Neutrophilcount.

[0542] Still preferably, an elimination of Neutrophils in thepost-mitotic compartment is represented by a Poisson distribution.

[0543] Still preferably, the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.

[0544] Still preferably, kinetic of G-CSF is modeled as an exponentialdistribution.

[0545] Still preferably, a selection of an optimal treatment uses anobjective function that aims at minimizing G-CSF administration andreturning Neutrophil lineage to normal levels.

[0546] Still preferably, said selection is performed using linearprogramming.

[0547] Still preferably, pharmacokinetics and pharmacodynamics of G-CSFare defined using piecewise linear functions.

[0548] Yet another aspect of the present invention a method forrecommending an optimal treatment protocol for treating cancer usingdrugs, including chemotherapy, for an individual, said methodcomprising: creating a cancer system model; enumerating a plurality oftreatment protocols for treating cancer using drugs, includingchemotherapy; modifying the system model based on parameters specific tothe individual; and selecting an optimal treatment protocol from saidplurality of treatment protocols based on the modified system model.

[0549] Preferably, the system model further comprises: a realisticprocess model of cancer development; and a realistic treatment modelthat models the effects of treating cancer with drugs, includingchemotherapy.

[0550] Still preferably, said process model incorporates a distributionof cycling cells and quiescent cells.

[0551] Still preferably, where a tumor cell cycle is divided into atleast four compartments G1, S, G2 and M and a quiescent stage is denotedby G0, wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age Iin the corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.

[0552] Still preferably, the model traces development of cancer cellsusing a predetermined set of parameters by calculating a number of cellsin each subcompartment using stepwise equations.

[0553] Still preferably, a probability vector is used to determine afraction of cells that leaves any subcompartment in a compartment tomove to a first subcompartment of the next compartment.

[0554] Still preferably, a set of control functions uniquely determinean outcome of every single step, wherein said control functions dependon age of cells, state of a current population and associatedenvironment.

[0555] Still preferably, a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.

[0556] Still preferably, in each step, a number of cells in eachsub-compartment of each compartment of each group is calculatedaccording to factors including a previous state, parameters of tumor,tumor current microenvironment and drug concentration.

[0557] Still preferably, spatial structure of the tumor is included inthe model.

[0558] Still preferably, PK and PD, cytotoxic effects, cytostaticeffects and other effects on cell disintegration of anticancer drugs areincorporated into the model.

[0559] Still preferably, a dose-limiting toxicity is incorporated intothe model.

[0560] Still preferably, said parameters specific to the individualcomprise parameters related to tumor dynamics, patient specific drug PK,and dynamics of dose-limiting host tissues.

[0561] Still preferably, said parameters related to tumor dynamicscomprise age, weight, gender, percentage of limiting healthy cells,desired length of treatment protocol, previous reaction to treatment,molecular markers, genetic markers, pathologic specifics and cytologicspecifics.

[0562] Yet another aspect of the present invention is a method ofpredicting a progression of cancer in an individual, said methodcomprising: creating a cancer system model; enumerating a plurality oftreatment protocols for treating cancer using drugs, includingchemotherapy; modifying the system model based on parameters specific tothe individual; and selecting an optimal treatment protocol from saidplurality of treatment protocols based on the modified system model.

[0563] Preferably, the system model further comprises: a realisticprocess model of cancer development; and a realistic treatment modelthat models the effects of treating cancer with drugs, includingchemotherapy.

[0564] Still preferably, said process model incorporates a distributionof cycling cells and quiescent cells.

[0565] Still preferably, a tumor cell cycle is divided into at leastfour compartments G1, S, G2 and M and a quiescent stage is denoted byG0, wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age Iin the corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.

[0566] Still preferably, the model traces development of cancer cellsusing a predetermined set of parameters by calculating a number of cellsin each subcompartment using stepwise equations.

[0567] Still preferably, a probability vector is used to determine afraction of cells that leaves any subcompartment in a compartment tomove to a first subcompartment of the next compartment.

[0568] Still preferably, a set control functions uniquely determine anoutcome of every single step, wherein said control functions depend onage of cells, state of a current population and associated environment.

[0569] Still preferably, a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.

[0570] Still preferably, in each step, a number of cells in eachsub-compartment of each compartment of each group is calculatedaccording to factors including a previous state, parameters of tumor,tumor current microenvironment and drug concentration.

[0571] Still preferably, spatial structure of the tumor is included inthe model.

[0572] Still preferably, PK and PD, cytotoxic and other celldisintegration effects, and cytostatic effects of anticancer drugs areincorporated into the model.

[0573] Still preferably, a dose-limiting toxicity is incorporated intothe model.

[0574] Still preferably, said parameters specific to the individualcomprise parameters related to tumor dynamics, patient specific drug PK,and dynamics of dose-limiting host tissues.

[0575] Still preferably, said parameters related to tumor dynamicscomprise age, weight, gender, percentage of limiting healthy cells,desired length of treatment protocol, previous reaction to treatment,molecular markers, genetic markers, pathologic specifics and cytologicspecifics.

[0576] Yet another aspect of the present invention is a method ofpredicting a progression of cancer in a general patient, said methodcomprising: creating a cancer system model; enumerating a plurality oftreatment protocols for treating cancer using drugs, includingchemotherapy; and selecting an optimal treatment protocol from saidplurality of treatment protocols based on the modified system model.

[0577] Still preferably, the system model further comprises: a realisticprocess model of cancer development; and a realistic treatment modelthat models the effects of treating cancer with drugs, includingchemotherapy.

[0578] Still preferably, said process model incorporates a distributionof cycling cells and quiescent cells.

[0579] Still preferably, a tumor cell cycle is divided into at leastfour compartments G1, S, G2 and M and a quiescent stage is denoted byG0, wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age Iin the corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.

[0580] Still preferably, the model traces development of cancer cellsusing a predetermined set of parameters by calculating a number of cellsin each subcompartment using stepwise equations.

[0581] Still preferably, a probability vector is used to determine afraction of cells that leaves any subcompartment in a compartment tomove to a first subcompartment of the next compartment.

[0582] Still preferably, a set control functions uniquely determine anoutcome of every single step, wherein said control functions depend onage of cells, state of a current population and associated environment.

[0583] Still preferably, a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.

[0584] Still preferably, in each step, a number of cells in eachsub-compartment of each compartment of each group is calculatedaccording to factors including a previous state, parameters of tumor,tumor current microenvironment and drug concentration.

[0585] Still preferably, spatial structure of the tumor is included inthe model.

[0586] Still preferably, PK and PD, cytotoxic effects and cytostaticeffects of anticancer drugs are incorporated into the model.

[0587] Still preferably, a dose-limiting toxicity is incorporated intothe model.

[0588] Yet another aspect of the present invention is a computer programproduct, including a computer readable medium, said program productcomprising a set of instruction to enable a computer system to aid inrecommending an optimal treatment protocol for an individual comprising:

[0589] a system model code; treatment protocol code for a plurality oftreatment protocols;

[0590] a system model modifier code, wherein said system model ismodified by the system model modifier based on parameters specific tothe individual; and

[0591] a selector code to select an optimal treatment protocol from saidplurality of treatment protocols based on the modified system model.

[0592] Preferably, the system model code further comprises: a realisticbiological process model code; and a realistic treatment model code thatenables a computer to model the effects of a treatment on the biologicalprocess.

[0593] Yet another aspect of the present invention is a computer programproduct, including a computer readable medium, said program productcomprising a set of instructions to enable a computer system to aid inrecommending an optimal treatment protocol for a general patientcomprising: a system model code; treatment protocol code for a pluralityof treatment protocols; and a selector code to select an optimaltreatment protocol from said plurality of treatment protocols based onthe modified system model.

[0594] Preferably, the system model code further comprises: a realisticbiological process model code; and

[0595] a realistic treatment model code that enables a computer to modelthe effects of a treatment on the biological process.

III. BRIEF DESCRIPTION OF THE DRAWINGS

[0596] The present invention will be understood and appreciated morefully from the following detailed description taken in conjunction withthe appended drawings in which:

[0597]FIG. 1 is a schematic illustration of the basis of the presentinvention;

[0598]FIG. 2 is a flow chart illustration of steps of the invention,useful in understanding FIG. 1; FIG. 2a further illustrates a protocolspace;

[0599]FIG. 3 is a schematic illustration of a biological model, inaccordance with one embodiment of the present invention;

[0600]FIG. 4 is a chart illustration of the biological model of FIG. 3;

[0601]FIG. 5 is a graphical illustration of the chart of FIG. 4;

[0602]FIG. 6 is a chart illustration of the biological model of FIG. 3in a different format;

[0603]FIG. 7 is a graphical illustration of the chart of FIG. 6;

[0604]FIGS. 8A and 8B are graphical illustrations of the output of themodel of FIG. 3;

[0605]FIGS. 9A and 9B are graphical illustrations of experimental dataas compared to the output shown in FIGS. 8A and 8B;

[0606]FIG. 10 is a schematic illustration of a biological model, inaccordance with a further embodiment of the present invention;

[0607]FIG. 11 is a graphical illustration of results of the simulationof the model shown in FIG. 10;

[0608]FIGS. 12A and 12B are graphical illustrations of the effects oftwo doses of G-CSF on the Neutrophil line, according to the model ofFIG. 10;

[0609]FIG. 13 is a schematic illustration of a biological model, inaccordance with a further embodiment of the present invention;

[0610]FIGS. 14 and 15 show a comparison of Neutrophil productionaccording to the described model and experimental data in theliterature.

IV. DETAILED DESCRIPTION OF THE PRESENT INVENTION

[0611] Systems and methods have been disclosed for identifying optimaltreatment strategies for a general patient and a specific individualpatient, and for predicting progression of a biological process andtreatment, using selected parameters. The techniques are based onbiological and clinical knowledge, mathematical models, computersimulations, and optimization methods. The optimization techniques couldbe any available mathematical techniques including, but not limited to,linear programming and heuristic search. The disclosed heuristic searchtechniques use heuristic (or rules of thumb) determinations.

[0612] Such a use of heuristics search enables the user to find nearoptimal solutions even for complex mathematical descriptions of acombination of relevant biological, clinical, pharmacological scenarios.These complex mathematical descriptions are contemplated to be realisticsimulations of actual scenarios. It is contemplated that this holds bothfor the general case (“optimal generic treatment”), as well as at thelevel of an individual patient.

[0613] The general case is intended for several purposes including useby pharmaceutical companies and by researches who are more concernedwith designing systems and recommending treatment for a general patientas opposed to recommending treatment for a specific patient in aclinical setting. It is also contemplated that the general case can beused for a better understanding of the underlying processes for anyother use. Likewise, the individual case is intended for severalpurposes including, for example, the use by a doctor to understand theprogress of a treatment protocol or the progression of a disease, and tooptimize the treatment for a specific individual patient. Theseindicated uses are not intended to be restrictive. It should be clear tothe skilled practitioner that the techniques disclosed can be put toseveral other uses.

[0614]FIG. 1 illustrates the general concept behind the disclosedtechnique. Detailed parameters are input to a protocol space. Theprotocol space comprises a plurality of treatment protocols. From thisprotocol space an optimal treatment protocol is selected by performing aheuristic search.

[0615]FIG. 2 shows a diagram chart that depicts an illustration of anembodiment of the disclosed techniques for optimization. The Figuregenerally depicts the basic concept. The disclosed techniques are usedto optimize a drug delivery protocol after consideration of a pluralityof possible protocols. The plurality of protocols together form aprotocol space 2.5. Determination of an optimal protocol is partiallybased on specific parameters input by a user. The user may be aphysician, a drug developer, a scientist, or anyone else who may need todetermine a treatment strategy, including drug protocols. The specificparameters may include several categories and needs of a specific userand other particulars such as patient survival, efficacy, time to death,time to reach a specified disease stage (including cure), tumor load,pathogen load, cytotoxicity, side effects, quality of life, cost oftreatment, and pain. maximum length of treatment, confidence level, etc.In case of the disclosed techniques for the individual patient, generalcharacteristic parameters which determine the system's behaviour, arealtered according to individual patient characteristics and/or medicalhistory of the patient.

[0616] Initially, system models are created. These included models tosimulate all the relevant biological, clinical and pharmaceuticalprocess 2.1. These models include mathematical models for processes thataffect healthy cells as well as mathematical models for processes thataffect cell populations with one or more diseases. In addition, a modelof treatment effects 2.3 on each of these processes is created. Thetreatment effects include processes that are specific to individualtreatment. Such a treatment may be based on the effects of a drug'sprocess that affects the relevant cell population. Examples of theseeffects include interactions invovlving pharmacokinetic (PK),pharmacodynamics (PD), cytotoxic and cytostatics, or any other method ofaffecting cell biology and causing cell death, with associatedbiological processes.

[0617] The combination of these models provides a detailed mathematicalmodel of the overall bio-clinical scenario in a general sense or for aspecific patient, together with the specific effects of a particulartreatment. Once the comprehensive model is constructed, thecharacteristic parameters are incorporated in it. The characteristicparameters could be either population averaged or patient specific. Incase of the general case, average patient parameters are incorporated.The average patient parameters include parameters related to biologicalprocess dynamics, average drug PK, average drug PD and dynamics ofdoes-limiting host tissues. In this way a “virtual general patient” inthe form of a complete detailed model 2.4 is generated.

[0618] In case of the individual case, patient specific parameters 2.2are incorporated. The patient specific parameters include parametersrelated to biological process dynamics, patient specific drug PK,patient specific drug PD and dynamics of does-limiting host tissues. Theparameters related to biological process dynamics include, age, gender,weight, blood picture, desired length of the treatment protocol,previous reactions to treatment, molecular markers, genetic markers,pathologic specifics and cytologic specifics or clinical indications. Inthis way a “virtual individual patient” in the form of a completedetailed model 2.4 is generated.

[0619] Then a protocol space 2.5 is generated. To do this, possiblepermutations of certain parameters such as drug doses, dosing intervals,etc. are considered. Thus, a number of possible treatment protocols isgenerated. This number could be very large because of the number ofpermutations possible. The amount of possibilities depends on the numberand ranges of parameters considered.

[0620] A fitness function 2.6 is then constructed by mathematicallyconsidering different possible factors which may be influenced by thetreatment. These may include patient survival, time to death, time toreach a specified disease stage (including cure), tumor load, pathogenload, cytotoxicity to normal or diseased tissues, other side effects,quality of life, cost of treatment, pain, etc.

[0621] The user can alter certain specific parameters in the fitnessfunction so as to adjust this function to the user's specific goals. Theuser can be anybody, including a medical doctor, a scientist or a drugdeveloper. Based on the selected parameters, the fitness function isapplied. This results in the calculation of a fitness score for each andevery protocol in the protocol space. Finally, the optimization step iscarried out 2.7, either by search heuristics or by analytical methods,in order to select the optimal treatment protocol 2.8 from all thescored possibilities. The analytical methods include the use ofOperations Research techniques. In selecting the optimal treatmentprotocol cytotoxic effects as well as treatment efficacy areincorporated, as well as other objectives of the said fitness function.The heuristics, or rules of thumb employed include computationalfacility. The optimal treatment protocol is a combination of disease andtreatment strategy, including type of treatment, device, drug or drugcombination, radiotherapy, surgery and treatment schedule.

[0622] In this way, a disease specific, patient specific, situationspecific, treatment type specific (e.g. drug therapy, operation,radiotherapy), drug specific, or an objective specific treatmentprotocol may be obtained. The actual time it takes once the parametersare entered may be negligibly short or up to hours, depending on thelength of the simulated treatment period and the power of the specificsearch heuristics and the computational tools, making this a veryfeasible tool.

[0623] Systems and methods embodying the above disclosed technique for ageneral patient as well as for an individual patient are within thescope of the present invention.

[0624] The system can be implemented remotely over a distributedcomputing system with the user remotely dialing in. It can also beimplemented over the internet. The computer could be a PC, mainframe, aworkstation or a remote computer on a network.

[0625] Another aspect of the disclosed technique is a computer programcode. The computer program product includes a computer readable medium.It should be noted that the computer readable medium includes any fixedmedia including, but not limited to, floppy disk, hard disk, CD, chips,tapes, cartridges with Ics, etc. The computer readable media alsoincludes instructions transmitted through a network or downloaded fromthe internet. The computer program product includes instructions forenabling a computer to aid in selecting a treatment protocol. Theinstructions include a system model code. A treatment protocol code isprovided for a plurality of treatment protocols. In case of thedisclosed technique for an individual patient, a system model modifiercode is provided that enables the computer to modify the system modelbased on parameters specific to the individual. A selector code enablesa computer to select an optimal treatment protocol from the plurality oftreatment protocols based on the modified system model.

[0626] Construction of detailed mathematical models for biologicalprocesses and treatments are discussed herein in relation to variousother embodiments of the disclosed technique. Techniques involving amodel of platelets production and related diseases, includingThrombocytopenia, with treatment by TPO, a model of Neutrophilproduction and related diseases, including Neutropenia, and treatment byG-CSF, and a model of cancer growth and cancer treatment, includingchemotherapy, are disclosed herein. An embodiment for specificoptimization (by linear programming) is implemented for the systeminvolving the Neutrophil model. An embodiment that uses a generalheuristic optimization method is disclosed as well.

IV.A. Thrombopoiesis and Thrombopoietin (TPO)

[0627] An embodiment of the present invention involves the disclosedtechniques for modeling the Thrombopietic lineage, diseasedThrombopoiesis such as Thrombocytopenia and treatment withThrombopoietin. Thrombocytopenia is a common hazardous blood condition,which may appear in different clinical situations, including cancerchemotherapy. Recently, a Thrombopoiesis-controlling cytokine,Thrombopoietin (TPO), was isolated and its human recombinant analogbecame available. A mathematical model is disclosed herein thatsimulated dynamics of a Thrombopoietic lineage in the bone marrow, ofplatelet counts in the periphery, and effects of TPO administration onthe lineage and platelet counts.

[0628] TPO is a cytokine, glycoprotein of about 350 amino acids, thatresembles erythropoiesis-stimulating hormone, erythropoietin. Itssynthetic analogs, recombinant human Thrombopoietin (rHuTPO) andrecombinant human megakaryocyte growth and development factor (rHuMGDF),are available as well and are undergoing clinical trials.

[0629] For further details see Alexander W S: Thrombopoietin. GrowthFactors. 1999; 17(1); pp. 13-24.; Kaushansky K: Thrombopoietin: theprimary regulator of platelet production. Blood. July 1995; Vol. 86(2);pp. 419-431; Vadhan_Raj-Raj S: Recombinant human Thrombopoietin:clinical experience and in vivo biology. Seminars Hem. July 1998; Vol.35(3); pp. 261-268.; Harker L A: Physiology and clinical applications ofplatelet growth factors. Current Opinion Haematol. 1999; Vol. 6; pp.127-134; and Neelis K J, Hartong S C, Egeland T, Thomas G R, Eaton D L,Wagemaker G: The efficacy of single-dose administration ofThrombopoietin with coadministration of either Granulocyte/macrophage orGranulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.Blood. October 1997; Vol. 90(7); pp. 2565-2573.

[0630] These compounds have been shown to have the same biologicalactivity as TPO has, so the term TPO will be used without distinguishingbetween its different forms and analogs.

[0631] TPO is a primary growth factor of the Thrombopoietic cell lineboth in vivo and in vitro. Aside from this, TPO may be potent instimulation and co-stimulation of other haemopoietic lineages (e.g.,Granulopoietic or erythropoietic).

[0632] IV.A.1. Model of the Biological System

[0633] a) Background of Thrombopoiesis

[0634] Like all other haemopoietic lines, the Thrombopoietic lineoriginates from poorly differentiated, multipotential cells, that arecapable of some division and self-reconstitution. For more backgrounddetails, see Swinburne J L, Mackey M C: Cyclical Thrombocytopenia:characterization by spectral analysis and a review. J Theor Medicine.2000; Vol. 2; pp. 81-91.; and Beutler E, Lichtman M A, Coller B S, KippsT J: Williams HAEMATOLOGY. 5^(th) edition McGraw-Hill, Inc. 1995;Chapter 118; pp. 1149-1161. Such bone marrow cell compartments aspluripotential haemopoietic stem cells and common myeloid progenitorcells (CFU-GEMM) have more or less these characteristics. For morebackground details, see Beutler E, Lichtman M A, Coller B S, Kipps T J:Williams HAEMATOLOGY. 5^(th) edition McGraw-Hill, Inc. 1995; Chapter118; pp. 1149-1161.

[0635] Gradually, the cells become more and more differentiated and thuscommitted to the Thrombopoietic line. At this stage they proliferateextensively. Colony-forming Units—megakaryocytes (CFU-Meg) is an exampleof such compartment. Sometimes burst-forming units—megakaryocyte(BFU-Meg), promegakaryoblasts or megakaryoblasts are considered ashaving the similar properties. For more background details, seeSwinburne J L, Mackey M C: Cyclical Thrombocytopenia: characterizationby spectral analysis and a review. J Theor Medicine. 2000; Vol. 2; pp.81-91.; and Beutler E, Lichtman M A, Coller BS, Kipps T J: WilliamsHAEMATOLOGY. 5^(th) edition McGraw-Hill, Inc. 1995; Chapter 118; pp.1149-1161.

[0636] The committed megakaryocytopoietic cells, megakaryocyteprecursors, go through several stages of maturation. However,megakaryocyte maturation is somewhat different from that of otherhaemopoietic lines. Here, along with cytoplasmic maturation, cell nucleiundergo mitotic events. However, although the DNA material of thesecells doubles, cell division does not happen. Such incomplete mitosis istermed endomitosis or endoreduplication. Consequently, the cell becomespoliploid with 2N, 4N, 8N, etc., amount of DNA. Some authors call thecells with 2N to 4N chromosome number promegakaryoblasts, others callthem megakaryoblasts or immature megakaryocytes. For more backgrounddetails, see Swinburne J L, Mackey M C: Cyclical Thrombocytopenia:characterization by spectral analysis and a review. J Theor Medicine.2000; Vol. 2; pp. 81-91.; and Beutler E, Lichtman M A, Coller B S, KippsT J: Williams HAEMATOLOGY. 5^(th) edition McGraw-Hill, Inc. 1995;Chapter 118; pp. 1149-1161.

[0637] Usually, megakaryocytes do not start to release platelets untilthey reach 8N to 16N state. For more background details, see Gordon A S:Regulation of haematopoiesis. N. -Y. 1970 Vol. 2, Section IX (textbook);and Beutler E, Lichtman M A, Coller B S, Kipps T J: WilliamsHAEMATOLOGY. 5th edition McGraw-Hill, Inc. 1995; Chapter 118; pp.1149-1161.

[0638] Then they begin to create demarcation membranes that envelopcytoplasm fragments generating platelets. The platelets are releasedinto the blood stream. A small fraction of the megakaryocytes do notcease their endoreduplication at the 16N-stage, but rather continue withone or more additional endomitoses and get thus a ploidy of 32N or more.For background details, see Swinburne J L, Mackey M C: CyclicalThrombocytopenia: characterization by spectral analysis and a review. JTheor Medicine. 2000; Vol. 2; pp. 81-91.

[0639] The amounts of cytoplasm, cell volume and the ability to releaseplatelets increase proportionally to the cell ploidy. For backgrounddetails, see Harker L A, Finch C A: Thrombokinetics in man. J ClinInvest. 1969; Vol.48; pp. 963-974; and Harker L A: Thrombokinetics inidiopathic Thrombocytopenic purpura. Br J Haematol. 1970; Vol. 19; pp.95-104.

[0640] b) B. Mathematical Model

[0641] Reference is now made to FIG. 3, which is a detailed illustrationof a model predicting Thrombopoiesis. As shown in FIG. 3, theThrombopoietic lineage is divided into eight compartments. The firstcompartment, called Stem Cells (SC) and labeled 30, refers to all bonemarrow haemopoietic progenitors that have an ability to differentiateinto more than one line (e.g., pluripotential stem cells, CFU-GEMM, andothers). Cells of SC compartment 30 proliferate, giving rise to “new”stem cells, or mature, and subsequently differentiate intomegakaryocytes or other precursors. Although the consideration of theformer process, i.e. the renewal of the stem cells by “new” ones, is notcompletely understood biologically, our simple description may serve asan acceptable assumption since the characteristics of this populationare not elaborated in details. For background details, see, Schofield R,Lord B I et al: Self-maintenance capacity of CFU-S. J Cellular Phisiol.1980; Vol. 103: 355-362; and Rosendaal M, Hodgson G S, Bradley T R:Organization of haemopoietic stem cells: the generation-age hypothesis.Cell Tissue Kinetics. 1979; Vol. 12: 17-29.

[0642] Cell death through apoptosis may have a significant effect oncell number within proliferating compartments. For background details,see, Swinburne J L, Mackey M C: Cyclical Thrombocytopenia:characterization by spectral analysis and a review. J Theor Medicine.2000; Vol. 2; pp. 81-91.

[0643] However, the effect of apoptosis is combined with the effect ofcell proliferation into a total amplification of cell number in a givencompartment (for example α_(SC)). An assumption is made that noapoptosis occurs in non-proliferating megakaryocytic compartments, dueto lack of evidence to the contrary. However, an assumption of apoptoticnon-proliferating megakaryocytes can be incorporated in the mathematicalmodel.

[0644] Biologically, rates of proliferation and maturation, the abilityto reconstitute, and other characteristics differ between particularcell types within a primitive progenitor population. However, in thismodel there is no distinction between them; all progenitor cells areconsidered to be one population with common properties.

[0645] It has been shown conventionally that probabilities of stem celldifferentiation into one or another haemopoietic lineage are constant intime. Thus, it is assumed here that a flow of stem cells into themegakaryocyte lineage is fixed (for example Φ_(SC)). For backgrounddetails, see Mayani H, Dragowska W, Lansdorp P M: Lineage commitment inhuman hemopoiesis involves asymmetric cell division of multipotentprogenitors and does not appear to be influenced by cytokines. JCellular Physiol. 1993; Vol. 157; pp. 579-580; Golde D W: The Stem Cell.Medicine. December 1991; Morrison S J, Uchida N, Weissman I L: Thebiology of haematopoietic stem cells. Annu Rev Cell Dev Biol. 1995; Vol.11; pp. 35-71; and von Schulthess G K, Gessner U: Oscillating plateletcounts in healthy individuals: experimental investigation andquantitative evaluation of Thrombopoietic feedback control. Scand JHaematol. 1986; Vol. 36; pp. 473-479.

[0646] The same was assumed about the stem cell self-renewal. Thus,after the cells spend a defined transit time, for example τ_(SC), in SCcompartment 30, a certain constant fraction of the cells return to their“young state”, i.e. start their passage through SC compartment 30 again,as shown in line 31. Another constant fraction (Φ_(SC), for example) ofcells pass into the next compartment named Colony-Forming Units(CFU-Meg), labeled 40. It is presumed that remaining stem cellsdifferentiate into haematopoietic lineages other than megakaryocytic.

[0647] CFU-Meg refers to all cells that are already committed to themegakaryocyte line but are still capable of proliferation. Cells ofCFU-Meg compartment 40, like those of SC compartment 30, spend some timemultiplying at an amplification rate of about α_(SFU), for example, andmaturing before losing their proliferative abilities and passing on tothe next compartment 50, called megakaryoblasts (MKB). For backgrounddetails see, Eller J, Gyori I et al: Modelling Thrombopoiesisregulation—I: model description and simulation results. Comput MathApplic. 1987; Vol. 14 (9-12); pp. 841-848.

[0648] The time they spent in CFU-Meg compartment is τ_(CFU).

[0649] MKB compartment 50 includes all the cells that have lost theability to proliferate, but are not yet sufficiently mature to releaseplatelets. For the purposes of the model, the assumption is made thatmegakaryocytes do not start to release platelets until they reach the16N-ploidy phase. For background details, see Gordon A S: Regulation ofhaematopoiesis. N. -Y. 1970 Vol. 2, Section IX (textbook).

[0650] Hence, MKB refers to 2N, 4N and 8N cells of megakaryocyte lineagethat cannot divide, at all stages of cytoplasmic maturity. After thesecells spend the designated transit time τ_(MKB), for example, in MKBcompartment 50, they move to the next compartment 60, which is a MK16bone marrow compartment.

[0651] The cells of MK16 compartment 60 are megakaryocytes of 16N-ploidyclass that release platelets at a constant uniform rate (γ_(MK16)) untilthey exhaust their capacity (C_(MK16), for example), and then aredisintegrated. For background details, see, Harker L A, Finch C A:Thrombokinetics in man. J Clin Invest. 1969; Vol.48; pp. 963-974; andEller J, Gyori I et al: Modelling Thrombopoiesis regulation—I: modeldescription and simulation results. Comput Math Applic. 1987; Vol. 14(9-12); pp. 841-848.

[0652] Cell volume has a linear relationship with megakaryocyte ploidy.Hence, it is assumed that all 16N-megakaryocytes have the same volumeand, thus, the same platelet-releasing capacity. For background details,see, Harker L A, Finch C A: Thrombokinetics in man. J Clin Invest. 1969;Vol.48; pp. 963-974.

[0653] Therefore all platelet-releasing 16N-megakaryocytes are intransit for the same amount of time (τ_(MK16), for example) until theyare exhausted and disintegrated.

[0654] However, some 16N-megakaryocytes do not participate in plateletrelease, but rather continue with another endomitosis over a 48-hourtime period, and become 32N-megakaryocytes. These constitute a new anddistinct MK32 compartment 70. Thus, after time μ in MK16 compartment 60,a certain fraction of the cells leave MK16 compartment 60 and go on toMK32 compartment 70.

[0655] 32N-megakaryocytes release platelets as well. The rate ofplatelet release is constant for every compartment and proportional tothe ploidy state of megakaryocytes in it. For background details, see,Harker L A, Finch C A: Thrombokinetics in man. J Clin Invest. 1969;Vol.48; pp. 963-974; and Harker L A: Thrombokinetics in idiopathicThrombocytopenic purpura. Br J Haematol. 1970; Vol. 19; pp. 95-104.

[0656] Thus, every 16N-megakaryocyte releases, for example, γ_(MK16)platelets per hour and every 32N-megakaryocyte, for example, releasesγ_(MK32) platelets per hour (twice as much). However, 32N-megakaryocytesare not exhausted more quickly than 16N-megakaryocytes, since they have2 times greater volume and platelet-releasing capacity. Consequently,all platelet-releasing megakaryocyte compartments have the same transittime.

[0657] Once again, some fraction of cells, for example Φ_(MK32), are notengaged in platelet formation, and continue to the 64N-stage. Additionalendomitosis in MK32 compartment 70 takes the same amount of time μ as inMK16 compartment 60. The 64N-megakaryocytes continue the process in anew MK64 compartment 80, and Φ_(MK64) of them become 128N-cells in yetanother MK128 compartment 90. Additional endomitosis in MK64 compartment80 takes the same amount of time μ as before. Megakaryocytes of greaterploidy classes have not been known to be encountered in humans.

[0658] Finally, there is a platelet (PL) compartment 100. This is not abone marrow compartment, but rather the platelet pool in the peripheralblood Platelets released from megakaryocytes of 16N-, 32N-, 64N-, and128N-ploidy classes enter platelet compartment 100. There are twomechanisms of platelet elimination from circulation: By age-dependentdestruction and by the normal utilization in order to maintain theintegrity of blood vessels. For background detials, see, Harker LA,Roskos L K, Marzec U M, Carter R A, Cherry J K, Sundell B, Cheung E N,Terry D, Sheridan W: Effects of megakaryocyte growth and developmentfactor on platelet production, platelet life span, and platelet functionin healthy human volunteers. Blood. 2000 April; Vol. 95(8); pp.2514-2522; and von Schulthess G K, Gessner U Oscillating platelet countsin healthy individuals: experimental investigation and quantitativeevaluation of Thrombopoietic feedback control. Scand J Haematol. 1986;Vol. 36; pp. 473-479.

[0659] The first mechanism is reflected as platelet disappearance afterthey spend their designated transit time, for example, in the PLcompartment. The second one is rather age-independent and it isreflected as constant platelet efflux (d) throughout all plateletage-stages.

[0660] IV.A.2. Model of Treatment Effects

[0661] a) A. Background of TPO

[0662] The major sites of TPO production are the liver and kidney. TPOis also produced in the spleen and bone marrow, but the production ratein these organs is 5 times lower than in the liver and kidney Forbackground details, see, Alexander W S: Thrombopoietin. Growth Factors.1999; 17(1); pp. 13-24; Sungaran R, Markovic B, Chong B H: Localizationand regulation of Thrombopoietin mRNA expression in human kidney, liver,bone marrow, and spleen using in situ hybridization. Blood. January1997; Vol. 89(1); pp. 101-107; Nagata Y, Shozaki Y, Nagahisa H, NagasawaT, Abe T, Todokoro K: Serum Thrombopoietin level is not regulated bytranscription but by the total counts of both megakaryocytes andplatelets during Thrombocytopenia and Thrombocytosis. Thromb Haemost.1997; Vol. 77; pp. 808-814; Nagahisa H, Nagata Y, Ohnuki T, Osada M,Nagasawa T, Abe T, Todokoro K: Bone marrow stromal cells produceThrombopoietin and stimulate megakaryocyte growth and maturation butsuppress proplatelet formation. Blood. February 1996; Vol. 87(4); pp.1309-1316; and Rasko J E J, Begley C G: Molecules in focus: TheThrombopoietic factor, Mpl-ligand. Int J Bioch Cell Biol. 1998; Vol. 30:657-660.

[0663] Some low TPO production has also been found in many other sitesin the body. For background details, see Nagata Y, Shozaki Y, NagahisaH, Nagasawa T, Abe T, Todokoro K: Serum Thrombopoietin level is notregulated by transcription but by the total counts of bothmegakaryocytes and platelets during Thrombocytopenia and Thrombocytosis.Thromb Haemost. 1997; Vol. 77; pp. 808-814; and Wichmann H E, GerhardtsM D, Spechtmeyer H, Gross R: A mathematical model of Thrombopoiesis inrats. Cell Tissue Kinet. 1979; Vol. 12; pp. 551-567.

[0664] Rates of liver and kidney TPO production are constant underThrombocytopenia and Thrombocytosis of varying degrees of severity. Forbackground details, see, Alexander W S: Thrombopoietin. Growth Factors.1999; 17(1); pp. 13-24; Sungaran R, Markovic B, Chong B H: Localizationand regulation of Thrombopoietin mRNA expression in human kidney, liver,bone marrow, and spleen using in situ hybridization. Blood. January1997; Vol. 89(1); pp. 101-107; and Nagahisa H, Nagata Y, Ohnuki T, OsadaM, Nagasawa T, Abe T, Todokoro K: Bone marrow stromal cells produceThrombopoietin and stimulate megakaryocyte growth and maturation butsuppress proplatelet formation. Blood. February 1996; Vol. 87(4); pp.1309-1316.

[0665] TPO production in the spleen and bone marrow is inversely relatedto the megakaryocyte mass, but the actual contribution is negligiblewith regard to total TPO production. For background details, see,Alexander W S: Thrombopoietin. Growth Factors. 1999; 17(1); pp. 13-24;and Sungaran R, Markovic B, Chong B H: Localization and regulation ofThrombopoietin mRNA expression in human kidney, liver, bone marrow, andspleen using in situ hybridization. Blood. January 1997; Vol. 89(1); pp.101-107.

[0666] Another mechanism of TPO concentration regulation isreceptor-mediated TPO uptake, since TPO-receptors on the platelet andmegakaryocyte surfaces are the main TPO-clearance mechanism. Thus, TPOconcentration is inversely related to the total platelet andmegakaryocyte mass. For background details, see, Alexander W S:Thrombopoietin. Growth Factors. 1999; 17(1); pp. 13-24; Harker L A:Physiology and clinical applications of platelet growth factors. CurrentOpinion Haematol. 1999; Vol. 6; pp. 127-134; Hsu H C, Tsai W H, Jiang ML, Ho C H, Hsu M L, Ho C K, Wang S Y: Circulating levels ofThrombopoietic and inflammatory cytokines in patients with clonal andreactive Thrombocytosis. J Lab Clin Med. 1999; Vol. 134(4); pp. 392-397;Stoffel R, Wiestner A, Skoda R C: Thrombopoietin in Thrombocytopenicmice: evidence against regulation at the mRNA level and for a directregulation role of platelets. Blood. January 1996; Vol. 87(2); pp.567-573; Alexander W S: Thrombopoietin and the c-Mpl receptor: insightsfrom gene targeting. Int J Biochem Cell Biol. 1999 October; Vol. 31(10);pp. 1027-1035. [ABSTRACT]; Miyazaki M, Fujiwara Y, Isobe T, Yamakido M,Kato T, Miyazaki H: The relationship between carboplatin AUC and serumThrombopoietin kinetics in patients with lung cancer. AnticancerResearch. 1999; Vol. 19; pp. 667-670; and Rasko J E J, Begley C G:Molecules in focus: The Thrombopoietic factor, Mpl-ligand. Int J BiochCell Biol. 1998; Vol. 30: 657-660.

[0667] The effects of TPO on the Thrombopoietic line may be divided intothree types: (i) stimulation of proliferation of megakaryocyteprogenitors that have an ability to proliferate; (ii) stimulation ofmaturation of all megakaryocyte progenitors; (iii) induction ofadditional endomitosis of already mature megakaryocytes, which leads toan increase in the modal megakaryocyte ploidy. For background details,see, Kaushansky K: Thrombopoietin: the primary regulator of plateletproduction. Blood. July 1995; Vol. 86(2), pp. 419-431; Somlo G,Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Paviovic S, BhatiaR, Chow W, Leong L, Morgan R, Margolin K, Raschko J, Shibata S, Tetef M,Yen Y, Forman S, Jones D, Ashby M, Fyfe G, Hellmann S, Doroshow J H:Recombinant Human Thrombopoietin in combination with Granulocytecolony-stimulating factor enhances mobilization of peripheral bloodprogenitor cells, increases peripheral blood platelet concentration, andaccelerates haematopoietic recovery following high-dose chemotherapy.Blood. May 1999; Vol. 93(9); pp. 2798-2806; Murray L J, Luens K M,Estrada M F, Bruno E, Hoffman R, Cohen R L, Ashby M A, Vadhan-Raj S:Thrombopoietin mobilizes CD34⁺ cell subsets into peripheral blood andexpand multilineage progenitors in bone marrow of cancer patients withnormal haematopoiesis. Exp Hem. 1998; Vol. 26; pp. 207-216; Vadhan-RajS, Murray L J, Bueso-Ramos C, Patel S, Reddy S P, Hoots W K, Johnston T,Papadopolous N E, Hittelman W N, Johnston D A, Yang T A, Paton V E,Cohen R L, Hellmann S D, Benjamin R S, Broxmeyer H E: Stimulation ofmegakaryocyte and platelet production by a single dose of recombinanthuman Thrombopoietin in patients with cancer. Ann Intern Med. May 1997;Vol. 126(9); pp. 673-681; Wichmann H E, Gerhardts M D, Spechtmeyer H,Gross R: A mathematical model of Thrombopoiesis in rats. Cell TissueKinet. 1979; Vol. 12; pp. 551-567;.Harker L A, Roskos L K, Marzec U M,Carter R A, Cherry J K, Sundell B, Cheung E N, Terry D, Sheridan W:Effects of megakaryocyte growth and development factor on plateletproduction, platelet life span, and platelet function in healthy humanvolunteers. Blood. 2000 April; Vol. 95(8); pp. 2514-2522; Swinburne J L,Mackey M C: Cyclical Thrombocytopenia: characterization by spectralanalysis and a review. J Theor Medicine. 2000; Vol. 2; pp. 81-91; RaskoJ E J, Begley C G: Molecules in focus: The Thrombopoietic factor,Mpl-ligand. Int J Bioch Cell Biol. 1998; Vol. 30: 657-660; and DeSauvage F J, Carver-Moore K, Luoh S-M, Ryan A, Dowd M, Eaton D L, MooreM W: Physiological regulation of early and late stages ofmegakaryocytopoiesis by Thrombopoietin. J Esp Med. 1996 February; Vol.183: 651-656.

[0668] b) Mathematical Model of TPO Effects

[0669] TPO concentration effects on the Thrombopoiesis line is nowconsidered. As discussed above, three things depend on TPOconcentration: (i) amplification rate (amp), (ii) the rate of cellmaturation or, alternatively, transit time through a given compartment(transit), and (iii) the fraction of megakaryocytes of given ploidy thatundergo additional endomitosis and pass on to the next ploidy class.

[0670] (1) TPO Concentration

[0671] Recombinant human full-length TPO and its truncated form rHuMGDFare fully active biologically. Therefore, in our model we addexogenously administered recombinant protein to endogenously producedTPO in order to calculate actual TPO concentration (c).

[0672] As mentioned above, the rate of TPO production in the main TPOproduction sites, i.e. liver and kidney, is constant underThrombocytopenia or Thrombocytosis. For background details, see,Alexander W S: Thrombopoietin. Growth Factors. 1999; 17(1); pp. 13-24;Sungaran R, Markovic B, Chong B H: Localization and regulation ofThrombopoietin mRNA expression in human kidney, liver, bone marrow, andspleen using in situ hybridization. Blood. January 1997; Vol. 89(1); pp.101-107; and Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T,Todokoro K: Serum Thrombopoietin level is not regulated by transcriptionbut by the total counts of both megakaryocytes and platelets duringThrombocytopenia and Thrombocytosis. Thromb Haemost. 1997; Vol. 77; pp.808-814.

[0673] The level of TPO mRNA in sites like the bone marrow and spleen,where it is produced in a 5-fold lower rate than in the liver andkidney, is not significantly different from the TPO level in peripheralblood. For background details, see Hsu H C, Tsai W H, Jiang M L, Ho C H,Hsu M L, Ho C K, Wang S Y: Circulating levels of Thrombopoietic andinflammatory cytokines in patients with clonal and reactiveThrombocytosis. J Lab Clin Med. 1999; Vol. 134(4); pp. 392-397.

[0674] Therefore, the assumption is made that the bone marrow and spleencontributions to the total TPO concentration are insignificant.Endogenously produced TPO is assumed to have a constant rate ofproduction p. However, this number can change.

[0675] The main mechanism that controls TPO concentration in the bloodis receptor-mediated TPO uptake (u). For background details, see,Alexander W S: Thrombopoietin. Growth Factors. 1999; 17(1); pp. 13-24;Harker L A: Physiology and clinical applications of platelet growthfactors. Current Opinion Haematol. 1999; Vol. 6; pp. 127-134; Hsu H C,Tsai W H, Jiang M L, Ho C H, Hsu M L, Ho C K, Wang S Y: Circulatinglevels of Thrombopoietic and inflammatory cytokines in patients withclonal and reactive Thrombocytosis. J Lab Clin Med. 1999; Vol. 134(4);pp. 392-397; Stoffel R, Wiestner A, Skoda R C: Thrombopoietin inThrombocytopenic mice: evidence against regulation at the mRNA level andfor a direct regulation role of platelets. Blood. January 1996; Vol.87(2); pp. 567-573; Alexander W S: Thrombopoietin and the c-Mplreceptor: insights from gene targeting. Int J Biochem Cell Biol. 1999October; Vol. 31(10); pp. 1027-1035. [ABSTRACT].

[0676] Another mechanism of TPO removal from the blood is non-specificTPO-receptor-independent clearance (l). This mechanism is ratherinsignificant in the normal state, when receptor-mediated TPO binding,endocytosis, and degradation remove most of the TPO. Thus, the formulathat calculates TPO concentration hourly is given in Equation 1 asfollows:

C* _(i+1) =C _(i) +p+x _(i) −u _(i) −l _(I) p,x _(i) ,u _(i) l _(i)≧0 C_(i)>0  (1)

[0677] where Ci is TPO concentration at the current hour (i); C*i+1 isapproximation of the TPO concentration at the next hour (detailedbelow); p is TPO concentration produced per hour endogenously; xi is theaddition to TPO concentration due to exogenous TPO administration; ui isTPO concentration removed from the blood by receptor-mediated binding;li is TPO concentration cleared from circulation by non-specificmechanisms.

[0678] It is assume that receptor-mediated TPO clearance depends on thetotal number of TPO receptors (n) and on the ability of each receptor touptake TPO (a):

u _(i) =n _(i) ·a n _(i) ,a≧0  (2)

[0679] where ni represents the receptor pool and a is TPO-clearingability of the receptors, i.e. amount of TPO that each receptor removesper hour.

[0680] Both, megakaryocyte and platelet mass contribute to the totalreceptor number (n) and, thus, to the rate of TPO clearance (u).15 Weassume that every platelet bears the same number of TPO receptors (mPL).The receptor number on megakaryocytes, however, changes. Thus, thereceptor pool (n) is: $\begin{matrix}{{n_{i} = {{\sum\limits_{{comp} = 1}^{4}\left( {\sum\limits_{j = 1}^{\lbrack r_{comp}\rbrack}\left( {q_{{comp},j,i} \cdot m_{{comp},j}} \right)} \right)} + {q_{PLi} \cdot m_{PL}}}}{q_{{comp},j,i},q_{{PL},i},m_{{comp},j},{m_{PL} \geq 0}}} & (3)\end{matrix}$

[0681] where comp (1 to 4) is one of the platelet releasingmegakaryocyte compartments (MK16, MK32, MK64, MK128, respectively); j isthe period (in hours) that a given megakaryocyte already spent in thespecific compartment; [τ] denotes τ rounded to an integer; q_(comp,j,i)is the quantity of the megakaryocytes of the specific compartment(comp), which spent a given period (j) in it; m_(comp,j), is thereceptor number on given megakaryocyte; q_(PL) i is the platelet number;m_(PL) is the receptor number per platelet.

[0682] It is assumed that the number of TPO receptors on eachmegakaryocyte (m_(comp,j)) equals the number of platelets that themegakaryocyte is capable of releasing (C_(comp)) times the averagenumber of receptors per every potential platelet (b).

m _(comp,j)=(C _(comp) −r _(comp) ·j)·b C _(comp) ,r _(comp) ,j,b≧0  (4)

[0683] where ccomp is the number of platelets that the megakaryocyte ofthe specific compartment comp can release during its entire life-span(τ_(comp)); rcomp is the rate of platelet release by the megakaryocyte;j is the period that this megakaryocyte already spent in thiscompartment; b is the number of receptor on the megakaryocyte perpotential platelet.

[0684] It is also assumed that the non-specific TPO clearance (_(li)) isexponential, i.e. every hour some fraction (f) of a current amount ofTPO (_(Ci)) is removed from circulation:

l _(i) =f·C _(i) f≧0  (5)

[0685] where f is the coefficient of non-specific TPO clearance and Ciis the current TPO concentration. Other modes of non-specific TPOremoval can be assumed as well. Exogenous TPO is included in the modelas a linear relation of the initial maximum TPO blood concentration(x_(i)) to the administered intravenous (IV) dose (s) (the relationcoefficient is 0.0167) 21:

x _(i)=0.0167·s _(i) s _(i)≧0  (6)

[0686] The state when TPO completely disappears from the blood seemsvery unlikely based on biological logic, so we restricted the lowerlimit of possible TPO concentration to certain minimum ε (positive).Thus, the equation (1) is modified to receive the full TPO concentrationequation:

C _(i+1)=max((C _(i) +p+x _(i) −a·n _(i) −f·C _(i)),ε) ε>0  (7)

[0687] In steady state, the TPO concentration (C) is constant.

[0688] (2) TPO Effects on Amplification Rate

[0689] In the disclosed model, there are only two compartments, SCcompartment 30 and CFU-Meg compartment 40, whose cells are capable ofdividing. These compartments differ significantly from each other, thus,we shall discuss them separately. Cells of other model compartments donot proliferate, and so their amplification rate equals 1 under allcircumstances.

[0690] SC compartment 30:

[0691] Since TPO is primarily a Thrombopoiesis-stimulating cytokine, weassume that the cells, which are not committed to Thrombopoietic lineyet (the SC compartment in our model), are relatively insensitive toTPO, compared to committed megakaryocytic cells. In the disclosed modelthis is considered as a threshold (θ) in TPO concentration. Only abovethis threshold (θ) TPO affects stem cells. As long as TPO remains belowthe threshold (θ), stem cells in the model are regulated by intrinsicTPO-independent mechanism that keeps the size of their population almostconstant.

[0692] Thus, below the threshold (θ), SC amplification rate (α_(SC)) isdetermined hourly depending on the current number of cells in the SCcompartment. It is biologically reasonable that the dependence equationis a sigmoidal function where α_(SC) changes from 1 (i.e., noamplification, the cell number remains the same) when the cell numberapproaches infinity, up to the maximal value α_(SCw) when the cellnumber approaches zero. The increase in amplification rate (α_(SC)) isrelatively gradual as long as the cell number (q_(SCi)) exceeds certaincritical value (we assumed it to be a fraction (ν) of the normal cellnumber (q_(SCnorm))). However, when the cell number falls bellow thisthreshold, α_(SC) begins to increase rapidly in order to restore the SCcompartment as soon as possible. It is assumed that at normal cellnumbers (q_(SCnorm)), α_(SCi) should be a fraction (γ) of its maximalvalue α_(SCw). Following is an example of such equation: $\begin{matrix}{\underset{C_{i} \leq \theta}{\alpha_{{SC},{i + 1}}^{*}\left( {q_{{SC},i},C_{i}} \right)} = \left\{ {{\begin{matrix}{\quad {{{\left( {\alpha_{SCw} - 1} \right) \cdot \frac{1}{{\left( {\frac{1}{y} - 1} \right) \cdot \left( \frac{q_{{SC},i}}{q_{{SC},{norm}}} \right)^{S_{i}}} + 1}} + 1},{q_{{SC},i} \geq {v \cdot q_{{SC},{norm}}}}}} \\{\quad {{\alpha_{SCw} - {\left( {\alpha_{SCw} - \alpha_{SC}^{\sim}} \right) \cdot \left( \frac{q_{{SC},i}}{v \cdot q_{{SC},{norm}}} \right)^{S_{2}}}},{q_{{SC},i} < {v \cdot q_{{SC},{norm}}}}}}\end{matrix}\alpha_{SC}^{\sim}} = \left. {{\left( {\alpha_{SCw} - 1} \right) \cdot \frac{1}{{\left( {\frac{1}{y} - 1} \right) \cdot v^{S_{i}}} + 1}} + 1} \middle| \begin{matrix}{\quad {q_{SC},S_{1,2},{\theta \geq 0}}} \\{\quad {\alpha_{SCw} \geq 1}\quad} \\{\quad {{0 < y},{v \leq 1}}\quad}\end{matrix} \right.} \right.} & (8)\end{matrix}$

[0693] where α*_(SC,i+1) is the amplification rate calculated basedsolely on the cell number; α_(SCw) is the maximal possible rate of cellamplification in the SC compartment when TPO concentration (Ci) is belowthe threshold; q_(SC,i) is a quantity of cells in the SC compartment;q_(SC) norm is the normal quantity of cells there. S1 and S2 are thesensitivity coefficients in the regions of q_(SC,i) higher or lower thanthe critical value (vq_(SCnorm)), respectively. These values determinethe sensitivity of the mechanism that links the amplification rate(α_(SC)) with the cell number (q_(SC,i)). In other words, they determinethe steepness of the dependence curve in the corresponding regions. HighS1 or S2 mean that α_(SC) changes significantly due to slight changes ofq_(SC), and low S1 or S2 mean that α_(SC) remains relatively constantwhatever the changes of q_(SC) are. Distinguishing between S1 and S2allows us to force the amplification rate (α_(SC)) to grow rapidly asthe cell number (q_(SC,i)) falls below the critical value, therebyincreasing the resistance of the system to further cell number(q_(SC,i)) decay. Although the symbols S1 and S2 appear in severalequations, their values are specific for every equation.

[0694] It is suggested that TPO concentration (C) increase above thethreshold should occur in severe platelet and/or megakaryocytedeficiency, or when TPO is administered exogenously. It is assumed thatat these circumstances, TPO further increases the rate of cellamplification in the “Stem Cell” compartment (α_(SC)). It is alsoassumed that the increase is proportional to the difference betweenactual TPO concentration (Ci) and the threshold. Thus, TPO effectsappear gradually from the zero increase, when TPO concentration (Ci)equals the threshold. Saturation of the mechanisms of TPO effect isreflected in the concavity of the effect function.

[0695] The following is an example of such a function: $\begin{matrix}{{{\alpha_{{SC},{i + 1}}\left( {\underset{C_{i} > \theta}{q_{{SC},i}},C_{i}} \right)} = {{\alpha_{{SC},{i + 1}}^{*}\left( {q_{{SC},i},C_{i}} \right)} + {{t \cdot {\ln \left( {C_{i} - \theta + 1} \right)}}\quad t}}},{\theta \geq 0}} & (9)\end{matrix}$

[0696] where α*_(SC,i+1) is the same expression as in equation (8), i.e.amplification calculated based on a TPO-independent mechanism, and thesecond operand is the TPO-related contribution to the amplification rate(α_(SC,i+1)). t determines the steepness of the dependence curve (t isnon-negative). Although the symbol t appears in several equations, itsvalue is specific for every equation. One is added to the ln argument inorder to ensure positivity of the ln result.

[0697] CFU-Meg compartment 40:

[0698] In contrast to the cells of the SC compartment, we assume thatcells of this compartment are fully sensitive to TPO and respond to theabsolute TPO concentration (Ci), not to its difference with a threshold(Ci−θ). In the disclosed model, there is no TPO-independentproliferative mechanism, and CFU-Meg cease to proliferate when deprivedof TPO. On the other hand, when TPO concentration (Ci) in the systemincreases, α_(CFU) does not rise to infinity, but rather graduallyreaches saturation, which also seems reasonable biologically. At normalTPO concentrations (C_(norm)), we assume α_(CFU) to be a fraction (h) ofits maximal value (α_(CFUmax)). Thus an equation that describes therelation of the amplification rate of CFU-Meg cells (α_(CFU)) to TPOconcentration (Ci) represents a sigmoidal function with α_(CFU) equaling1 when TPO concentration (Ci) is zero, passing through h timesα_(CFUmax) when TPO concentration is normal (Ci), and approaching anasymptote in α_(CFUmax) when TPO concentration (Ci) approaches infinity.In addition, in order to enable the system to be sensitive both to theregulation by endogenously produced TPO and to the effect of theexogenously administered drug, it was assumed that the function changesrelatively rapidly in the region of normal TPO concentration (C_(norm))and with a much smaller rate when a TPO concentration (Ci) is somewhathigher than normal (C_(norm)). The following is an example of such afunction: $\begin{matrix}{{\alpha_{{CFU},{i + 1}}\left( C_{i} \right)} = \left. {{\left( {\alpha_{{CFU}\quad \max} - 1} \right) \cdot \left( {1 - \frac{1}{{\frac{1}{\frac{1}{h} - 1} \cdot \left( \frac{C_{i}}{C_{norm}} \right)^{t}} + 1}} \right)} + 1} \middle| \begin{matrix}{\quad {C_{norm} > 0}\quad} \\{\quad {t \geq 0}\quad} \\{\quad {0 < h \leq 1}\quad}\end{matrix} \right.} & (10)\end{matrix}$

[0699] where α_(CFU,i+1) is an amplification rate of the CFUcompartment; α_(CFUmax) is a maximal value of amplification rate there;C_(norm) is normal TPO concentration; t is the parameter that determinesthe steepness of the dependence curve.

[0700] (3) TPO Effects on Transit Time

[0701] For the reason noted earlier, it is assumed that allplatelet-releasing megakaryocyte compartments have the same transit time(τ_(MK)). It is also assumed that neither the relation of megakaryocytevolume (and thus, its platelet releasing capacity C_(comp)) nor of itsrate of platelet release rcomp to megakaryocyte ploidy, is affected byTPO. Therefore, the transit time (τ_(MK)) through the noted compartmentsis constant. Platelets also spend in average a constant time in thecirculation (τ_(PL)), which is not affected by TPO concentration (Ci).

[0702] In contrast, the transit times of the SC, CFU-Meg, and MKBcompartments (τ_(SC), τ_(CFU), τ_(MKB), respectively) are functions ofthe micro-environmental conditions. Since cells that are far frommaturation are not expected biologically to undergo a sudden shift tomaturation, it seems that these functions determine the value thetransit time should approach, rather than the actual transit time. Theactual transit time changes gradually: every hour it changes by 1-2hours towards the function-determined value. Thus, the mean of the valueis determined, that transit time approaches rather than the transit timeitself when speaking about transit time (τ) calculations below.

[0703] a. SC Compartment:

[0704] It is assumed that regarding transit time (τ_(SC)), the SCcompartment differs from others in the same way as regardingamplification rate (α_(SC)). It means that the cells of this compartmentrespond to TPO only when its concentration (Ci) rises above a threshold(θ). This threshold is the same as for the amplification rate (α_(SC)).Below the threshold SC transit time is assumed to be regulated by aTPO-unrelated mechanism dependent on the current cell number (q_(SCi))only. The function of this dependence changes the transit time from itsminimal value (τ_(SCu)) when the cell numbers (q_(SCi)) approachinfinity, through the normal value that is greater than the minimal oneby factor g, up to the highest value ((τ_(SCmax)) determined solely bybiological reasons. This means that when the cell number in SCcompartment (q_(SCi)) is relatively large, the cells will passrelatively rapidly to the next compartment, thus reducing the SC one;and they will remain longer in the SC compartment when their number(q_(SCi)) is low, thus repopulating it. This manner of regulation seemsreasonable biologically.

[0705] It is suggested that similar to the amplification rate (α_(SC)),the transit time (τ_(SC)) in the range of very low cell numbers(q_(SCi)) (lower than a certain fraction (ν) of the normal(q_(SCnorm))), is very sensitive to further cell number decrease, andgrows rapidly, thereby resisting compartment exhaustion. This fraction(ν) is the same as for the SC amplification rate.

[0706] Following is an example of such a function: $\begin{matrix}{\underset{C_{i} \leq \theta}{\tau_{{SC},{i + 1}}^{*}\left( {q_{{SC},i},C_{i}} \right)} = \left\{ {{\begin{matrix}{\quad {{\tau_{SCu} \cdot \left( {1 + {\left( {g - 1} \right) \cdot \left( \frac{q_{{SC},{norm}}}{q_{{SC},i}} \right)^{S_{1}}}} \right)},{q_{{SC},i} \geq {v \cdot q_{{SC},{norm}}}}}} \\{\quad {{\tau_{{SC}\quad \max} - {\left( {\tau_{{SC}\quad \max} - \tau_{SC}^{\sim}} \right) \cdot \left( \frac{q_{{SC},i}}{v \cdot q_{{SC},{norm}}} \right)^{S_{2}}}},{q_{{SC},i} < {v \cdot q_{{SC},{norm}}}}}}\end{matrix}\tau_{SC}^{\sim}} = \left. {\tau_{SCu} \cdot \left( {1 + {\left( {g - 1} \right) \cdot \frac{1}{v^{S_{1}}}}} \right)} \middle| \begin{matrix}{\quad {S_{1,2} \geq 0}} \\{\quad {\tau_{SCu} > 0}} \\{\quad {g \geq 1}} \\{\quad {0 < v \leq 1}}\end{matrix} \right.} \right.} & (11)\end{matrix}$

[0707] where τ*_(SC,i+1) is the transit time calculated based on cellnumbers (q_(SC,i)) only, i.e. when TPO concentration (Ci) remains belowthe threshold; τ_(SCu) is the minimal possible transit time through SCcompartment in these circumstances; ν is the fraction of normal cellnumber (q_(SCnorm)), below which the dependence of the transit time(τ*_(SC,i+1)) on the cell number (q_(SC,i)) changes; S1 and S2 are thesensitivity coefficients in the regions of q_(SC,i) lower and higherthan vqSCnorm, respectively.

[0708] If TPO concentration (Ci) in the model rises above the threshold,the transit time (τ_(SC)) is assumed to shorten in a dose dependentmanner. As for the amplification rate (α_(SC)), its decrease is presumedto be proportional to the difference between actual TPO concentration(Ci) and the threshold. However, a shortening of the transit time downto zero by TPO is biologically illogical, so we assume that the transittime (τ_(SC)) approaches some minimal value as TPO concentration (Ci)increases. In our model this minimum represents a fraction (k) of thetransit time calculated on the basis of cell numbers (τ*_(SC,i+1)) asdescribed earlier (equation (11)).

[0709] Following is an example of such an equation: $\begin{matrix}{{\underset{C_{i} > \theta}{\tau_{{SC},{i + 1}}\left( {q_{{SC},i},C_{i}} \right)} = {{\tau_{{SC},{i + 1}}^{*}\left( {q_{{SC},i},C_{i}} \right)} \cdot k \cdot \left( {\frac{1}{{t \cdot \left( \frac{C_{i} - \theta}{C^{*} - \theta} \right)^{t}} + \frac{k}{1 - k}} + 1} \right)}}{0 < k \leq {1\quad t} \geq 0}} & (12)\end{matrix}$

[0710] where τ_(SC,i+1) is the transit time when TPO concentration (Ci)is higher than the threshold; τ*_(SC,i+1) is the transit time calculatedon the basis of cell numbers as described in equation (11); k is thefraction of τ*_(SC,i+1) that gives the minimum transit time approachesas TPO concentration (Ci) increases; C* determines the point of TPOconcentration (Ci), around which the transit time (τ_(SC)) is the mostsensitive to concentration (C) change; t determines the steepness of thedependence curve (t is non-negative). Multiplication by t enables toregulate the sensitivity to Ci with t<1 in the same manner as when t>1.

[0711] b. CFU-Meg and MKB Compartments:

[0712] It is assumed that the transit time parameters of these twocompartments (τ_(CFU), τ_(MKB), respectively) are dependent solely onTPO and respond to the absolute TPO concentration (Ci), rather than toits difference with a threshold (Ci−θ). As TPO level (Ci) drops, thecell passage through these compartments slows, i.e. transit time(τ_(comp)) increases up to the values limited solely by biologicalreasons (τ_(comp,max)) (it is assumed that the cells cannot stay inthese compartments for an infinite period of time). On the other hand,when the TPO concentration (Ci) in the system increases, τ_(comp) doesnot shorten to zero, but rather asymptotically reaches τ_(comp,min),thus bounding the function from below. This also seems biologicallyreasonable, as the cells cannot move through the compartment in oneinstant. At normal TPO concentrations (Cnorm), we set τ_(comp) to equalits normal value (τ_(comp,norm)). In addition, in order to enable thesystem to be sensitive both to the regulation by endogenously producedTPO and to the effect of the exogenously administered drug, it wasassumed that the function changes relatively rapidly in the region ofTPO concentrations (Ci) lower than normal (C_(norm)) and with a smallerrate when a TPO concentration (Ci) is higher than normal (C_(norm)). Thefollowing is an example of such a function: $\begin{matrix}{\tau_{{comp},{i + 1}} = \left\{ \begin{matrix}{{\tau_{{comp},\max} - {\left( {\tau_{{comp},\max} - \tau_{{comp},{norm}}} \right) \cdot \left( \frac{C_{i}}{C_{norm}} \right)^{t_{1}}}},{C_{i} \leq C_{norm}}} \\{{{\left( {\tau_{{comp},{norm}} - \tau_{{comp},\min}} \right) \cdot \frac{2}{\left( \frac{C_{i}}{C_{norm}} \right)^{t_{2}} + 1}} + \tau_{{comp},\min}},{C_{i} > C_{norm}}}\end{matrix} \middle| \begin{matrix}{\quad {0 < \tau_{{comp},\min} \leq \tau_{{comp},{norm}} \leq \tau_{{comp},\max}}} \\{\quad {t_{1,2} \geq 0}}\end{matrix} \right.} & (13)\end{matrix}$

[0713] where comp is one of the aforementioned compartments (CFU-Meg orMKB); τ_(comp,i+1) represents the transit times through thesecompartments; τ_(comp,min), τ_(comp,norm), and τ_(comp,max) are theminimal, normal and maximal transit times when TPO concentration isnormal; t1 and t2 determine the steepness of the dependence curve in theregions of Ci lower and higher than Cnorm, respectively.

[0714] (4) TPO Effects on the Fraction of Cells that Flow from oneCompartment to the Next.

[0715] The discussed parameter is the proportion of cells that passes tothe next compartment at any given moment (φ). As was noted earlier, itis assumed that the fraction of the SC that commits to themegakaryocytic lineage (φ_(SC)) is constant and TPO-independent. TPO inour model does not affect the two subsequent compartments, CFU-Meg andMKB.

[0716] In contrast, the fractions of MK16-, MK32-, andMK64-megakaryocytes that undergo additional endomitoses and flow to thenext compartment (φ_(comp)) are assumed to be in the range of 0 to 1depending on TPO concentration (Ci). Because there is no compartmentwith ploidy greater than 128N, the megakaryocytes of the MK128compartment do not flow to any other compartment.

[0717] The dependence of MK16, MK32, and MK64 φ parameters on TPOconcentration assumed to be delayed with φ calculated based on TPOconcentration prior to last endomitosis (Ci−μ).

[0718] In the model, this dependence is expressed by a sigmoidalfunction with φ set to 0 when TPO concentration (Ci) is 0, equaling thenormal value (φ_(norm)) when TPO concentration is normal (C_(norm)), andapproaching 1 asymptotically. $\begin{matrix}{{{\phi_{{comp},{i + 1}}\left( C_{i - \mu} \right)} = {1 - \frac{C_{norm}^{t} \cdot \left( {\frac{1}{\phi_{{comp},{norm}}} - 1} \right)}{C_{i - \mu}^{t} + {C_{norm}^{t} \cdot \left( {\frac{1}{\phi_{{comp},{norm}}} - 1} \right)}}}}{{0 \leq \phi_{{comp},{norm}} \leq {1\quad t}},{\mu \geq 0}}} & (14)\end{matrix}$

[0719] where comp is one of the discussed compartments (MK16, MK32, orMK64); φ_(comp,i+1) is a φ parameter of these compartments; μ is thetime needed for one additional endomitosis; φ_(comp,norm) is the valueof φ_(comp) under normal TPO concentration (C_(norm)); t determines thesteepness of the dependence function (t is non-negative).

[0720] The time needed for an additional endomitosis (μ) assumed to bethe same in the three relevant compartments (MK16, MK32, and MK64).

[0721] IV.A.3. Complete Detailed Model

[0722] The complete model was built as an imitation of what happens inreal bone marrow. Each compartment is subdivided into small sectionsthat contain the cells of a specific age with a resolution of one hour.For example, the fifth age-section of MKB compartment 50 contains cellswithin MKB compartment 50 that have been within that compartment for 5hours. Every hour, all the cells in the “bone marrow” pass to the nextage-section in the same compartment.

[0723] When the cell has spent all the transit time predetermined for itin a given compartment, it passes to the next compartment to the zeroage-section. Thus, every hour the cells that leave one compartment fillthe zero age-section of the next one. The cells that leave MK128compartment 90 die. The zero age-section of SC compartment 30 is filledby a certain fraction of the cells that leave SC compartment 30.

[0724] The cells that release platelets add a certain platelet number tothe zero age-section of PL compartment 100 every hour.

[0725] Reference is now made to FIG. 4, which is an illustration of theimplementation of the model. The model is implemented as a chart of 8rows and 360 columns. The 8 rows relate to 8 cell compartments, and thecolumns relate to the age sections, with the assumption that transittime does not exceed 360 hours. This chart is updated hourly accordingto the rules described above.

[0726] Reference is now made to FIG. 5, which shows a graphicalrepresentation of the chart of FIG. 4. Within the compartments whereproliferation occurs (SC and CFU-Meg), the number of proliferating cellsincreases from the first to the last age-section. In contrast, the cellnumber in the compartments that have no proliferating ability remainsconstant (MKB, MK128, PL), or decreases when cells that have undergoneadditional endomitosis leave the compartment for the next one (MK16,MK32, MK64).

[0727] Reference is now made to FIG. 6, which is an illustration ofanother representation of the model, based on the time courses ofdifferent compartments. The rows in the chart represent cellcompartments and the columns represent time of simulation course. Atevery time-step of the simulation (one hour of “patient's life”), thenumber of cells in all age-sections is summarized for each compartmentand the next column in time-course chart (FIG. 6) is filled. Thus, everycell in the chart represents the total number of cells in a givencompartment at a given time point.

[0728] There is an additional row in the time-course chart that relatesto the TPO concentration in the blood. TPO concentration is monitoredand out-put every time-step concurrently with the cell numbers.

[0729] Reference is now made to FIG. 7, which is a graphicalrepresentation of the chart of FIG. 6, and is the most useful modeloutput The implementation of the described model results in a computersimulator that describes the changes that occur in the humanThrombopoietic system (platelet counts, bone marrow precursor numbers,and TPO concentration) over a time span that may last several years. Theresolution of the simulator output is one hour.

[0730] Time units and periods that will mentioned hereafter relate tothe simulated patient's life, rather to the running time of the program.

[0731] IV.A.4. Parameter-Specific Adaptation of Model

[0732] This model may be fit to patients with diverse blood and bonemarrow parameters. People differ in their baseline platelet counts andnumbers of bone marrow precursors, in the sensitivity of their stem cell“intrinsic” regulation mechanism, in their minimum and normal transittimes and maximal amplification rates, rates of platelet release bymegakaryocytes, fractions that each megakaryocyte ploidy classcontribute for additional endocytosis, and the time needed forendomitosis (μ). Furthermore, the baseline TPO level, the rate of TPOproduction, receptor- and non-receptor-mediated TPO clearance, thethreshold of TPO effect on the SC compartment, and the sensitivity ofdifferent cell parameters to TPO also differ between patients.

[0733] To obtain an ideal fitness of the model to each patient, thepatient-related parameters should be given individually for eachpatient. However, practically, it would be extremely difficult topredetermine many of these parameters for every patient. Therefore,certain average parameters have been calculated based on published data,and are shown in Table 1 below. These averaged parameters are used as aframework into which known individual characteristics are included.Thus, before a particular simulation is begun, relevant knowninformation about the individual may be included, sometimes replacingcertain parameters of the model. TABLE COMMON PARAMETERS CompartmentParameter SC CFU-Meg MKB MK16 MK32 MK64 MK128 PL q_(norm) 480 650 59593900 1380 15 3 17,857,000 (×1000/kg body weight) τ_(min) (τ_(u) in SC)12 30 143 — — — — — (hours) τ_(norm) — 60 186 250 250 250 250      240(hours) τ_(max) 350 360 360 — — — — — (hours) ψ_(norm) 0.2846 1 1 0.26820.0128 0.1685 — — (/hour) c — — — 4000 8000 16000 32000 — (platelets) r— — — 11.19 22.38 44.76 89.52 (platelet/hr) STEEPNESSES (t) OF THETPO-SENSITIVITY CURVES a_(SC) a_(CFU) τ_(SC) τ_(CFU)(t₁) τ_(CFU)(t₂)τ_(MKB)(t₁) τ_(MKB)(t₂) ψ_(MK16) ψ_(MK32) ψ_(MK64) 0.02 0.1 0 10⁻¹⁰ 1 11 2 2 4 SC-RELATED PARAMETERS S₁ for S₂ for S₂ for ν a_(SC) a_(SC) S₁for τ_(SC) τ_(SC) k a_(ω) γ g 0.01 0.5 0.5 1 0 0.5 1.116 0.25 5TPO-RELATED PARAMETERS a (pg/ml/hr/ p θ ƒ receptor C_(norm) ε C* (pg/ml)(pg/ml) (/hr) molecule) (pg/ml) (pg/ml) (pg/ml) 48 10,000 0.1 38 1000.01 θ+ 50 OTHER PARAMETERS d (fraction from each age- μ section per(hours) m_(PL) b a_(CFUmax) h hour) 16 220 220 1.204 0.125 2.59 × 10⁻⁴

[0734] Usually, the known patient-related data are not parameters in theform defined by our model, but rather measurements obtained in theclinic (e.g., day and value of post-chemotherapy Thrombocytopenia nadir,day and value of platelet peak after TPO administration, change inmegakaryocyte modal ploidy following some perturbation, etc.). In thesecases, the available data is converted into a model-compatible format.

[0735] Sometimes, the only available patient-related data are thegraphic representation of the patient's platelet course following someperturbation (e.g., cell-suppressive therapy or TPO administration). Thedata may also be a picture of the platelet course without any externaldisturbance (e.g., cyclic Thrombocytopenia). In these cases the modelparameters are changed by trial-and-error until a good compliance of themodel graphic output and the patient's graphs is achieved. It should benoted, however, that even in the case of trial and error, the choices ofparameter sets are not random but rather are also based on someanalysis.

[0736] Specifically, the following tools are available for providingmaximum flexibility:

[0737] 1) The user can set the baseline values and all other knownpatient-specific Thrombopoietic parameters before starting thesimulation.

[0738] 2) The user (e.g., physician) can determine how long of a timeperiod to simulate, from a number of hours up to several years.

[0739] 3) The user can determine the frequency of showing the course ofa patient counts up to the moment. The frequency can change from as muchas every 12 hours to once during the overall period of simulation.

[0740] 4) The user can determine the resolution of the output graph,from the hourly representation of the patient's state down to any otherresolution.

[0741] 5) The user can choose to view the graphical representation ofthe age distribution through the compartments at any moment of thesimulation.

[0742] 6) The user can simulate a cell-suppressive therapy at any momentwhile running the simulation by reducing one or several of thecompartments by any value.

[0743] 7) The user can simulate exogenous TPO administration at anymoment while running the simulation by controlling dose height, numberof dosings or frequency of dosings.

[0744] The simulation tool has been carefully tested with respect to thepublished experimental results, and has proved to be well calibrated foraverage human data. Parameters may be modified relatively quickly forefficient use of the system. The following model parameters areimportant for individualized adjustment of the model:

[0745] baseline number of: SC, CFU-Meg, MKB, MK16, MK32, platelets.

[0746] amplification rate of: SC, CFU-Meg.

[0747] transit time of: MKB, MK16, MK32, MK64.

[0748] fraction undergoing additional endomitosis in: MK16, MK32, MK64.

[0749] rate of platelet release of: MK16, MK32, MK64, MK128.

[0750] Time needed for additional endomitosis.

[0751] Rate of endogenous TPO production.

[0752] Ratio of receptor- and non-receptor-mediated TPO clearance.

[0753] Steepness of the sensitivity curve of: CFU-Meg amplificationrate; MKB transit time; MK16, MK32, and MK64 fraction undergoingadditional endomitosis.

[0754] Reference is now made to FIGS. 8A, 8B, 9A and 9B, which show acomparison between experimentally obtained data and the simulated model.Experimentally obtained in vivo platelet counts following TPOadministration are shown in FIG. 8A and chemotherapy without TPO isshown in FIG. 9A. FIGS. 8B and 9B show simulations of the same. By usinga TPO schedule designed by the described model, one can obtain plateletprofiles that are similar to those obtained clinically (FIG. 8B) or evenmore effective (FIG. 9B). In this case, these results are achieved byadministering a pre-calculated TPO protocol whose total dose amounts to25% of the original total dose.

[0755] The complete model simulates cell and platelet counts in thesteady state, as well as after perturbations to the haematopoieticsystem, e.g., cell-suppressive therapy, recombinant Thrombopoietinadministration for uses such as platelets harvesting, etc. It ispossible to simulate any protocol of drug administration and anyhaematological state of a patient, regarding his/her platelet count andnumber of bone marrow megakaryocytes and their precursors. The model canbe adapted to many categories of patients, or healthy platelet donors.It can also be modified to fit species other than human. By providingspecific parameters one can adjust the model so as to yield particularpredictions about the Thrombopoietic profile of an individual patient.Other platelet disorders, such as cyclic Thrombocytopenia, may also besimulated.

IV.B. Neutrophil Production in the Bone Marrow and its Concentration inthe Peripheral Blood Compartment Alone or Under the Effects ofGrowth-Factors and Treatment with Granulocyte Colony Stimulating Factor(G-CSF)

[0756] Another embodiment of the present invention involves thedisclosed techniques for Neutrophil lineage, Granulopoietic disorders,including Neutropenia and its treatment with GCS-F. The Neutrophillineage originates in pluripotent stem cells that proliferate and becomecommitted to the Neutrophil lineage. These cells then undergo gradualmaturation accompanied with further proliferation. The present modeluses the state-of-the-art discrete compartmentalization of thiscontinuous maturation-proliferation process, but is not restricted to itand can easily accomodate other modes of describing this continuousprocess using.

[0757] It is customary to divide the neutrophil maturation process inthe bone marrow into three morphologically distinguishable mitoticcompartments: Myeloblasts, promyelocytes and myelocytes.

[0758] The myelocytes then mature and lose their capacity toproliferate, and thus enter the post mitotic compartment. In thepost-mitotic compartment the cells continue their gradual maturation,which is not accompanied with proliferation through the threemorphologically distinguishable sub-compartments: Metamyelocyte, bandand segmented-Neutrophils. Cells exit the various sub-compartments inthe post-mitotic compartment and enter the blood as Neutrophils. Theythen migrate from the blood to the tissues.

[0759] The Granulocyte-Colony Stimulating Factor (G-CSF) generates anincrease in blood Neutrophil levels primarily by increasing productionin the mitotic compartment and shortening the transit time of thepost-mitotic compartment.

[0760] Thus, the first compartment of the mitotic pool (myeloblast)receives an inflow of cells from stem-cell precursors. Inflow for eachof the other compartments is from outflow of the previous one, subjectto multiplication factors due to cell replication in the mitotic stages.

[0761] Models regarding Granulopoiesis in normal humans and in humanswith pathologies of the bone marrow were suggested previously in orderto give a coherent description of the kinetics of Granulocytes fromexperimental data. For background details, see, Cartwright G E, Athens JW, Wintrobe M M. 1964. The kinetics of Granulopoiesis in normal man.Blood. 24(6): 780-803;

[0762] In recent years Schmitz et al. developed a kinetic simulationmodel for the effects of G-CSF on Granulopoiesis (for further details,see Schmitz, S., Franke, H., Brusis, J., Wichmann, H. E. 1993.Quantification of the Cell Kinetic Effects of G-CSF Using a Model ofHuman Granulopoiesis. Experimental Haematology. 21:755-760), and used itfor the analysis of administration of G-CSF to patients suffering fromcyclic Neutropenia (for further details, see Schmitz, S., Franke, H.,Wichmann, H. E., Diehl, V. 1995. The Effect of Continuous G-CSFApplication in Human Cyclic Neutropenia: A Model Analysis. BritishJournal of Haematology. 90:41-47.). However, the data Schmitz rests uponfor his model has been more accurately assessed in recent years by Priceet al. and Chatta et al. For further details, see Price T H, Chatta G S,Dale D C. 1996. Effect of Recombinant Granulocyte Colony-StimulatingFactor on Neutrophil Kinetics in Normal Young and Elderly Humans. Blood.88(1): 335-40; and Chatta G S, Price T H, Allen R C, Dale D C. 1994.Effects of in vivo Recombinant Methionyl Human GranulocyteColony-Stimulating Factor on the Neutrophil Response and PeripheralBlood Colony-Forming Cells in Healthy Young and Elderly AdultVolunteers. Blood. 84(9): 2923-9. Actual empirical data regardingcompartment sizes and their transit times was not incorporated intotheir model despite the importance of these data (For further details,see Dancey J T, Deubelbeiss K A, Harker L A, Finch C A. 1976. NeutrophilKinetics in Man. J Clin Invest. 58(3): 705-15).

[0763] IV.B.1. Model of Neutrophil Lineage and Effects of G-CSF

[0764] a) G-CSF

[0765] The effects of G-CSF on the Neutrophil lineage are relayed in themodel in three stages. The first is the administered amount of cytokinegiven at time t, which is marked: G_(adm)^(t)

[0766] The G_(adm) vector serves as the control variable foroptimization of G-CSF administration.

[0767] The second stage represents the pharmacokinetic behavior of G-CSFin circulation. It incorporates, for instance, the half-life of G-CSF,and could in the future be modified to express more of the effects oftime on G-CSF activity. This level is marked: G_(blood)^(t)

[0768] G-CSF is eliminated from the blood in a Poissonic manneraccording to the following equation, as stated by Stute N, Furman W L,Schell M and Evans W E in “Pharmocokinetics of recombinant humanGranulocyte-macrophage colony stimulating factor in children afterintravenous and subcutaneous administration”” Journal of PharmaceuticalScience, 84(7): 824-828, 1995: $\begin{matrix}{G_{blood}^{t + 1} = {{G_{blood}^{t}\left( {1 - \frac{\ln \quad 2}{{\overset{\sim}{t}}_{\frac{1}{2}}}} \right)} + G_{adm}^{t + 1}}} & (14)\end{matrix}$

[0769] where {tilde over (t)}_(1/2) is the half-life of G-CSF in theblood, and G_(blood) ¹=G_(adm) ¹.

[0770] Recent data by Terashi K, Oka M, Ohdo S, Furudubo T, Ideda C,Fukuda M, Soda H, Higuchi S and Kohno S, in “Close association betweenclearance of recombinant human Granulocyte colony stimulating factor(G-CSF) and G-CSF receptor on Neutrophils in cancer patients”,Antimicrobial Agents and Chemotherapy, 43(1): 21-24, 1999, points to thedependence of the half-life of G-CSF on Neutrophil counts. In theabsence of exact kinetics of G-CSF effects on the Neutrophil lineage,the half-life is considered as a constant, though this could be modifiedshould more exact information emerge.

[0771] Only exogenously produced G-CSF is considered to affect thekinetic parameters, and endogenously produced G-CSF levels and effectsare set to zero. If more empirical data regarding the production ofendogenous G-CSF is made available, it could be incorporated into theequation as well.

[0772] The third and final stage models the pharmacodynamic effects ofG-CSF on the kinetic parameters. As will be elaborated subsequently, thedependence of the various kinetic parameters of the Neutrophil lineageon the level of G-CSF in the blood is assumed to be through eithernon-decreasing concave or non-increasing convex functions. Thisreproduces the effects of saturation that are seen in clinical studieson the effects of G-CSF, such as the study by Duhrsen U, Villeval J L,Boyd J Kannourakis G, Morstyn G and Metcalf D in “Effects of recombinanthuman Granulocyte colony-stimulating factor on haematopoietic progenitorcells in cancer patients”, Blood, 72(6): 2074-2081, 1988. That is,addition of G-CSF carries a lesser effect when its level in circulationis already high.

[0773] b) Biological Mode

[0774] (1) Mitotic Compartment

[0775] Long-term effects of G-CSF administration take place in themitotic compartment. Although the major contributor to heightened bloodNeutrophil counts in the short term is the post mitotic compartment'sshortening of transit time due to G-CSF administration, this high levelcannot be maintained over the long term without increased production inthe mitotic compartment.

[0776] The mitotic compartment is divided into subcompartments. The kthsubcompartment contains all cells of chronological age between k−1 and khours, relative to the time of entry into the mitotic compartment. Thenumber of cells in subcompartment k at time t is marked as m_(k)^(t).

kε{1 . . . τ}

[0777] $\begin{matrix}{m_{1}^{t} = {l_{1}^{t}\left( G_{blood}^{t} \right)}} & (15)\end{matrix}$

[0778] where τ is the transit time of the entire mitotic compartment,and is assumed to be the same and constant for all cells entering themitotic compartment, and l₁ is a vector reflecting the flow of newlycommitted cells into the mitotic compartment. The biological grounds forthis definition is the existence of a myeloid stem cell reservoir, whichis known to supply new committed cells to the mitotic compartment.However, the reservoir's actual kinetics are not very well exploredempirically. Therefore l₁ is fixed to levels such that the overall sizeof the mitotic compartment as well as the kinetics of the Neutrophils incirculation would match those obtained empirically.

[0779] Any new biological data that emerges may help define the kineticsmore accurately within the framework of this model, although results ofthis model indicate that the assumption of a constant rate of stem cellsflowing into the mitotic compartment in the absence of G-CSF isplausible. For every nε{1 . . . τ} and for every t, amplification occursat the exit from m_(n) ^(t), according to Equation 15 as follows:$\begin{matrix}{m_{n + 1}^{t + 1} = {m_{n}^{t} \cdot {\alpha_{n}\left( G_{blood}^{t} \right)}}} & (16)\end{matrix}$

[0780] where:

[0781] α_(n) is a non-decreasing concave function of G-CSF levels in theblood, which determines the factor of amplification in the hourlysubcompartment n. If, for instance, no amplification occurs atsubcompartment n₀ at time t then α_(n₀) = 1∀n, G_(blood)^(t)1 ≤ α_(n)(G_(blood)^(t)) ≤ 2

[0782] The size of the morphological sub-compartments in the mitoticcompartment at time t is determined as:(18)$\sum\limits_{n = n_{o}}^{n_{i}}m_{n}^{t}$

[0783] Where n₀ is the first hourly sub-compartment of a morphologicalsub-compartment and n₁ is its last hourly sub-compartment. The divisioninto the morphological sub-compartments is used only for fine-tuning ofthe kinetic parameters with the use of experimental data.

[0784] The mitotic compartment was modeled with an intention tofacilitate the specific cell-cycle cytotoxic effects of chemotherapy.Therefore, cohorts of one hour are modeled as undergoing a process ofmaturation and amplification culminating in their entry into thepost-mitotic as described below. Effects of chemotherapy may beincorporated into the model by mapping the various cell-cycle phases(G1, S, G2, M) to the hourly cohorts modeled and formulating a functionof the cytotoxic effects of chemotherapy on these phases.

[0785] The experimental literature shows wide agreement regarding thesteady state normal amounts of circulating Neutrohpils, size of thepost-mitotic compartment and the three morphologically distinctsub-compartments of the mitotic compartment, and post-mitotic transittime and amplification rates in the mitotic sub-compartments (see, forexample, Dancey J T, Deubelbeiss K A, Harker L A and Finch C A, in“Neutrophil kinetics” in Man. Journal of Clinical Investigation, 58(3):705-715, 1976; Price TH, Chatta G S and Dale D C, “Effect of recombinantGranulocytee colony-stimulating factor on Neutrophil kinetics in normalyoung and elderly humans”, Blood 88(1): 335-340, 1996; and Dresch Maryin “Growth fraction of myelocytes in normal human Granulopoiesis”, CellTissue Kinetics 19: 11-22, 1986). To determine other relevant kineticparameters, which were either not available in the literature or weregiven a wide range by experimentalists, steady state kinetics wasassumed and an iterative process was employed. These parameters includethe inflow of stem cells to the myeloblast compartment and the transittimes of the mitotic sub-compartments.

[0786] The half life of blood Neutrophils and the steady state number ofNeutrophils were taken as 7.6 h and 0.4×10⁹ cells/kg body weight,respectively (taken from Dancey J T, Deubelbeiss K A, Harker L A, FinchC A. 1976. Neutrophil Kinetics in Man. J Clin Invest. 58(3): 705-15).Similarly, the same calculation may be made for each patient that is tobe modeled. This would allow the dynamics of every patient to bedescribed by the simulation. The average size of the post-mitoticcompartment (5.84×10⁹ cells/kg body weight—Dancey J T, Deubelbeiss K A,Harker L A, Finch C A. 1976. Neutrophil Kinetics in Man. J Clin Invest.58(3): 705-15) and the transit time of the compartment (160 h—Dancey JT, Deubelbeiss K A, Harker L A, Finch C A. 1976. Neutrophil Kinetics inMan. J Clin Invest. 58(3): 705-15; Dresch, Mary. 1986. Growth Fractionof Myelocytes in Normal Human Granulopoiesis. Cell Tissue Kin. 19:11-22; Price T H, Chatta G S, Dale D C. 1996. Effect of RecombinantGranulocyte Colony-Stimulating Factor on Neutrophil Kinetics in NormalYoung and Elderly Humans. Blood. 88(1): 335-40) are compatible with thesize and half-life of the circulating Neutrophil compartment reported byDancey, thus supporting the steady state analysis.

[0787] In order to determine the amount of cells in the hourlysub-compartments in the mitotic compartment, all compartments in thelineage were modeled using a steady state assumption. The number ofcells exiting the circulating Neutrophil pool equals the number of cellsexiting the post mitotic compartment, which in turn equals the hourlyproduction of cells in the mitotic compartment. Thus, the number ofcells in the last hourly cohort of the mitotic compartment can bedetermined from the Neutrophil decay rate, which is available in theliterature. However, this calculation is based on assumptions that thereis no apoptosis in the post-mitotic compartment. Direct experimentaldata by Thiele J, Zirbes T K, Lorenzen J, Kvasnicka H M, Scholz S,Erdmann A, Flucke U, Diehl V and Fischer R, in “Haematopoietic turnoverindex in reactive and neoplastic bone marrow lesions: Quantification byapoptosis and PCNA labeling,” Annals of Haematology 75(1-2): 33-39,1997, suggests that apoptosis is not a significant phenomenon in normalhuman bone marrow. The size calculated for the mitotic compartment isclose to that experimentally obtained by Dancey and Price, thussupporting the notion that apoptosis is not a significant kinetic factorin the lineage. Values for the production of cells in the mitoticcompartment can later be modified in light of new evidence.

[0788] Regarding the transit time of the mitotic compartment there islittle agreement in the literature, with a range of 90-160 hours givenby most experimentalists (see Dresch Mary in “Growth fraction ofmyelocytes in normal hman Granulopoiesis,” Cell Tissue Kinetics 19:11-22, 1986). In order to determine the transit times of the mitoticmorphological sub-compartments, as in Equation 18, the followingconstraints were considered:

[0789] 1. The sizes of the theoretically obtained morphologicalsub-compartments must fit those reported experimentally in normal humanhaematopoiesis (Dancey J T, Deubelbeiss K A, Harker L A, Finch C A.1976. Neutrophil Kinetics in Man. J Clin Invest. 58(3): 705-15) andunder the effects of G-CSF (Price T H, Chatta G S, Dale D C. 1996.Effect of Recombinant Granulocyte Colony-Stimulating Factor onNeutrophil Kinetics in Normal Young and Elderly Humans. Blood. 88(1):335-40);

[0790] 2. At least 24 hours, the typical cell cycle, must separateamplification points;

[0791] 3. The size of the last hourly sub-compartment must equal thehourly production of the mitotic compartment (calculated with theaforementioned iterative process assuming steady state kinetics);

[0792] 4. Amplification inside the compartment is set at the levelsdetermined by Mary, J. Y. 1984. Normal Human Granulopoiesis Revisited I.Blood data, II. Bone Marrow Data. Biomedicine & Pharmacotherapy. 38:33-43, 66-67; and

[0793] 5. The total transit time of the mitotic compartment must bewithin the 90-160 hour range.

[0794] By using the values shown in Table x, an excellent fit wasobtained within the above-mentioned constraints.

[0795] It should be noted that when other alternatives with shortertransit times were attempted, results could not be obtained that agreedwith the literature regarding the size of the mitotic pool or itsproduction. Furthermore, a fit between our simulation model's resultsregarding Polymorphonuclear (PMN) cell counts in peripheral blood withempirical data could not be achieved without speculating extensively onthe nature of G-CSF effects on non-committed stem cells. It should benoted, that little empirical quantitative data is available regardingstem cells.

[0796] The effects of G-CSF on this compartment are modeled as anincrease in the rate of cells entering the myeloblasts from theuncommitted stem cell pool, increases in the rates of mitosis, andintroduction of new points of amplification as shown in Equation 15, 16.Since little data is available regarding the increases in amplificationdue to G-CSF, an initial assumption was made that amplification reachesfull potential at points that under normal conditions undergo anamplification of below a factor of 2. Additionally, it was assumed thatthe transit time in all mitotic sub-compartments and the typical cellcycle duration are not affected by G-CSF, based on lack of evidence tothe contrary.

[0797] Reference is now made to FIGS. 14 and 25 which show a comparisonof Neutrophil production according to the described model andexperimental data in the literature. Increased Neutrophil production isin accordance with the Neutrophil counts reported by Price et al. Inaddition, these increases are in accordance with Price's data aboutNeutrophil bone marrow pool sizes.

[0798] Reproduction of the effect of G-CSF on Neutrophil counts and themitotic compartment sizes beyond day 5 of administration wasaccomplished by assuming an increase (15% with the highest dose ofG-CSF) in the rate of cells entering the myeloblast compartment.Alternatively, G-CSF may change the behavior of the myeloblastcompartment such that some of the cells there undergo self-renewalinstead of moving on to the promyelocyte compartment. However, noempirical data to support this is available. The model can be modifiedin light of new experimental data in the future.

[0799] (2) Post-Mitotic Compartment

[0800] The different post mitotic compartments seem indistinguishable ininsensitivy to cytotoxic chemotherapy. Therefore, it is biologicallyacceptable and computationally sensible to model this compartment as asingle pool of cells, such that the last hourly cohort of the mitoticcompartment enters the compartment, and a proportion of the cells withinthe compartment enter the Neutrophil pool every hour.

[0801] The post mitotic compartment at time t is a single quantity ofcells p^(t), such that: $\begin{matrix}{p^{t + 1} = {{{l_{3}\left( G_{blood}^{t} \right)} \cdot p^{t}} + m_{\tau}^{t}}} & (19)\end{matrix}$

[0802] where l₃ is a convex, non-increasing function of G-CSF levels inthe blood, which takes values in the range of [0-1]. This definitionentails p^(t)>0.

[0803] We shall mark as ot the outflow from the post mitoticcompartment: $\begin{matrix}{o^{t} = {m_{\tau}^{t} + p^{t} - p^{t + 1}}} & (20)\end{matrix}$

[0804] The number of Neutrophils in the circulating blood compartment attime t is marked nt and is modeled as a single quantity of cells, suchthat: $\begin{matrix}{n^{t + 1} = {o^{t} + {n^{t}\left( {1 - \frac{\ln \quad 2}{t_{\frac{1}{2}}}} \right)}}} & (21)\end{matrix}$

[0805] where t½ is the half-life of Neutrophils in the blood, as definedin the biological literature. t½ is assumed to be held constantregardless of G-CSF levels (Lord B. I, Bronchud, M. H., Owens, S.,Chang, J., Howell, A., Souza, L., Dexter, T. M. 1989. The Kinetics ofHuman Granulopoiesis Following Treatment with GranulocyteColony-Stimulating Factor in vivo. Proc. Natl. Sci. USA. 86: 9499-9503),though this could be easily modified. The kinetics of Neutrophils in thetissues are not modeled in this work.

[0806] This model will be incorporated into an optimization scheme thatwill have as its objective function both the aims of minimizing G-CSFadministration and returning the Neutrophil lineage to its normallevels.

[0807] At G_(blood)^(t) = 0, p^(t) = Π, m_(τ)^(t)

[0808] at the normal healthy level we have the following obviousrelationship: $\begin{matrix}{\frac{\Pi}{T} = {m_{\tau}^{t} = {o^{t} = {\frac{n^{t}}{t_{\frac{1}{2}}} \times \ln \quad 2}}}} & (21)\end{matrix}$

[0809] Which reflects the stability of the steady state.

[0810] G-CSF affects the post-mitotic compartment by shortening itstransit time (i.e. decreasing l₃). Price notes that the number of cellsin the post mitotic compartment is not significantly changed followingadministration of G-CSF. This determination is based on counts made onday 5 after G-CSF administration. Thus, it can be safely assumed thatany increased production of the mitotic compartment flowing into thepost mitotic compartment is translated over the long-term to an increasein the flow of cells from the post mitotic compartment to the Neutrophilpool. This increased flow is compensated by increased production in themitotic compartment only at a later stage. Therefore, an upper limit tothe number of cells in the post mitotic compartment was set, which is atthe values given as steady state counts (Π).

[0811] In brief, the effects of G-CSF on the Neutrophil lineage aremodeled during the first few days primarily as a decrease in the countsof the post-mitotic compartment, which is then compensated by anincreased production in the mitotic pool. This compensation sustains theincrease in Neutrophil counts in peripheral blood.

[0812] Reference is now made to FIG. 11, which is a graphicalillustration of a simulation of the model. Though no empirical data isavailable on this point, simulations of the model predict that thenumber of cells in the post-mitotic compartment decreases substantiallyduring the first two days of G-CSF administration, and then replenishes,so that on the sixth day the counts return almost to their normallevels. This replenishment lags behind that of Price et al report by afew hours. A testable hypothesis can thus be formulated, i.e., whetherusing the same G-CSF protocol Price et al used, there is indeed a nadiron day 3 of the treatment. TABLE 1 Day 0 (no G- CSF) Day 15 of G-Relative (×10⁹ CSF treatment increase in cells/ (×10⁹ cells/ compartmentkg. Body kg. body size due to G- Compartment weight) weight) CSFMyeloblasts 0.140 0.153 1.09 Promyelocytes 0.582 0.898 1.54 Myelocytes1.373 3.564 2.60 Mitotic Total = 2.10 4.615 2.20 Circulating 0.4 2.355.88 Neutrophils

[0813] IV.B.2. Neutrophils and G-CSF in the Circulating Blood

[0814] The elimination of Neutrophils from peripheral blood follows aPoisson distribution, and can therefore be described as an exponentialfunction, as shown by Cartwright G E, Athens J W, Wintrobe M M. 1964.The kinetics of Granulopoiesis in normal man. Blood. 24(6): 780-803.Therefore the rate of cells leaving this compartment is based onhalf-life determinations available in the literature. Since no directcytotoxic effects of chemotherapy have been described for thiscompartment it is also modeled as a single pool of cells.

[0815] The kinetics of G-CSF is also modeled as an exponentialdistribution with a half-life of 3.5 hours (Eq. 14).

[0816] The effects of G-CSF on the kinetics of the Neutrophil lineageappear not to be a linear function of G-CSF administration levels. Sincedata provided in the literature (Chatta G S, Price T H, Allen R C, DaleD C. 1994. Effects of in vivo Recombinant Methionyl Human GranulocyteColony-Stimulating Factor on the Neutrophil Response and PeripheralBlood Colony-Forming Cells in Healthy Young and Elderly AdultVolunteers. Blood. 84(9): 2923-9) only refers to two doses (30 and 300μgram/kg body weight) we can only speculate on the effects of otherlevels of G-CSF. After trial and error analysis, it was found thatassuming that the effects of the 300 -μgram dose are the maximal, at the30-μgram its effects are about 30% of the maximum.

[0817] Reference is now made to FIGS. 12A and 12B, which are graphicalillustrations of the effects of G-CSF at the two doses. The effects as afunction of G-CSF level are connected piece-wise linearly. This way, theNeutrophil levels observed clinically under both the 300 and the30-μgram protocols are obtained.

IV.C. Linear Implementation of the Model

[0818] Another embodiment of the present invention is the implementationof the above model by incorporating it into an optimization scheme thathas as its objective function both the aims of minimizing G-CSFadministration and returning the Neutrophil lineage to its normallevels.

[0819] Although the above-outlined model may be implemented in anynumber of optimization methods, the disclosed embodiment using linearprogramming was chosen because of its inherent advantages compared withsome other techniques, i.e. its ability to provide an optimal solutionusing partially analytical methods, and therefore being morecomputationally tractable (Gill 1991). On the other hand, implementationof this model in linear programming carries with it the disadvantagethat certain computations must be approximated linearly since theycannot be performed directly using linear methods. Thus, we shallcompare the ‘closeness’ of the solution obtained through linearprogramming with that obtained through another, non-linear method ofoptimization.

[0820] The significant parts of the model that must be modified due tothe linear programming implementation are the sections in whichmultiplication of two

[0821] {(x_(min), y_(min), x_(min)·y_(min)),(x_(min), y_(max),x_(min)·y_(max)), (x_(max), y_(min), x_(max)·y_(min)), (x_(max),y_(max), x_(max)·y_(max))}

[0822] variables is defined, since this operator is not itself linear.Therefore, multiplication is defined as an approximated valueconstrained within piecewise linear constraints that most closely boundthe product within a four-faced polyhedron in 3-dimensional space whosevertices are

[0823] Where x_(min), x_(max), y_(min), y_(max) are the constantbiologically defined minima and maxima of x and y. $\begin{matrix}{{M\left( {x,y} \right)}\left\{ \begin{matrix}{\geq {{y_{\min}x} + {x_{\min}y} - {x_{\min}y_{\min}}}} \\{\geq {{y_{\max}x} + {x_{\max}y} - {x_{\max}y_{\max}}}} \\{\leq {{y_{\min}x} + {x_{\max}y} - {x_{\max}y_{\min}}}} \\{\leq {{y_{\max}x} + {x_{\min}y} - {x_{\min}y_{\max}}}}\end{matrix} \right.} & (22)\end{matrix}$

[0824] Multiplication may also be approximated with variations on thelinear least squares method, by finding one plane that's closest to thefour vertices defined.

[0825] The other functions that need to be defined linearly are thoseconcerning the pharmacodynamics of G-CSF. Due to the nature of thesefunctions (either non-increasing convex or non-decreasing concave),these effects are implemented as piece-wise linear functions whosebreakpoints are the doses for which actual experimental data isavailable (Chatta G S, Price T H, Allen R C, Dale D C. 1994. Effects ofin vivo Recombinant Methionyl Human Granulocyte Colony-StimulatingFactor on the Neutrophil Response and Peripheral Blood Colony-FormingCells in Healthy Young and Elderly Adult Volunteers. Blood. 84(9):2923-9). Note that the effects of G-CSF on each of the kineticparameters have not been determined in a detailed manner byexperimentalists. Rather its effects over a few dose levels on theNeutrophil blood counts and the size of the morphologically differentmitotic compartments and the post mitotic compartment have beendetermined. From these data, the effects of G-CSF on the actual kineticparameters (probability of mitosis, transit time and inflow of cellsinto the myeloblast compartment from stem cell progenitors) has beenreconstructed at the dose levels available in the literature. Thesepoints are then connected linearly to obtain piecewise linear functionsrelating G-CSF levels to their effect on those parameters. Furtherexperimental data in the future could be used to produce more accuratefunctions.

[0826] At the amplification points within the mitotic compartment, thelinearly approximated multiplication operator (Eq 22) is used instead ofthe product defined in Eq. 16.

[0827] At points where no amplification occurs the quantity from onecompartment is simply transferred to the next according to the followingEquation: $\begin{matrix}{{m_{n + 1}^{t + 1} = m_{n}^{t}}m_{n}^{0}} & (23)\end{matrix}$

[0828] Values are set according to the steady state values of themitotic compartment, or are depleted according to the kill function ofthe chemotherapy.

[0829] The flow out of the post mitotic compartment (Eq. 20) issimilarly defined as a linear approximation of a product.

[0830] IV.C.1. Formulation of the Model as an Optimization Problem forLinear Programming

[0831] The simulation spans a finite number of discrete time stepsdenoted by T.

[0832] We define as the control variable the vector that representsG-CSF administration at every given hour t:G_(adm)^(t), t ∈ {1  …  T}

[0833] The objective function is defined as maximization of thefollowing expression: $\begin{matrix}{\sum\limits_{t = 1}^{T}\left( {{\beta^{t} \cdot p^{t}} - G_{adm}^{t}} \right)} & \left( {{Eq}.\quad 24} \right)\end{matrix}$

[0834] where p^(t) is the number of cells in the post mitoticcompartment at time t, and β is a scalar weighting coefficient. Thelogic for formulating the objective function this way is that theability to maintain the post mitotic compartment's steady state size fora prolonged period of time is sufficient for rehabilitation of theNeutrophil lineage as a whole. Also, our goal is to minimize the totaladministered quantity of G-CSF. β is introduced to allow us to factor inboth these goals in one objective. Also, this would allow a differentweight to be given for certain times, e.g. were it determined (byclinicians) that the later states of the post-mitotic compartment shouldbe weighted more than the first ones. Obviously this is only one of thepossible formulations of the objective function as defined in theprevious section.

[0835] The pharmacokinetics and pharmacodynamics of G-CSF that weredefined generally in the mathematical model are defined piecewiselinearly. Some of the considerations that was put into formulating thesefunctions were based directly on experimental evidence (elaborated inthe main body of text). It is noted however, that actual experimentaldata regarding the direct effects of G-CSF on the kinetic parameters inwhich this model is interested is rather scant. Therefore, someformulations were conducted through partly analytic and partlytrial-and-error methods.

[0836] The formulation of the model in piecewise linear terms will allowuse of this model as a clinical tool in three ways. First, the modelwill determine the effectiveness of various protocols suggested byclinicians prior to their actual use on human patients. Second, themodel allows computation of the optimal protocol in a given situation ofNeutrophil counts, so that the e.g., Neutropenic period followingchemotherapy is either shortened or completely avoided at a minimal costand exposure to G-CSF. Third, the model serves as a constituent in abroader framework of clinical tools that will compute the most optimaltreatment plan for chemotherapy and growth factors. These uses shouldhelp clinicians administer more rational treatment to their patientsminimizing both suffering and medical costs. TABLE 1 Kinetics understeady state conditions in healthy humans. Size (10⁶ Amplification Meantransit cells/kg at the exit time (hours) weight) Compartment  2⁺ 24⁻0.139* Myeloblasts  2⁺ 48⁻ 0.558* Promyelocytes    1.5⁺ 48⁻ 1.4*Myelocytes 1 160*  5.84* Post mitotic 0    10.96* 0.4* Neutrophils

IV.D. Cancer and Treatment with Cytotoxic Drug Delivery

[0837] IV.D.1. Introduction

[0838] Still another embodiment of the present invention deals withcancer and its treatment using chemotherapy. Cancer is the secondleading cause of mortality in the US, resulting in approximately 550,000deaths a year. There has been a significant overall rise in cancer casesin recent years, attributable to the aging of the population. Anothercontributing factor to the rise in the verifiable number of cases is thewider use of screening tests, such as mammography and elevated levels ofprostate specific antigen (PSA) in the blood.

[0839] Neither better detection nor the natural phenomenon of aging,however, can entirely explain the increase in new cases of tumors.Meanwhile, other cancers, like brain tumors and non-Hodgkin's lymphoma,are becoming more common. Their increase could reflect changes inexposures to as yet unidentified carcinogens. Current trends suggestthat cancer may overtake heart disease as the nation's no. 1 killer inthe foreseeable future. As gene therapy still faces significant hurdlesbefore it becomes an established therapeutic strategy, present controlof cancer depends entirely on chemotherapeutic methods.

[0840] Chemotherapy is treatment with drugs to destroy cancer cells.There are more than 50 drugs that are now used to delay or stop thegrowth of cancer. More than a dozen cancers that formerly were fatal arenow treatable, prolonging patients' lives with chemotherapy.

[0841] Treatment is performed using agents that are widelynon-cancer-specific, killing cells that have a high proliferation rate.Therefore, in addition to the malignant cells, most chemotherapeuticagents also cause severe side-effects because of the damage inflicted onnormal body cells. Many patients develop severe nausea and vomiting,become very tired, and lose their hair temporarily. Special drugs aregiven to alleviate some of these symptoms, particularly the nausea andvomiting. Chemotherapeutic drugs are usually given in combination withone another or in a particular sequence for a relatively short time.

[0842] Chemotherapy is a problem involving many interactive nonlinearprocesses which operate on different organizational levels of thebiological system. It usually involves genomic dynamics, namely, pointmutations, gene amplification or other changes on the genomic level,which may result in increasing virulence of the neoplasia, or in theemergence of drug resistance. Chemotherapy may affect many events on thecellular level, such as cell-cycle arrest at different checkpoints, celltransition in and out of the proliferation cycle, etc. Chemotherapy mayalso interfere with the function of entire organs, most notably, withbone marrow blood production. In recent years molecular biology andgenetics has made an important step forward in documenting many of theseprocesses. Yet, for assessing the contribution of specific molecularelements to the great variety of disease profiles, experimental biologymust be provided with tools that allow a formal and systematic analysisof the intricate interaction between the genomic, cellular and cellpopulations processes in the host and in the disease agent. This systemis so complex that there is no intuitive way to know how small changesin the drug protocol will affect prognosis. But in spite of thisintricacy, attempts to improve chemotherapy have been carried out by“trial and error” alone, with no formal theory underlying theapplication of specific drug schedules. Such an approach “is apt toresult in no improvement, only discouragement and little usefulinformation for future planning” (Skipper, 1986).

[0843] The treatment of cancer by cytotoxic drug (or drug combination)delivery is addressed. In the current model, two generic types of cellsare considered: the limiting (i.e. the most drug-sensitive) host cellsand the target cells. Target cells are, in fact, the tumor. Both typesof cells may be damaged while exposed to chemotherapy. The aim is toobtain the most suitable treatment protocol according to specifiedconditions and limitations. It is assumed that the cell dynamics aredeterministic and known, and that both types of cells are sensitive tochemotherapeutic agents in certain known period (fraction of thecell-cycle time ranging from 0 to 1) of the cell-cycle (denoted criticalphase). If a cell is exposed to chemotherapy during part of its criticalphase, there is a chance that it will be eliminated, blocked or affectedin any other known way. The description of the dynamics of the delivereddrugs is assumed to be known as well.

[0844] In order to achieve the goal optimization process is applied tothe model. The optimization module uses the model predictions in orderto search for the suitable solution to posted optimization problem.Precise defining of optimization objectives as well as the relevantparameters adjustment is done according to the settings defined byuser/operator for every special case. The method can be applied ingeneral cases as well as in specific ones.

[0845] IV.D.2. Model of Biological System

[0846] The basic layer of the model incorporates a description of agedistribution of cycling cells and number of resting (quiescent) cells.The term “age of the cell” here refers to chronological age startingfrom the conventional beginning point of mitotic cycle.

[0847] Reference is now made to FIG. 13, which is a schematicillustration of the tumor cell cycle layer. The whole cycle is dividedinto 4 compartments, or stages (G₁, S, G₂ and M). Each compartment isdivided into equal subcompartments, where i^(th) subcompartment in eachstage represents cells of age i in the particular stage (i.e. they havespent i time-steps in this stage). The quiescent stage is denoted G₀.The cell cycle follows a direction as shown by arrows (#). Thus, cellsenter each stage starting with the first subcompartment, denoted G₁.

[0848] The model can be described mathematically as follows: Let T_(k)denote the maximum duration of kth stage in the cycle. Let Δt the symbolis showing up as a rectangle] denote the time resolution of the model indiscrete time steps. X_(k) ^(i)(t) is a function, which represents thenumber of cells in stage k in the I^(th) sub-compartment, at time t tot+Δt. Both time and age are measured in the same unit, in this case,hours. Let Q(t) represent the number of resting cells at time t to t+Δt.Trans(k,i,t) represents the probability that a cell of age i in thestage k will move to the next (k+1) compartment. Cells entering the newstage always start from the first subcompartment, i.e. from i=1. Thisprobability may change with time, representing the influence ofconditions on cycle length distribution.

[0849] By definition, the cell cannot remain more than T_(k) timestepsin the k^(th) compartment, as described in the following equation.

∀k:Trans(k,T _(k))=1

[0850] The restriction point (R-point) represents a cell's commitment tocomplete the mitotic cycle. Let T_(R) denote the age at which the cellpasses through the restriction point in G1. Only cells in G₁ withI<T_(R) can the cycle (in the absence of a drug).

[0851] The total number of proliferating cells P(t) can be calculated asfollows:${P(t)} = {\sum\limits_{{k = {G1}},S,{G2},M}\left( {\sum\limits_{i = 1}^{T_{k}}{x_{k}^{i}(t)}} \right)}$

[0852] In every time interval, quiescent cells may return to theproliferation pool. Alternatively, proliferating cells may change theirstate to become quiescent if and only if they are in the G1 stage and atage i, where T_(R)≧i>0. To describe this process we introduce thefunction G₁ ₀(i,t) which describes the number of G1 cells in age i whichbecome quiescent during time interval [t,t+Δt]. This function mayreceive negative values, accounting for cells that return from restingto proliferation.

[0853] As it is assumed that the exit to quiescence can occur only priorto the R-point (even in cancer cells), and that a resting cell thatreturns to proliferation enters the cycle at T₀, it can be stated:

∀i>T _(R) , ∀t:G _(1→0)(i,t)=0

[0854] It must be noted that this function is not dependent on i and tsolely. Its value is determined according to current cell distributionand all the general parameters that characterize the described cellsgroup. The same should be said about the values of Trans vector that canchange during the history of given population.

[0855] The model traces the development of described group of cancercells using given parameters, by calculating the number of cells in eachand every subcompartment according to the following stepwise equations:${x_{k}^{i}(t)} = \left\{ {{\begin{matrix}{{{x_{k}^{i - 1}\left( {t - 1} \right)} \cdot \left\lbrack {1 - {{Trans}\left( {k,{i - 1},{t - 1}} \right)}} \right\rbrack},{1 \leq i \leq T_{k}}} \\{{\sum\limits_{j = 1}^{T_{k - 1}}\left\lbrack {{x_{k - 1}^{j}\left( {t - 1} \right)} \cdot {{Trans}\left( {{k - 1},j,{t - 1}} \right)}} \right\rbrack},{i = 1}}\end{matrix}{x_{s}^{i}(t)}} = \left\{ \begin{matrix}{{{x_{s}^{i - 1}\left( {t - 1} \right)} \cdot \left\lbrack {1 - {{Trans}\left( {S,{i - 1},{t - 1}} \right)}} \right\rbrack},{1 < i \leq T_{G1}}} \\{\sum\limits_{j = 1}^{T_{G1}}{\left\lbrack {{x_{G1}^{j}\left( {t - 1} \right)} \cdot {{Trans}\left( {{G1},j,{t - 1}} \right)}} \right\rbrack \cdot \left\lbrack {{1 - {G_{1\rightarrow 0}\left( {{i - 1},{t - 1}} \right)}},{i = 1}} \right.}}\end{matrix} \right.} \right.$

[0856] for k=G₂,M, k−1 returns the previous stage (e.g. G₂−1=S).

[0857] These equations make it possible to calculate the number of cellsin each subcompartment at every time interval [t,Δt] starting frominitial distribution (e.g. at time t=0). Since in this model cell agesare measured in absolute time units, these measurements refer to thechronological age of the cell, and not the biological age, whose unitsare relative to a maturation rate that differs from cell to cell.Consequently, in this model no cell can remain in the same agesubcompartment after every time step. On the other hand, a fraction ofthe cells that leaves any subcompartment may be transferred to the firstsubcompartment of the next stage, according to probability vectorTrans(k,i,t). This vector provides the ability to account forvariability of cycle lengths while retaining a deterministic approach.

[0858] The behavior of the cell populations in this model is completelycontrolled by two components: Trans vector, and G1→G0 function. Thesetwo functions determine uniquely the outcome of every single time step,and, consequently the result over long periods. Thus, they are referredto as “control functions”. The values of these functions may bedependent not only on time and age of cells, but also on the currentpopulation state (or, generally, on the whole history of the population)as well as on the environment associated with a given cell group.However, those parameters are similar for all the cells in the group,implying that the model presented here is suitable for describing highlyhomogenous group of cells. Therefore, the basic layer of the modelshould give a realistic description for a uniform group of cancer cellsfor which environmental conditions and relevant biological propertiesare defined, in a way that will allow the construction of the controlfunctions for the group.

[0859] IV.D.3. The General Tumor Model

[0860] In the general approach the whole model is viewed as constructedfrom similar components, each of them derived from the basic structuredescribed in the previous paragraph. Each component represents cellsthat are subjected to the same environmental conditions and, thereforebehaves similarly (to be denoted homogenous group). The whole tumor ismodeled as a union of many different homogenous groups of cells, wherethe development of each group can be accurately predicted (when localconditions are known).

[0861] This general model simulates progress of the tumor in discretesteps of time. At each step the number of cells in each subcompartmentof each group is calculated according to the previous state, parametersof tumor, drug concentration, etc. The parameters of the tumor mustinclude all the information that is relevant to prognosis. Some of theseparameters are defined locally, e.g., those relating to the tumor'sgeometry. For this reason the representation of the spatial structurewill be included.

[0862] The cells will be able to pass between the groups during thedevelopment of the tumor. This allows the representation of the changesin the local conditions during the tumor evolution (e.g. forming ofnecrotic core, improvement in “living conditions” in vascularizedregions, etc.). In addition, all the parameters of the tumor may changein accordance with the dynamics of the cancer.

[0863] The calculation of the tumor development over time will be doneby stepwise execution of the described simulation and can be used topredict the outcome of the treatment or in fitness function for searchalgorithms.

[0864] IV.D.4. From General to Individual Tumor Model

[0865] When the general theoretical description of the model isaccomplished, the model is fitted to represent the actual tumors. It isrendered patient-specific by adjusting all the parameters that determinethe behavior of the modeled tumor to those of the real cancer in thepatient's body. In order to accomplish this task we will establish theconnections between mathematical parameters (most of them will havedirect biological implication) and every kind of data that ispractically obtainable in the clinic. These connections may be definedthrough research on statistic correlation between different parameters(including genotype-phenotype correlation), or using advancedbiochemical research showing the relationships between a givenbio-marker and its effects on the reaction rates described by our model.

[0866] Thus defined, the model will be able to give realisticpredictions for treatment outcomes either for specific patient or for abroad range profiles of patients and diseases. This tool can serve toperform the prognosis of either an untreated cancer patient, or as abasis for treatment modeling as is described below.

[0867] IV.D.5. Introducing Pharmacology

[0868] In order to simulate cancer treatment pharmacologic component isadded to the above model. Pharmacokinetics as well as pharmacodynamicsfor specific anticancer drugs are modelled. Cell-cycle specific drugsand cell-cycle unspecific drugs are taken account of by our model.

[0869] The distribution of the drug in and around the tumor as well asin the blood (the drug kinetics) are modelled. For this purpose, asuitable model is used, defining it precisely for every certain type ofthe drug. The concentrations of drug in the body are calculated at everytime step in accordance with the drug administration specified by theprotocol, and different processes that define drug kinetics in the body.

[0870] The dynamics of the drug are represented through the directinfluence of the drug on tumor cells. The effects on the proliferatingcells are mostly blocking the cycle in different stages (which can bemodeled as cell arrest) and cell death (immediate or some time after theblock). Cell-cycle specific drugs are believed to have no directinfluence on quiescent cells, but can affect them indirectly by killingproliferative cells and therefore changing local conditions. Whereadditional types of drugs added to the model, their effect on any kindof cells is modeled as killing certain fraction of cells (which isdose-dependent) or changing the behavior of the cells.

[0871] Additional phenomena that may prove significant in drug kineticsand dynamics (e.g. rate of absorption by the cells, development of tumorresistance to specific drug, angiogenesis etc.) can be introduced intothe model to make it as realistic as needed.

[0872] The description of the drug in the model is done in terms ofquantitative functions, which enable to calculate the drug amounts atcertain locations and the tumor response to it at every time step. Inthe general case, these functions include parameters that depend on thespecific data (drug type, body parameters, characteristic of the tumor,etc.) and can be determined in given situation (patient/case).

[0873] The combination of cancer model with the limiting normal tissue(see below), and the drug model described above makes it possible topredict the outcome of the treatment, given the relevant parameters forthe drug, the cancer and the patient. Again, the prognosis may be madefor specified cases as well as for broad profiles of patients ordisease. This simulation also serves to build the fitness function usedfor the optimization objectives.

[0874] IV.D.6. Combining with Minimizing Host Toxicity.

[0875] Although an accurate predictive tool, the model that representschemotherapy of tumor alone hardly suffice for optimization of drugprotocols. Actually, this model implies using as much drug as possibleuntil the final elimination of the tumor; while in the living system thetoxicity of the drug is the most important constraint limiting thetreatment. In most cases of anticancer chemotherapy the dose-limitingtoxicity is bone marrow suppression, the two most sensitive bone marrowlineages being Granulopoiesis and Thrombopoiesis. Accordingly, those twowere chosen as an example and are modeled separately and in a similarway to predict the negative effect of the chemotherapy on them. Thesemodels reconstruct the damage caused by the chemotherapy to the bonemarrow cells and the recovery of these lineages (treated by specificgrowth factors).

[0876] Thus, the whole system is capable of predicting the result ofchemotherapy treatment for the tumor as well as for bone marrow cells,allowing the use of the protocols that combine anticancer drugs andgrowth factors for healthy cells.

[0877] Chemotherapy toxicity to any other normal host cell populationscan be similarly taken into account, if it is defined as relevant fordose and schedule optimization.

[0878] IV.D.7. Individualization of the Models

[0879] Due to a great degree of heterogeneity between malignant tumors(even among similar tissue types) and between patients, it would beadvantageous to adjust the treatment protocol to the individual case.This individualization procedure includes three aspects:

[0880] 1) individual parameters of tumor dynamics.

[0881] 2) individual parameters of patient-specific drugpharmacokinetics and interaction.

[0882] 3) individual parameters of the dynamics of dose-limiting normalhost tissues.

[0883] Relevant data concerning individual cases can be obtained byresearch on statistic correlation between different parameters(including genotype-phenotype correlation), or using advancedbiochemical research (which may establish quantitative relations). Inthe general model, important dynamic parameters are estimated fromexperimental studies conducted in certain patient populations. Any ofthese parameters, when available on the per patient basis, can beindividualized, while those that are unavailable can be left as apopulation-based figure. This approach allows continuous increase in thedegree of individualization of the treatment protocols with progress inthe technology of parameter evaluation (e.g., oncochips).

[0884] All different parameters may then be adjusted, which will resultin an adjusted array of models to be simulated. Parameters may includemany different factors, which are adjustable according to the needs of aresearcher or a pharmaceutical company for general use of the treatment,or may even be individualized for use by a specific clinician for aparticular individual. Examples of parameters may include, but are notlimited to age, weight, gender, previous reaction to treatment, desiredpercentage of healthy body cells, desired length of treatment protocol,pathologic or cytologic specifics, molecular markers, genetic markersetc.

[0885] In order for the system to be user-friendly, all possibleparameters are termed in ways that are easy for the user to understand.

[0886] Once all the parameters are set, an array of solutions isproduced based on the input parameters. A number of possible protocolscan be set (is thus generated by the computer). a fitness function isapplied, which results in scores for each of the proposed solutions.

[0887] IV.D.8. Generation of Protocol Space

[0888] Referring back to FIG. 2, this model makes it possible to checkany given treatment protocol and to choose a very good one according touser's criteria. The user may be a physician, a drug developer, ascientist, or anyone else who may need to determine a treatment protocolfor a drug. The specific parameters may include several categories, suchas individual patient characteristics and/or medical history, needs of aspecific user (research, efficacy, treatment, etc.), and otherparticulars (such as maximum length of treatment, confidence level,etc.).

[0889] That is, an array of possible treatment protocols is created fromwhich the optimal treatment protocol can then be chosen. It should benoted that the method does not imply the fitness estimation for allpossible protocols. The use of operation research allows a much moresophisticated, yet resource saving procedure.

[0890] An example of this procedure will be described as it relates tocancer treatment by chemotherapy, as described in above-disclosedembodiment of the invention. However, it should be noted that a similarprocedure may be performed in any of the embodiments.

[0891] The procedure implements cell growth and cell death procedures,as defined in the detailed model above. There are certain pre-definedparameters, including the lengths of the host and target life-cycles,the lengths of their critical phases, and a resolution factor, thatdetermines the length of a single time unit. The user is asked to definean action (treatment or non-treatment). Simulation of cell growth anddeath is then performed for the single time unit. This procedure isrepeated until the end of the total simulation. Alternatively, thechoice of treatment or non-treatment is made by the processor, with manypossible permutations considered. In that case, the protocol space wouldbe very large, and the resolution would depend on the (selected) lengthof the time unit (and computer capacity)

[0892] There are two procedures: one for growth simulation duringtreatment and one without. The array in which the numbers of cells arekept is updated once per time unit, whether with or without treatmentpresent at that time.

[0893] IV.D.9. Defining the Fitness Function

[0894] The fitness function is an important tool in Operation Research.In this case of protocol optimization, it allows the comparison betweena number of different protocols each one of them scoring differentlywith respect to various objectives that can be set by the developers orby the users and identifying the protocol for which the highest weightedscore is predicted. The fitness function calculates for any givenprotocol its relative efficacy (“score” or “fitness”), thus enabling adefinite decision of the best protocol from a given set of protocols.

[0895] In different cases, different objectives can be formulated. Thereare several settings in which such a model can be used, including butnot limited to:

[0896] One) clinical practice—where objectives can change depending ontype of disease, condition of the patient, purpose of treatment, etc.

[0897] Two) pharmaceutical company—where objectives can be aimed atfinding the therapeutic window and an optimal schedule.

[0898] Three) scientific setting—research oriented objectives can beaimed at.

[0899] In each case, a particular fitness function can be formulated,reflecting all given requirements. Thus, in any particular case one cancompare between different protocols and obtain the most suitable tohis/her special purposes and needs.

[0900] Examples for some alternative objectives are given:

[0901] 1. The smallest number of drug dosings required for achieving anygiven aim.

[0902] 2. The lowest total drug dose required for achieving any givenaim.

[0903] 3. The minimal total amount of drug needed for rehabilitation.

[0904] 4. The smallest deviation from the baseline at normal cellpopulations count (e.g., platlet nadir) after chemotherapy or anothercell-suppressive treatment.

[0905] 5. The shortest period of disease (e.g., Thrombocytopenia).

[0906] Using the fitness function it is possible to a) estimate theefficacy of a given protocol, b) search for the solution of anoptimization problem, i.e., predict which protocol will be best of manypotential protocols considered for curing/relieving the patient.

[0907] IV.D.10. Solving the Optimization Problem

[0908] The optimization problem is stated using the described models: tofind the protocol for drug administration (with option to growth factoradministration) which maximizes the given fitness function.

[0909] As explained above, the fitness function is defined according tothe user requirements. For example, the goal of the treatment may bedefined as minimizing the number of cancer cells at the end of thetreatment, minimizing the damage to the BM cells throughout thetreatment or at its end, and curing the patient (where cure is definedprecisely) as quickly as possible. Note that the fitness function mayalso include goals such as maximizing life expectancy, minimizing costof treatment, minimizing treatment hazards and/or discomfort etc.Generally, the aim of optimization is to find the best protocol, i.e.the protocol that generates the best value of fitness. Customarily, thisis achieved by mathematical analysis. However, mathematical analysis isrestricted to over simplified models, whereas, in order to accommodatebiologically realistic parameters, the described models are very complexand, therefore, cannot be solved analytically. On the other hand, thepractical purpose of the treatment is not to find the best possibleprotocol (i.e., the global optimum) but “only” one that will suit theuser's objectives, even if its fitness is not absolutely the best (i.e.,the local optimum). For this reason the solution that can be shown topromise the pre-defined objectives is deemed satisfactory.

[0910] Hence, the optimization problem may be reformulated as follows:for given initial conditions, find the treatment protocol which willfulfill the user's requirements (e.g. curing a patient according togiven definitions of cure) and subjected to given limitations (e.g.treatment duration, drug amounts, etc.). To this end it is notcompulsory to find the global solution. It is enough, with regards toobjectives and limitations, to perform search, using search algorithms,in certain regions of the protocols' space, and find the local maxima ofthe fitness function. After determining the locally best protocols, wecan verify that they serve one's objectives and check them numericallyfor stability.

[0911] Such a strategy can be used for identifying patient-specifictreatment, as well as in the general case, where only the profile of thedisease and the drug are specified. If more patient-specific data aresupplied, the solution will be tailored more specifically. On the otherhand, the optimization program could propose general recommendations forthe protocol types for certain kinds of disease, treated with a certainkind of medication.

[0912] It will be appreciated that the present invention is not limitedby what has been described hereinabove and that numerous modifications,all of which fall within the scope of the present invention, exist. Forexample, while the present invention has been described with respect tocertain specific cell lineages, the concept can be extended to any otherlineage and treatment protocol which can be detailed mathematically(e.g., viral or bacterial diseases). Furthermore, certain assumptionswere necessarily used in computing the mathematical models of theembodiments. Values and equations based on these assumptions can bechanged if new information becomes available.

[0913] It will be appreciated by persons skilled in the art that thepresent invention is not limited by what has been particularly shown anddescribed herein above. Rather the scope of the invention is defined bythe claims which follow.

[0914] Other modifications and variations to the invention will beapparent to those skilled in the art from the foregoing disclosure andteachings. Thus, while only certain embodiments of the invention havebeen specifically described herein, it will be apparent that numerousmodifications may be made thereto without departing from the spirit andscope of the invention.

What is claimed is:
 1. A system for recommending an optimal treatmentprotocol for an individual comprising: a system model; a plurality oftreatment protocols; a system model modifier, wherein said system modelis modified by the system model modifier based on parameters specific tothe individual; and a selector to select an optimal treatment protocolfrom said plurality of treatment protocols based on the modified systemmodel.
 2. The system of claim 1 wherein the system model furthercomprises: a realistic biological process model; and a realistictreatment model that models the effects of a treatment on saidbiological process.
 3. The system of claim 2, wherein said biologicalprocess model comprises mathematical models for biological processesaffecting healthy cell populations and biological processes affectingcell populations with at least one disease.
 4. The system of claim 3wherein said healthy cell populations include bone-marrow cells and hosttissue cells that are affected by said treatment model.
 5. The system ofclaim 3 wherein said cell populations with at least one disease is oneof cancer cells, and diseased bone-marrow cells including diseasedNeutrophil cells and diseased Thrompocyte cells.
 6. The system of claim2, wherein said treatment models comprise treatment specific processesthat affect cell populations.
 7. The system of claim 6 wherein saidtreatment specific process is interactions involving one of a groupcomprising pharmacokinetic, pharmacodynamic, cytostatic, cytotoxic, andmethods of affecting cell biology and causing cell death, withassociated biological processes.
 8. The method of claim 1 wherein, saidparameters specific to the individual include one or more selected froma group consisting of parameters related to the biological process'dynamics, patient specific drug PK, PD and dynamics of dose-limitinghost tissues.
 9. The method of claim 8, wherein said parameters relatedto biological process' dynamics comprise age, weight, gender, bloodpicture, desired length of treatment protocol, previous reaction totreatment, molecular markers, genetic markers, pathologic specifics andcytologic specifics.
 10. The system of claim 1, wherein the selectorincorporates user-specific parameters in performing selection.
 11. Thesystem of claim 10 wherein said incorporation is done by using a fitnessfunction.
 12. The system of claim 11 wherein said fitness functionincorporates at least one parameter selected from a group comprisingpatient survival, time to death, time to reach a specified disease stage(including cure), tumor load, pathogen load, cytotoxicity, side effects,quality of life, cost of treatment, and pain.
 13. The system of claim12, wherein a user can input specific coefficients for said at least oneparameter to adjust the fitness function to satisfy the user's goals.14. The system of claim 10, wherein the user-specific parameters arebased on a user, said user being a medical doctor.
 15. The system ofclaim 10, wherein the user-specific parameters are based on a user, saiduser being a scientist.
 16. The system of claim 10, wherein theuser-specific parameters are based on a user, said user being a drugdeveloper.
 17. The system of claim 1 wherein said selection of treatmentprotocols incorporate cytotoxic effects.
 18. The system of claim 1wherein said selection of treatment protocols incorporate drug efficacy.19. The system of claim 1, wherein the selector performs the selectionusing operation research methods.
 20. The system of claim 1, wherein theselector further comprises heuristics, said heuristics being used toperform searching and selection.
 21. The system of claim 20 wherein,said heuristics comprise computational feasibility.
 22. The system ofclaim 1 wherein said recommendation is a combination of disease andtreatment strategy, including types of treatment, e.g. chemotherapy,radiotherapy, surgery, immunotherapy, etc, device, drug or drugcombination and treatment schedule and dosage.
 23. The system of claim1, wherein, said system is implemented over a distributed computingsystem.
 24. The system of claim 23, wherein the distributed computingsystem is the Internet.
 25. The system of claim 23, wherein a user usesthe system remotely.
 26. A system for recommending an optimal treatmentprotocol for a general patient comprising: a system model; a pluralityof treatment protocols; and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on the systemmodel.
 27. The system of claim 26 wherein the system model furthercomprises: a realistic biological process model; and a realistictreatment model that models the effects of a treatment on saidbiological process.
 28. The system of claim 27, wherein said biologicalprocess model comprises mathematical models for biological processesaffecting healthy cell populations and biological processes affectingcell populations with at least one disease.
 29. The system of claim 28wherein said healthy cell populations include bone-marrow cells and hosttissue cells that are affected by said treatment model.
 30. The systemof claim 28 wherein said cell populations with at least one disease isone of cancer cells, and diseased bone-marrow cells including diseasedNeutrophil cells and diseased Thrompocyte cells.
 31. The system of claim27, wherein said treatment models comprise treatment specific processesthat affect cell populations.
 32. The system of claim 31 wherein saidtreatment specific process is interactions involving one of a groupcomprising pharmacokinetic, pharmacodynamic, cytostatic, cytotoxic, andmethods of affecting cell biology and causing cell death, withassociated biological processes.
 33. The system of claim 26, wherein theselector incorporates user-specific parameters in performing selection.34. The system of claim 33 wherein said incorporation is done by using afitness function.
 35. The system of claim 34 wherein said fitnessfunction incorporates at least one parameter selected from a groupcomprising patient survival, time to death, time to reach a specifieddisease stage (including cure), tumor load, pathogen load, cytotoxicity,side effects, quality of life, cost of treatment and pain.
 36. Thesystem of claim 35, wherein a user can input specific coefficients forsaid at least one parameter to adjust the fitness function to satisfythe user's goals.
 37. The system of claim 33, wherein the user-specificparameters are based on a user, said user being a medical doctor. 38.The system of claim 33, wherein the user-specific parameters are basedon a user, said user being a scientist.
 39. The system of claim 33,wherein the user-specific parameters are based on a user, said userbeing a drug developer.
 40. The system of claim 26 wherein saidselection of treatment protocols incorporate cytotoxic effects.
 41. Thesystem of claim 26 wherein said selection of treatment protocolsincorporate drug efficacy.
 42. The system of claim 26, wherein theselector performs the selection using operation research methods. 43.The system of claim 26, wherein the selector further comprisesheuristics, said heuristics being used to perform searching andselection.
 44. The system of claim 43 wherein, said heuristics comprisecomputational feasibility.
 45. The system of claim 26 wherein saidrecommendation is a combination of disease and treatment strategy,including types of treatment, e.g. chemotherapy, radiotherapy, surgery,immunotherapy, etc, device, drug or drug combination and treatmentschedule and dosage.
 46. The system of claim 26, wherein, said system isimplemented over a distributed computing system.
 47. The system of claim46, wherein the distributed computing system is the Internet.
 48. Thesystem of claim 46, wherein a user uses the system remotely.
 49. Thesystem of claim 48, wherein the remote system is a telephone.
 50. Asystem for predicting progression of a biological process in anindividual patient under a plurality of treatment protocols, whereinsaid biological process could be related to healthy or diseasedprocesses, said plurality of protocols including no treatment, saidsystem comprising: a system model; a plurality of treatment protocols;and a system model modifier, wherein said system model is modified bythe system model modifier based on parameters specific to theindividual. a predictor to predict the progression of at least one ofthe disease and the natural biological process under said plurality oftreatment protocols based on the modified system model.
 51. The systemof claim 50 wherein the system model further comprises: a realisticbiological process model; and a realistic treatment model that modelsthe effects of a treatment on said biological process.
 52. The system ofclaim 51, wherein said biological process model comprises mathematicalmodels for biological processes affecting healthy cell populations andbiological processes affecting cell populations with at least onedisease.
 53. The system of claim 52 wherein said healthy cellpopulations include bone-marrow cells and host tissue cells that areaffected by said treatment model.
 54. The system of claim 52 whereinsaid cell populations with at least one disease is one of cancer cells,and diseased bone-marrow cells including diseased at least one ofNeutrophil cells and diseased Thrombocyte cells.
 55. The system of claim51, wherein said treatment models comprise treatment specific processesthat affect cell populations.
 56. The system of claim 55 wherein saidtreatment specific process is interactions involving one of a groupcomprising PK, PD, drug cytostatics, drug cytotoxics, and methods ofaffecting cell biology and causing cell death, with associatedbiological processes.
 57. The system of claim 50 wherein, saidparameters specific to the individual include one or more selected froma group consisting of parameters related to the biological process'dynamics, patient specific drug PK, PD and dynamics of dose-limitinghost tissues.
 58. The system of claim 57, wherein said parametersrelated to biological process' dynamics comprise age, weight, gender,blood picture, desired length of treatment protocol, previous reactionto treatment, molecular markers, genetic markers, pathologic specificsand cytologic specifics.
 59. A system for predicting progression of abiological process in a general patient under a plurality of treatmentprotocols, wherein said biological process could be healthy or diseasedprocesses, said plurality of protocols including no treatment, saidsystem comprising: a system model; a plurality of treatment protocols;and a predictor to predict the progression of the disease or the naturalbiological process under said plurality of treatment protocols.
 60. Thesystem of claim 59 wherein the system model further comprises: arealistic biological process model; and a realistic treatment model thatmodels the effects of a treatment on said biological process.
 61. Thesystem of claim 60, wherein said biological process model comprisesmathematical models for biological processes affecting healthy cellpopulations and biological processes affecting cell populations with atleast one disease.
 62. The system of claim 61 wherein said healthy cellpopulations include bone-marrow cells as well as other host tissue cellsthat are affected by said treatment model.
 63. The system of claim 62wherein said cell populations with at least one disease is one of cancercells, and diseased bone-marrow cells including diseased Neutrophilcells and diseased Thrombocyte cells.
 64. The system of claim 60,wherein said treatment models comprise treatment specific processes thataffect cell populations.
 65. The system of claim 64 wherein saidtreatment specific process is interactions involving one of a groupcomprising PK, PD cytostatic, cytotoxic, and methods of affecting cellbiology and causing cell death, with associated biological processes.66. A system for modelling Thrombopietic lineage in an individual, saidsystem comprising: a Thrombopoiesis system model including a realisticprocess progression model, for cells involved in Thrombopoiesis, saidprogression model including multiplication and differentiation; and asystem model modifier, wherein said Thrombopoiesis system model ismodified by the system model modifier based on parameters specific tothe individual.
 67. The system of claim 66 wherein the system modelincorporates a realistic progression of cells involved in diseasedThrombopoiesis.
 68. The system of claim 67 wherein diseasedThrombopoiesis includes Thrombocytopenia.
 69. The system of claim 67wherein the system model incorporates effects of at least one drug inthe realistic progression of cells involved in Thrombopoiesis.
 70. Thesystem of claim 69 wherein said at least one drug is Thrombopoietin(TPO).
 71. The system of claim 67 wherein said process model imitates acourse of the individual's bone marrow progression, peripheral plateletcounts and TPO concentration changes.
 72. The system of claim 67,wherein said process model incorporates cell-suppressive treatmenteffects and administration of TPO to the patient.
 73. The system ofclaim 72, wherein said cell-suppressive treatment can be chemotherapy.74. The system of claim 66 wherein said process model further comprisesa plurality of compartments.
 75. The system of claim 74 wherein saidcompartments include: a stem cell (SC) compartment that comprises bonemarrow haemopoietic progenitors that have an ability to differentiateinto more than one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte progenitors; acolony forming units—megakaryocytes (CFU-Meg) compartment, wherein themegakaryocyte progenitors get committed as a megakaryocyte line andspend some time multiplying and maturing; a megakaryoblast (MKB)compartment, which receives the cells from CFU-Meg, wherein the cells inthe MKB compartment have lost their ability to proliferate but are notmature to release platelets; a MK16 compartment, which receives cellsfrom the MKB compartment, wherein a subset of cells in the MK16compartment release platelets at a constant rate until they exhausttheir capacity and are disintegrated and a second subset of cells do notrelease platelets but continue with endomitosis; a MK32 compartment thatreceives cells from the MK16 compartment, wherein a subset of cells inthis compartment release platelets and a second subset of cells do notrelease platelets but continue with endomitosis; a MK64 compartment thatreceives cells from the MK32 compartment wherein a subset of cells inthis compartment release platelets and a second subset of cells do notrelease platelets but continue with endomitosis; a MK128 compartmentthat receives cells from the MK64 compartment wherein a subset of cellsin this compartment release platelets; a platelets (PL) compartment. 76.The system of claim 75 wherein an effect of apoptosis is included withan overall effect of cell proliferation in giving rise to anamplification of cell numbers in a corresponding compartment.
 77. Thesystem of claim 75 wherein the process model further incorporates theeffects of TPO on the SC, CFU-Meg and MKB compartments.
 78. The systemof claim 77 wherein the effects are expressed in terms of effects of TPOconcentration on amplification rate, rate of cell maturation and afraction of cells that undergo endomitosis.
 79. The system of claim 78wherein when the TPO concentration is above a predetermined thresholdlevel, the amplification rate of cells in the SC compartment areaffected and below the threshold the amplification rate is dependentonly on a current number of cells.
 80. The system of claim 77 wherein inthe CFU-Meg compartment the cells are sensitive to TPO concentrationregardless of the concentration of TPO.
 81. The system of claim 77,wherein the transit time is same in all platelet releasing compartmentsand the transit time of the SC, CFU-Meg and MKB compartments arefunctions of micro-environmental conditions.
 82. The system of claim 81wherein in the SC compartment when the TPO concentration is above thethreshold, the transit time is shortened based the dose.
 83. The systemof claim 81 wherein in the CFU-Meg and MKB, the transit time is solelybased on TPO concentration.
 84. The system of claim 77 wherein afraction of cells in the SC compartment that commits to megakaryocyticlineage is constant.
 85. The system of claim 77 wherein in the CFU-Megand MKB compartments, every mature cell passes on to the nextcompartment.
 86. The system of claim 77 wherein in the MK16, MK32 andMK64 compartments, a fraction of cells pass on to the next compartment,said fraction being dependent on the TPO concentration.
 87. The systemof claim 77 wherein cells from MK128 compartment do not flow into anyother compartment.
 88. The system of claim 74, wherein each of saidcompartments is further divided into sub-compartments, each of saidsub-compartments containing cells of a specific age in hours.
 89. Thesystem of claim 88 wherein cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.
 90. The system ofclaim 88, wherein the platelet releasing cells contribute platelets tothe first sub-compartment of the PL compartment.
 91. The system of claim66, wherein said model is used for recommending an optimal treatmentprotocol, wherein said system further comprises: a plurality oftreatment protocols; and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on themodified system model.
 92. A system for modelling Thrombopietic lineagein a general patient, said system comprising a Thrombopoiesis systemmodel including a realistic process model for cells involved inThrombopoiesis.
 93. The system of claim 92 wherein the system modelincorporates a realistic progression of cells involved in diseasedThrombopoiesis.
 94. The system of claim 93 wherein diseasedThrombopoiesis includes Thrombocytopenia.
 95. The system of claim 93wherein the system model incorporates effects of at least one drug inthe realistic progression of cells involved in Thrombopoiesis.
 96. Thesystem of claim 95 wherein said at least one drug is Thrombopoietin(TPO).
 97. The system of claim 93 wherein said process model imitates acourse of the patient's bone marrow progression, peripheral plateletcounts and TPO concentration changes.
 98. The system of claim 93,wherein said process model incorporates cell-suppressive treatmenteffects and administration of TPO to the patient.
 99. The system ofclaim 98, wherein said cell-suppressive treatment is chemotherapy. 100.The system of claim 92 wherein said process model further comprises aplurality of compartments.
 101. The system of claim 100 wherein saidcompartments include: a stem cell (SC) compartment that comprises bonemarrow hemopoietic progenitors that have an ability to differentiateinto more than one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte progenitors; acolony forming units—megakaryocytes (CFU-Meg) compartment, wherein themegakaryocyte progenitors get committed as a megakaryocyte line andspend some time multiplying and maturing; a megakaryoblast (MKB)compartment, which receives the cells from CFU-Meg, wherein the cells inthe MKB compartment have lost their ability to proliferate but are notmature to release platelets; a MK16 compartment, which receives cellsfrom the MKB compartment, wherein a subset of cells in the MK16compartment release platelets at a constant rate until they exhausttheir capacity and are disintegrated and a second subset of cells do notrelease platelets but continue with endomitosis; a MK32 compartment thatreceives cells from the MK16 compartment, wherein a subset of cells inthis compartment release platelets and a second subset of cells do notrelease platelets but continue with endomitosis; a MK64 compartment thatreceives cells from the MK32 compartment wherein a subset of cells inthis compartment release platelets and a second subset of cells do notrelease platelets but continue with endomitosis; a MK128 compartmentthat receives cells from the MK64 compartment wherein a subset of cellsin this compartment release platelets; a platelets (PL) compartment.102. The system of claim 101 wherein an effect of apoptosis are includedwith an overall effect of cell proliferation in giving rise to anamplification of cell numbers in a corresponding compartment.
 103. Thesystem of claim 101 wherein the process model further incorporates theeffects of TPO on the SC, CFU-Meg and MKB compartments.
 104. The systemof claim 103 wherein the effects are expressed in terms of effects ofTPO concentration on amplification rate, rate of cell maturation and afraction of cells that undergo endomitosis.
 105. The system of claim 104wherein when the TPO concentration is above a predetermined thresholdlevel, the amplification rate of cells in the SC compartment areaffected and below the threshold the amplification rate is dependentonly on a current number of cells.
 106. The system of claim 103 whereinin the CFU-Meg compartment the cells are sensitive to TPO concentrationregardless of the concentration of TPO.
 107. The system of claim 103,wherein the transit time is same in all platelet releasing compartmentsand the transit time of the SC, CFU-Meg and MKB compartments arefunctions of micro-environmental conditions.
 108. The system of claim107 wherein in the SC compartment when the TPO concentration is abovethe threshold, the transit time is shortened based the dose.
 109. Thesystem of claim 107 wherein in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.
 110. The system of claim 103 whereina fraction of cells in the SC compartment that commits to megakaryocyticlineage is constant.
 111. The system of claim 103 wherein in the CFU-Megand MKB compartments, every mature cell passes on to the nextcompartment.
 112. The system of claim 103 wherein in the MK16, MK32 andMK64 compartments, a fraction of cells pass on to the next compartment,said fraction being dependent on the TPO concentration.
 113. The systemof claim 103 wherein cells from MK128 compartment do not flow into anyother compartment.
 114. The system of claim 100, wherein each of saidcompartments is further divided into sub-compartments, each of saidsub-compartments containing cells of a specific age in hours.
 115. Thesystem of claim 114 wherein cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.
 116. The system ofclaim 115, wherein the platelet releasing cells contribute platelets tothe first sub-compartment of the PL compartment.
 117. The system ofclaim 92, wherein said model is used for recommending an optimaltreatment protocol, wherein said system further comprises: a pluralityof treatment protocols; and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on themodified system model.
 118. A system for predicting progression ofThrombopoiesis and a model of Thrombocytopenia for an individual under aplurality of treatment protocols, said plurality of protocols includingno treatment, said system comprising: a Thrombopoiesis and aThrombocytopenia system model; a plurality of treatment protocols foraffecting Thrombopoiesis and treating Thrombocytopenia using at leastone drug; a system model modifier, wherein said Thrombopoiesis andThrombocytopenia system models are modified by the system model modifierbased on parameters specific to the individual; and a predictor topredict the progression of the disease or the natural biological processunder said plurality of treatment protocols based on the modified systemmodel.
 119. The system of claim 118 wherein the system modelincorporates a realistic progression of cells involved in diseasedThrombopoisis.
 120. The system of claim 119 wherein diseasedThrombopoiesis includes Thrombocytopenia.
 121. The system of claim 119wherein the system model incorporates effects of at least one drug onthe realistic progression of cells involved in Thrombocytopenia. 122.The system of claim 121 wherein said at least one drug is Thrombopoietin(TPO).
 123. The system of claim 119 wherein said process model imitatesa course of the individual's bone marrow progression, peripheralplatelet counts and TPO concentration changes.
 124. The system of claim119, wherein said process model incorporates cell-suppressive treatmenteffects and administration of TPO to the patient.
 125. The system ofclaim 124, wherein said cell-suppressive treatment is chemotherapy. 126.The system of claim 118 wherein said process model further comprises aplurality of compartments.
 127. The system of claim 126 wherein saidcompartments include: a stem cell (SC) compartment that comprises bonemarrow hemopoietic progenitors that have an ability to differentiateinto more than one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte progenitors; acolony forming units—megakaryocytes (CFU-Meg) compartment, wherein themegakaryocyte progenitors get committed as a megakaryocyte line andspend some time multiplying and maturing; a megakaryoblast (MKB)compartment, which receives the cells from CFU-Meg, wherein the cells inthe MKB compartment have lost their ability to proliferate but are notmature to release platelets; a MK16 compartment, which receives cellsfrom the MKB compartment, wherein a subset of cells in the MK16compartment release platelets at a constant rate until they exhausttheir capacity and are disintegrated and a second subset of cells do notrelease platelets but continue with endomitosis; a MK32 compartment thatreceives cells from the MK16 compartment, wherein a subset of cells inthis compartment release platelets and a second subset of cells do notrelease platelets but continue with endomitosis; a MK64 compartment thatreceives cells from the MK32 compartment wherein a subset of cells inthis compartment release platelets and a second subset of cells do notrelease platelets but continue with endomitosis; a MK128 compartmentthat receives cells from the MK64 compartment wherein a subset of cellsin this compartment release platelets; a platelets (PL) compartment.128. The system of claim 127 wherein an effect of apoptosis are includedwith an overall effect of cell proliferation in giving rise to anamplification of cell numbers in a corresponding compartment.
 129. Thesystem of claim 127 wherein the process model further incorporates theeffects of TPO on the SC, CFU-Meg and MKB compartments.
 130. The systemof claim 129 wherein the effects are expressed in terms of effects ofTPO concentration on amplification rate, rate of cell maturation and afraction of cells that undergo endomotisis.
 131. The system of claim 130wherein when the TPO concentration is above a predetermined thresholdlevel, the amplification rate of cells in the SC compartment areaffected and below the threshold the amplification rate is dependentonly on a current number of cells.
 132. The system of claim 129 whereinin the CFU-Meg compartment the cells are sensitive to TPO concentrationregardless of the concentration of TPO.
 133. The system of claim 129,wherein the transit time is same in all platelet releasing compartmentsand the transit time of the SC, CFU-Meg and MKB compartments arefunctions of micro-environmental conditions.
 134. The system of claim133 wherein in the SC compartment when the TPO concentration is abovethe threshold, the transit time is shortened based the dose.
 135. Thesystem of claim 133 wherein in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.
 136. The system of claim 135 whereina fraction of cells in the SC compartment that commits to megakaryocyticlineage is constant.
 137. The system of claim 129 wherein in the CFU-Megand MKB compartments, every mature cell passes on to the nextcompartment.
 138. The system of claim 129 wherein in the MK16, MK32 andMK64 compartments, a fraction of cells pass on to the next compartment,said fraction being dependent on the TPO concentration.
 139. The systemof claim 129 wherein cells from MK128 compartment do not flow into anyother compartment.
 140. The system of claim 126, wherein each of saidcompartments is further divided into sub-compartments, each of saidsub-compartments containing cells of a specific age in hours.
 141. Thesystem of claim 140 wherein cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.
 142. The system ofclaim 141, wherein the platelet releasing cells contribute platelets tothe first sub-compartment of the PL compartment.
 143. A system forpredicting progression of Thrombopoiesis and a model of Thrombocytopeniafor a general patient under a plurality of treatment protocols, saidplurality of protocols including no treatment, said system comprising: aThrombopoiesis and a Thrombocytopenia system model; a plurality oftreatment protocols for affecting Thrombopoiesis and treatingThrombocytopenia using at least one drug; and a predictor to predict theprogression of the disease or the natural biological process under saidplurality of treatment protocols based on the modified system model.144. The system of claim 143 wherein the system model incorporates arealistic progression of cells involved in diseased Thrombopoiesis 145.The system of claim 144 wherein diseased Thrombopoiesis includesThrombocytopenia.
 146. The system of claim 144 wherein the system modelincorporates effects of at least one drug in the realistic progressionof cells involved in Thrombocytopenia
 147. The system of claim 146wherein said at least one drug is Thrombopoietin (TPO).
 148. The systemof claim 144 wherein said process model imitates a course of theindividual's bone marrow progression, peripheral platelet counts and TPOconcentration changes.
 149. The system of claim 144, wherein saidprocess model incorporates cell-suppressive treatment effects andadministration of TPO to the patient.
 150. The system of claim 149,wherein said cell-suppressive treatment is chemotherapy.
 151. The systemof claim 144 wherein said process model further comprises a plurality ofcompartments.
 152. The system of claim 151 wherein said compartmentsinclude: a stem cell (SC) compartment that comprises bone marrowhemopoietic progenitors that have an ability to differentiate into morethan one cell line wherein cells in the stem cell compartmentproliferate and differentiate into one of megakaryocyte progenitors; acolony forming units—megakaryocytes (CFU-Meg) compartment, wherein themegakaryocyte progenitors get committed as a megakaryocyte line andspend some time multiplying and maturing; a megakaryoblast (MKB)compartment, which receives the cells from CFU-Meg, wherein the cells inthe MKB compartment have lost their ability to proliferate but are notmature to release platelets; a MK16 compartment, which receives cellsfrom the MKB compartment, wherein a subset of cells in the MK16compartment release platelets at a constant rate until they exhausttheir capacity and are disintegrated and a second subset of cells do notrelease platelets but continue with endomitosis; a MK32 compartment thatreceives cells from the MK16 compartment, wherein a subset of cells inthis compartment release platelets and a second subset of cells do notrelease platelets but continue with endomitosis; a MK64 compartment thatreceives cells from the MK32 compartment wherein a subset of cells inthis compartment release platelets and a second subset of cells do notrelease platelets but continue with endomitosis; a MK128 compartmentthat receives cells from the MK64 compartment wherein a subset of cellsin this compartment release platelets; a platelets (PL) compartment.153. The system of claim 152 wherein an effect of apoptosis are includedwith an overall effect of cell proliferation in giving rise to anamplification of cell numbers in a corresponding compartment.
 154. Thesystem of claim 152 wherein the process model further incorporates theeffects of TPO on the SC, CFU-Meg and MKB compartments.
 155. The systemof claim 154 wherein the effects are expressed in terms of effects ofTPO concentration on amplification rate, rate of cell maturation and afraction of cells that undergo endomotisis.
 156. The system of claim 155wherein when the TPO concentration is above a predetermined thresholdlevel, the amplification rate of cells in the SC compartment areaffected and below the threshold the amplification rate is dependentonly on a current number of cells.
 157. The system of claim 154 whereinin the CFU-Meg compartment the cells are sensitive to TPO concentrationregardless of the concentration of TPO.
 158. The system of claim 154,wherein the transit time is same in all platelet releasing compartmentsand the transit time of the SC, CFU-Meg and MKB compartments arefunctions of micro-environmental conditions.
 159. The system of claim158 wherein in the SC compartment when the TPO concentration is abovethe threshold, the transit time is shortened based the dose.
 160. Thesystem of claim 158 wherein in the CFU-Meg and MKB, the transit time issolely based on TPO concentration.
 161. The system of claim 154 whereina fraction of cells in the SC compartment that commits to megakaryocyticlineage is constant.
 162. The system of claim 154 wherein in the CFU-Megand MKB compartments, every mature cell passes on to the nextcompartment.
 163. The system of claim 154 wherein in the MK16, MK32 andMK64 compartments, a fraction of cells pass on to the next compartment,said fraction being dependent on the TPO concentration.
 164. The systemof claim 154 wherein cells from MK128 compartment do not flow into anyother compartment.
 165. The system of claim 151, wherein each of saidcompartments is further divided into sub-compartments, each of saidsub-compartments containing cells of a specific age in hours.
 166. Thesystem of claim 165 wherein cells that spend all their correspondingtransit time in a given compartment pass on to the next compartment,wherein cells that have left a corresponding compartment each hour fillthe first sub-compartment of the next compartment.
 167. The system ofclaim 166, wherein the platelet releasing cells contribute platelets tothe first sub-compartment of the PL compartment.
 168. A system formodelling Neutrophil lineage for an individual, said system comprising:a Neutrophil system model including a realistic process model for cellsinvolved in Granulopoiesis; and a system model modifier, wherein saidNeutrophil system model is modified by the system model modifier basedon parameters specific to the individual.
 169. The system of claim 168wherein the system model incorporates a realistic progression of cellsinvolved in Granulopoietic disorders, including Neutropenia.
 170. Thesystem of claim 169 wherein the system incorporates effects of at leastone drug in the realistic progression of cells involved inGranulopoiesis and Neutropenia.
 171. The system of claim 170 whereinsaid at least one drug is Granulocyte Colony Stimulating Factor (G-CSF).172. The system of claim 171 wherein said model comprises at least threestages, a first stage related to an administered amount of cytokine; asecond stage representing a pharmacokinetic behavior of G-CSF; and athird stage representing a phrmacodynamic effect of G-CSF on kineticparameters of the system.
 173. The system of claim 168 wherein saidmodel comprises a mitotic compartment, and a post mitotic compartment,said mitotic compartment being divided into subcompartments wherein akth sub-compartment contains cells of age between k−1 and k hoursrelative to a time of entry into the mitotic compartment.
 174. Thesystem of claim 173, wherein effects of toxic drugs, includingchemotherapy are incorporated by mapping various cell-cycle phases tothe sub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.
 175. Thesystem of claim 173 wherein the effects of G-CSF on the mitoticcompartment are modeled as an increase in a rate of cells entering themyeloblasts compartment from an uncommitted stem cell pool.
 176. Thesystem of claim 173 wherein the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters a Neutrophil poolevery hour.
 177. The system of claim 173 wherein effects of G-CSF on theNeutrophil lineage are modeled as a decrease in the cells in thepost-mitotic compartment which is subsequently compensated by anincreased production in the mitotic compartment, said compensationsustaining an increase in mature Neutrophil count.
 178. The system ofclaim 173, wherein an elimination of Neutrophils in the post-mitoticcompartment is represented by a Poisson distribution.
 179. The system ofclaim 173, wherein the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.
 180. The system of claim 173, wherein kinetic ofG-CSF is modeled as an exponential distribution.
 181. The system ofclaim 169, wherein a selection of an optimal treatment uses an objectivefunction that aims at minimizing G-CSF administration and returningNeutrophil lineage to normal levels.
 182. The system of claim 181,wherein said selection is performed using linear programming.
 183. Thesystem of claim 182, wherein phrmacokinetics and pharmacodynamics ofG-CSF are defined using piecewise linear functions.
 184. The system ofclaim 168, wherein said model is used for recommending an optimaltreatment protocol, wherein said system further comprises: a pluralityof treatment protocols; and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on themodified system model.
 185. A system for modelling Neutrophil lineagefor a general patient, said system comprising a Granulopoiesis systemmodel including a realistic process model for cells involved inNeutrophil production.
 186. The system of claim 185 wherein the systemmodel incorporates a realistic progression of cells involved inGranulopoiesis disorders including Neutropenia.
 187. The system of claim186 wherein the system incorporates effects of at least one drug in therealistic progression of cells involved in Granulopoiesis disordersincluding Neutropenia.
 188. The system of claim 187 wherein said atleast one drug is Granulocyte Colony Stimulating Factor (G-CSF). 189.The system of claim 188 wherein said model comprises at least threestages, a first stage related to an administered amount of cytokine; asecond stage representing a pharmacokinetic behavior of G-CSF; and athird stage representing a phrmacodynamic effect of G-CSF on kineticparameters.
 190. The system of claim 185 wherein said model comprises amitotic compartment, and a post mitotic compartment, said mitoticcompartment being divided into subcompartments wherein a kthsub-compartment contains cells of age between k−1 and k hours relativeto a time of entry into the mitotic compartment.
 191. The system ofclaim 190, wherein effects of toxic drugs, including chemotherapy areincorporated by mapping various cell-cycle phases to thesub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.
 192. Thesystem of claim 190 wherein the effects of G-CSF on the mitoticcompartment are modeled as an increase in a rate of cells entering themyeloblasts compartment from an uncommitted stem cell pool.
 193. Thesystem of claim 190 wherein the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters a Neutrophil poolevery hour.
 194. The system of claim 190 wherein effects of G-CSF on theNeutrophil lineage are modeled as a decrease in the cells in thepost-mitotic compartment which is subsequently compensated by anincreased production in the mitotic compartment, said compensationsustaining an increase in Neutrophil count.
 195. The system of claim190, wherein an elimination of Neutrophils in the post-mitoticcompartment is represented by a Poisson distribution.
 196. The system ofclaim 190, wherein the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.
 197. The system of claim 190, wherein kinetic ofG-CSF is modeled as an exponential distribution.
 198. The system ofclaim 186, wherein a selection of an optimal treatment uses an objectivefunction that aims at minimizing G-CSF administration and returningNeutrophil lineage to normal levels.
 199. The system of claim 198,wherein said selection is performed using linear programming.
 200. Thesystem of claim 199, wherein phrmacokinetics and pharmacodynamics ofG-CSF are defined using piecewise linear functions.
 201. The system ofclaim 185, wherein said model is used for recommending an optimaltreatment protocol, wherein said system further comprises: a pluralityof treatment protocols; and a selector to select an optimal treatmentprotocol from said plurality of treatment protocols based on themodified system model.
 202. A system for predicting progression ofGranulopoiesis for an individual under a plurality of treatmentprotocols, said plurality of protocols including no treatment, saidsystem comprising: a Granulopoiesis system model including a realisticprocess model for cells involved in Neutrophil production; a pluralityof treatment protocols; and a system model modifier, wherein saidNeutrophil production system model is modified by the system modelmodifier based on parameters specific to the individual; and a predictorthat predicts the progression under the plurality of treatment protocolsbased on the modified system model.
 203. The system of claim 202 whereinthe system model incorporates a realistic progression of cells involvedin Granulopoietic disorders, including Neutropenia.
 204. The system ofclaim 203 wherein the system incorporates effects of at least one drugin the realistic progression of cells involved in Granulopoiesis andNeutropenia.
 205. The system of claim 204 wherein said at least one drugis Granulocyte Colony Stimulating Factor (G-CSF).
 206. The system ofclaim 205 wherein said model comprises at least three stages, a firststage related to an administered amount of cytokine; a second stagerepresenting a pharmacokinetic behavior of G-CSF; and a third stagerepresenting a phrmacodynamic effect of G-CSF on kinetic parameters.207. The system of claim 202 wherein said model comprises a mitoticcompartment, and a post mitotic compartment, said mitotic compartmentbeing divided into subcompartments wherein a kth sub-compartmentcontains cells of age between k−1 and k hours relative to a time ofentry into the mitotic compartment.
 208. The system of claim 207,wherein effects of toxic drugs, including chemotherapy are incorporatedby mapping various cell-cycle phases to the sub-compartments andformulating a function of cytotoxic effects of toxic drugs, includingchemotherapy on the cell-cycle phases.
 209. The system of claim 207wherein the effects of G-CSF on the mitotic compartment are modeled asan increase in a rate of cells entering the myeloblasts compartment froman uncommitted stem cell pool.
 210. The system of claim 207 wherein thepost-mitotic compartment is modeled as a single pool of cells whereincells in a last sub-compartment of the mitotic compartment enters thepost-mitotic compartment and a proportion of cells within thepost-mitotic compartment enters a Neutrophil pool every hour.
 211. Thesystem of claim 207 wherein effects of G-CSF on the Neutrophil lineageare modeled as a decrease in the cells in the post-mitotic compartmentwhich is subsequently compensated by an increased production in themitotic compartment, said compensation sustaining an increase in matureNeutrophil count.
 212. The system of claim 207, wherein an eliminationof Neutrophils in the post-mitotic compartment is represented by aPoisson distribution.
 213. The system of claim 207, wherein thecytotoxic effects of toxic drugs, including chemotherapy in thepost-mitotic compartment is modeled as an effect on a single pool ofcells.
 214. The system of claim 207, wherein kinetic of G-CSF is modeledas an exponential distribution.
 215. The system of claim 203, wherein aselection of an optimal treatment uses an objective function that aimsat minimizing G-CSF administration and returning Neutrophil lineage tonormal levels.
 216. The system of claim 215, wherein said selection isperformed using linear programming.
 217. The system of claim 216,wherein phrmacokinetics and pharmacodynamics of G-CSF are defined usingpiecewise linear functions.
 218. A system for predicting progression ofGranulopoiesis for a general patient under a plurality of treatmentprotocols, said plurality of protocols including no treatment, saidsystem comprising: a Neutrophil system model including a realisticprocess model for cells involved in Neutrophil production; a pluralityof treatment protocols; and a predictor that predicts the progressionunder the plurality of treatment protocols based on the modified systemmodel.
 219. The system of claim 218 wherein the system modelincorporates a realistic progression of cells involved in Granulopoieticdisorders, including Neutropenia.
 220. The system of claim 219 whereinthe system incorporates effects of at least one drug in the realisticprogression of cells involved in Granulopoiesis and Neutropenia. 221.The system of claim 220 wherein said at least one drug is GranulocyteColony Stimulating Factor (G-CSF).
 222. The system of claim 221 whereinsaid model comprises at least three stages, a first stage related to anadministered amount of cytokine; a second stage representing apharmacokinetic behavior of G-CSF; and a third stage representing aphrmacodynamic effect of G-CSF on kinetic parameters.
 223. The system ofclaim 218 wherein said model comprises a mitotic compartment, and a postmitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.
 224. The system of claim 223, wherein effects of toxicdrugs, including chemotherapy are incorporated by mapping variouscell-cycle phases to the sub-compartments and formulating a function ofcytotoxic effects of toxic drugs, including chemotherapy on thecell-cycle phases.
 225. The system of claim 223 wherein the effects ofG-CSF on the mitotic compartment are modeled as an increase in a rate ofcells entering the myeloblasts compartment from an uncommitted stem cellpool.
 226. The system of claim 223 wherein the post-mitotic compartmentis modeled as a single pool of cells wherein cells in a lastsub-compartment of the mitotic compartment enters the post-mitoticcompartment and a proportion of cells within the post-mitoticcompartment enters a Neutrophil pool every hour.
 227. The system ofclaim 223 wherein effects of G-CSF on the Neutrophil lineage are modeledas a decrease in the cells in the post-mitotic compartment which issubsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in matureNeutrophil count.
 228. The system of claim 223, wherein an eliminationof Neutrophils in the post-mitotic compartment is represented by aPoisson distribution.
 229. The system of claim 223, wherein thecytotoxic effects of toxic drugs, including chemotherapy in thepost-mitotic compartment is modeled as an effect on a single pool ofcells.
 230. The system of claim 223, wherein kinetic of G-CSF is modeledas an exponential distribution.
 231. The system of claim 219, wherein aselection of an optimal treatment uses an objective function that aimsat minimizing G-CSF administration and returning Neutrophil lineage tonormal levels.
 232. The system of claim 231, wherein said selection isperformed using linear programming.
 233. The system of claim 232,wherein phrmacokinetics and pharmacodynamics of G-CSF are defined usingpiecewise linear functions.
 234. A system for recommending an optimaltreatment protocol for treating cancer using drugs, includingchemotherapy, for an individual, said system comprising: a cancer systemmodel; a plurality of treatment protocols for treating cancer usingchemotherapy; a system model modifier, wherein said cancer system modelis modified by the system model modifier based on parameters specific tothe individual; and a selector to select an optimal treatment protocolfrom said plurality of treatment protocols based on the modified systemmodel.
 235. The system of claim 234 wherein the system model furthercomprises: a realistic process model of cancer development; and arealistic treatment model that models the effects of treating cancerwith drugs, including chemotherapy.
 236. The system of claim 235 whereinsaid process model incorporates a distribution of cycling cells andquiescent cells.
 237. The system of claim 235 where a tumor cell cycleis divided into at least four compartments G1, S, G2 and M and aquiescent stage is denoted by G0, wherein each of said four compartmentsis further subdivided into sub-compartments and an ith sub-compartmentrepresenting cells of age I in the corresponding compartment, whereincells entering a compartment always enter a first sub-compartment of thecompartment.
 238. The system of claim 237 wherein the model tracesdevelopment of cancer cells using a predetermined set of parameters bycalculating a number of cells in each subcompartment using stepwiseequations.
 239. The system of claim 238 wherein a probability vector isused to determine a fraction of cells that leaves any subcompartment ina compartment to move to a first subcompartment of the next compartment.240. The system of claim 238 where a set control functions uniquelydetermine an outcome of every single step, wherein said controlfunctions depend on age of cells, state of a current population andassociated environment.
 241. The system of claim 238 wherein a tumor ismodelled as a combination of a plurality of homogeneous group of cells,each of said homogeneous group of cells representing a similarlybehaving group of cells distributed between all the cell-cyclecompartments.
 242. The system of claim 241, wherein in each step, anumber of cells in each sub-compartment of each compartment of eachgroup is calculated according to factors including a previous state,parameters of tumor, tumor current microenvironment and drugconcentration.
 243. The system of claim 242 where spatial structure ofthe tumor is included in the model.
 244. The system of claim 243,wherein PK and PD, cytostatic effects, cytotoxic effects, and othereffects on cell disintegration of anticancer drugs are incorporated intothe model.
 245. The system of claim 244 wherein a dose-limiting toxicityis incorporated into the model.
 246. The system of claim 231 wherein,said parameters specific to the individual comprise parameters relatedto tumor dynamics, patient specific drug PK, and dynamics ofdose-limiting host tissues.
 247. The system of claim 246, wherein saidparameters related to tumor dynamics comprise age, weight, gender,percentage of limiting healthy cells, desired length of treatmentprotocol, previous reaction to treatment, molecular markers, geneticmarkers, pathologic specifics and cytologic specifics.
 248. A system forpredicting the a progression of cancer in individual patientscomprising: a cancer system model; a plurality of treatment protocolsfor treating cancer using drugs, including chemotherapy; a system modelmodifier, wherein said cancer system model is modified by the systemmodel modifier based on parameters specific to the individual; and apredictor to predict the progression of cancer under the plurality oftreatment protocols based on the modified system model.
 249. The systemof claim 248 wherein the system model further comprises: a realisticprocess model of cancer development; and a realistic treatment modelthat models the effects of treating cancer with drugs, includingchemotherapy.
 250. The system of claim 249 wherein said process modelincorporates a distribution of cycling cells and quiescent cells. 251.The system of claim 249 where a tumor cell cycle is divided into atleast four compartments G1, S, G2 and M and a quiescent stage is denotedby G0, wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age inthe corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.
 252. The systemof claim 251 wherein the model traces development of cancer cells usinga predetermined set of parameters by calculating a number of cells ineach subcompartment using stepwise equations.
 253. The system of claim252 wherein a probability vector is used to determine a fraction ofcells that leaves any subcompartment in a compartment to move to a firstsubcompartment of the next compartment.
 254. The system of claim 252where a set control functions uniquely determine an outcome of everysingle step, wherein said control functions depend on age of cells,state of a current population and associated environment.
 255. Thesystem of claim 252 wherein a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.
 256. The system of claim 255,wherein in each step, a number of cells in each sub-compartment of eachcompartment of each group is calculated according to factors including aprevious state, parameters of tumor, tumor current microenvironment anddrug concentration.
 257. The system of claim 256 where spatial structureof the tumor is included in the model.
 258. The system of claim 257,wherein PK and PD, cytotoxic effects and cytostatic effects ofanticancer drugs are incorporated into the model.
 259. The system ofclaim 258 wherein a dose-limiting toxicity is incorporated into themodel.
 260. The system of claim 248 wherein, said parameters specific tothe individual comprise parameters related to tumor dynamics, patientspecific drug PK, and dynamics of dose-limiting host tissues.
 261. Thesystem of claim 260, wherein said parameters related to tumor dynamicscomprise age, weight, gender, percentage of limiting healthy cells,desired length of treatment protocol, previous reaction to treatment,molecular markers, genetic markers, pathologic specifics and cytologicspecifics.
 262. A system for predicting the a progression of cancer in ageneral patients comprising: a cancer system model; a plurality oftreatment protocols for treating cancer using drugs, includingchemotherapy; and a predictor to predict the progression of cancer underthe plurality of treatment protocols based on the modified system model.263. The system of claim 262 wherein the system model further comprises:a realistic process model of cancer development; and a realistictreatment model that models the effects of treating cancer with drugs,including chemotherapy.
 264. The system of claim 263 wherein saidprocess model incorporates a distribution of cycling cells and quiescentcells.
 265. The system of claim 263 where a tumor cell cycle is dividedinto at least four compartments G1, S, G2 and M and a quiescent stage isdenoted by G0, wherein each of said four compartments is furthersubdivided into sub-compartments and an ith sub-compartment representingcells of age I in the corresponding compartment, wherein cells enteringa compartment always enter a first sub-compartment of the compartment.266. The system of claim 265 wherein the model traces development ofcancer cells using a predetermined set of parameters by calculating anumber of cells in each subcompartment using stepwise equations. 267.The system of claim 266 wherein a probability vector is used todetermine a fraction of cells that leaves any subcompartment in acompartment to move to a first subcompartment of the next compartment.268. The system of claim 266 where a set control functions uniquelydetermine an outcome of every single step, wherein said controlfunctions depend on age of cells, state of a current population andassociated environment.
 269. The system of claim 266 wherein a tumor ismodelled as a combination of a plurality of homogeneous group of cells,each of said homogeneous group of cells representing a similarlybehaving group of cells distributed between all the cell-cyclecompartments.
 270. The system of claim 269, wherein in each step, anumber of cells in each sub-compartment of each compartment of eachgroup is calculated according to factors including a previous state,parameters of tumor, tumor current microenvironment and drugconcentration.
 271. The system of claim 270 where spatial structure ofthe tumor is included in the model.
 272. The system of claim 271,wherein PK and PD, cytotoxic effects and cytostatic effects ofanticancer drugs are incorporated into the model.
 273. The system ofclaim 272 wherein a dose-limiting toxicity is incorporated into themodel.
 274. A method of recommending an optimal treatment protocol foran individual comprising: creating a system model; enumerating aplurality of treatment protocols; modifying the system model based onparameters specific to the individual; and selecting an optimaltreatment protocol from said plurality of treatment protocols based onthe modified system model.
 275. The method of claim 274 wherein the stepof creating the system model further comprises: modelling a biologicalprocess; and realistically modelling effects of a treatment on saidbiological process.
 276. The method of claim 275, wherein said modellingof biological processes is done by mathematical modelling biologicalprocesses affecting healthy cell populations and mathematicallymodelling biological processes affecting cell populations with at leastone disease.
 277. The method of claim 276 wherein said healthy cellpopulations include bone-marrow cells and host tissue cells that areaffected by said treatment model.
 278. The method of claim 276 whereinsaid cell populations with at least one disease is one of cancer cells,and diseased bone-marrow cells including diseased Neutrophil cells anddiseased Thrompocyte cells.
 279. The method of claim 275, wherein saidtreatment models comprise treatment specific processes that affect cellpopulations.
 280. The method of claim 279 wherein said treatmentspecific process is interactions involving at least one of a groupcomprising pharmacokinetic (PK), pharmacodynamic (PD), cytostatic,cytotoxic, and methods of affecting cell biology and causing cell death,with associated biological processes.
 281. The method of claim 274wherein, said parameters specific to the individual include one or moreselected from a group consisting of parameters related to the biologicalprocess' dynamics, patient specific drug PK, PD and dynamics ofdose-limiting host tissues.
 282. The method of claim 281, wherein saidparameters related to biological process' dynamics comprise age, weight,gender, blood picture, desired length of treatment protocol, previousreaction to treatment, molecular markers, genetic markers, pathologicspecifics and cytologic specifics.
 283. The method of claim 274, whereinuser-specific parameters are used in selecting the optimal treatment.284. The method of claim 283 wherein a fitness function is used toperform the selection.
 285. The method of claim 284 wherein said fitnessfunction incorporates at least one parameter selected from a groupconsisting patient survival, time to death, time to reach a specifieddisease stage (including cure), tumor load, pathogen load, cytotoxicity,side effects, quality of life, cost of treatment and pain.
 286. Themethod of claim 285, wherein a user can input specific coefficients forsaid at least one parameter to adjust the fitness function to satisfythe user's goals.
 287. The method of claim 283, wherein theuser-specific parameters are based on a user, said user being a medicaldoctor.
 288. The method of claim 283, wherein the user-specificparameters are based on a user, said user being a scientist.
 289. Themethod of claim 283, wherein the user-specific parameters are based on auser, said user being a drug developer.
 290. The method of claim 274wherein said selection of treatment protocols incorporate cytotoxiceffects.
 291. The method of claim 274 wherein said selection oftreatment protocols incorporate drug.
 292. The method of claim 274,wherein operation research techniques are used in performing theselection.
 293. The method of claim 274, wherein heuristics are used toperform searching and selection.
 294. The method of claim 293 wherein,said heuristics comprise computational feasibility.
 295. The method ofclaim 274 wherein said recommendation is a combination of disease andtreatment strategy, including types of treatment, e.g., chemotherapy,radiotherapy, surgery, immunotherapy, etc, device, drug or drugcombination, and treatment schedule.
 296. A Method of recommending anoptimal treatment protocol for a general patient comprising: creating asystem model; enumerating a plurality of treatment protocols; andselecting an optimal treatment protocol from said plurality of treatmentprotocols based on the modified system model.
 297. The method of claim296 wherein the step of creating the system model further comprises:modelling a biological process; and realistically modelling effects of atreatment on said biological process.
 298. The method of claim 297,wherein said modelling of biological processes is done by mathematicalmodelling biological processes affecting healthy cell populations andmathematically modelling biological processes affecting cell populationswith at least one disease.
 299. The method of claim 298 wherein saidhealthy cell populations include bone-marrow cells and host tissue cellsthat are affected by said treatment model.
 300. The method of claim 298wherein said cell populations with at least one disease is one of cancercells, and diseased bone-marrow cells including diseased Neutrophilcells and diseased Thrompocyte cells.
 301. The method of claim 297,wherein said treatment models comprise treatment specific processes thataffect cell populations.
 302. The method of claim 301 wherein saidtreatment specific process is interactions involving one of a groupcomprising pharmacokinetic, pharmacodynamic, cytostatic, cytotoxic, orany other method of affecting cell biology and causing cell death, withassociated biological processes.
 303. The method of claim 296, whereinuser-specific parameters are used in selecting the optimal treatment.304. The method of claim 303 wherein a fitness function is used toperform the selection.
 305. The method of claim 304 wherein said fitnessfunction incorporates at least one parameter selected from a groupcomprising patient survival, time to death, time to reach a specifieddisease stage (including cure), tumor load, pathogen load, cytotoxicity,side effects, quality of life, cost of treatment and pain.
 306. Themethod of claim 305, wherein a user can input specific coefficients forsaid at least one parameter to adjust the fitness function to satisfythe user's goals.
 307. The method of claim 303, wherein theuser-specific parameters are based on a user, said user being a medicaldoctor.
 308. The method of claim 303, wherein the user-specificparameters are based on a user, said user being a scientist.
 309. Themethod of claim 303, wherein the user-specific parameters are based on auser, said user being a drug developer.
 310. The method of claim 296wherein said selection of treatment protocols incorporate cytotoxiceffects.
 311. The method of claim 296 wherein said selection oftreatment protocols incorporate drug efficacy.
 312. The method of claim296, wherein operation research techniques are used in performing theselection.
 313. The method of claim 296, wherein heuristics are used toperform searching and selection.
 314. The method of claim 313 wherein,said heuristics comprise computational feasibility.
 315. The method ofclaim 296 wherein said recommendation is a combination of disease andtreatment strategy, including types of treatment, e.g., chemotherapy,radiotherapy, surgery, immunotherapy, etc, device, drug or drugcombination, and treatment schedule.
 316. A method of predictingprogression of a biological process in an individual patient under aplurality of treatment protocols, wherein said biological process couldbe related to healthy or diseased processes, said plurality of protocolsincluding no treatment, said method comprising: creating a system model;enumerating a plurality of treatment protocols; and modifying the systemmodel based on parameters specific to the individual. selecting anoptimal treatment protocol from said plurality of treatment protocolsbased on the modified system model.
 317. The method of claim 316 whereinthe step of creating a system model further comprises: realisticallymodelling a biological process; and realistically modelling the effectsof the treatment on said biological process.
 318. The method of claim317, wherein said step of modelling a biological process comprisescreating a mathematical model for biological processes affecting healthycell populations and creating a biological processes affecting cellpopulations with at least one disease.
 319. The method of claim 318wherein said healthy cell populations include bone-marrow cells and hosttissue cells that are affected by said treatment model.
 320. The methodof claim 318 wherein said cell populations with at least one disease isone of cancer cells, and diseased bone-marrow cells including diseasedNeutrophil cells and diseased Thrombocyte cells.
 321. The method ofclaim 317, wherein said treatment models comprise treatment specificprocesses that affect cell populations.
 322. The method of claim 321wherein said treatment specific process is interactions involving one ofa group comprising PK, PD, drug cytostatics, drug cytotoxics, or anyother method of affecting cell biology and causing cell death, withassociated biological processes.
 323. The method of claim 316 wherein,said parameters specific to the individual include one or more selectedfrom a group consisting of parameters related to the biological process'dynamics, patient specific drug PK, PD and dynamics of dose-limitinghost tissues.
 324. The method of claim 323, wherein said parametersrelated to biological process' dynamics comprise age, weight, gender,blood picture, desired length of treatment protocol, previous reactionto treatment, molecular markers, genetic markers, pathologic specificsand cytologic specifics.
 325. A method of predicting progression of abiological process in a general patient under a plurality of treatmentprotocols, wherein said biological process could be related to healthyor diseased, said plurality of protocols including no treatment, saidmethod comprising: creating a system model; enumerating a plurality oftreatment protocols; and selecting an optimal treatment protocol fromsaid plurality of treatment protocols based on the modified systemmodel.
 326. The method of claim 325 wherein the step of creating asystem model further comprises: realistically modelling a biologicalprocess; and realistically modelling the and the effects of thetreatment on said biological process.
 327. The method of claim 326,wherein said step of modelling a biological process comprises creating amathematical model for biological processes affecting healthy cellpopulations and creating a biological processes affecting cellpopulations with at least one disease.
 328. The method of claim 327wherein said healthy cell populations include bone-marrow cells and hosttissue cells that are affected by said treatment model.
 329. The methodof claim 327 wherein said cell populations with at least one disease isone of cancer cells, and diseased bone-marrow cells including at leastone of diseased Neutrophil cells and diseased Thrombocyte cells. 330.The method of claim 326, wherein said treatment models comprisetreatment specific processes that affect cell populations.
 331. Themethod of claim 330 wherein said treatment specific process isinteractions involving one of a group comprising PK, PD cytostatic,cytotoxic, and methods of affecting cell biology and causing cell death,with associated biological processes.
 332. A method for modellingThrombopietic lineage in an individual, said method comprising:realistically modelling a process to create a process model for cellsinvolved in Thrombopoiesis; and modifying the process model based onparameters specific to the individual.
 333. The method of claim 332wherein a realistic progression of cells involved in diseasedThrombopoiesis is incorporated in the process model.
 334. The method ofclaim 333 wherein diseased Thrombopoiesis includes Thrombocytopenia.335. The method of claim 333 wherein effects of at least one drug in therealistic progression of cells involved in Thrombopoiesis isincorporated.
 336. The method of claim 335 wherein said at least onedrug is Thrombopoietin (TPO).
 337. The method of claim 333 wherein saidprocess model imitates a course of the individual's bone marrowprogression, peripheral platelet counts and TPO concentration changes.338. The method of claim 333, wherein said process model incorporatescell-suppressive treatment effects and administration of TPO to thepatient.
 339. The method of claim 338, wherein said cell-suppressivetreatment is chemotherapy.
 340. The method of claim 333, wherein saidmethod is used for recommending an optimum treatment protocol, andwherein said method further comprises: enumerating a plurality oftreatment protocols; and selecting an optimal treatment protocol fromsaid plurality of treatment protocols based on the modified systemmodel.
 341. A method for modelling Thrombopietic lineage in a generalpatient, said method comprising: realistically modelling a process tocreate a process model for cells involved in Thrombopoiesis.
 342. Themethod of claim 341 wherein a realistic progression of cells involved indiseased thrombopoiesis is incorporated in the process model.
 343. Themethod of claim 342 wherein diseased Thrombopoiesis includesThrombocytopenia.
 344. The method of claim 342 wherein effects of atleast one drug in the realistic progression of cells involved inThrombopoiesis is incorporated.
 345. The method of claim 344 whereinsaid at least one drug is Thrombopoietin (TPO).
 346. The method of claim342 wherein said process model imitates a course of the individual'sbone marrow progression, peripheral platelet counts and TPOconcentration changes.
 347. The method of claim 342, wherein saidprocess model incorporates cell-suppressive treatment effects andadministration of TPO to the patient.
 348. The method of claim 347,wherein said cell-suppressive treatment is chemotherapy.
 349. The methodof claim 342, wherein said method is used for recommending an optimumtreatment protocol, and wherein said method further comprises:enumerating a plurality of treatment protocols; and selecting an optimaltreatment protocol from said plurality of treatment protocols based onthe modified system model.
 350. A method for predicting progression ofThrombopoiesis and Thrombocytopenia for an individual under a pluralityof treatment protocols, said plurality of protocols including notreatment, said method comprising: creating a realistic model ofThrombopoiesis and Thrombocytopenia; generating a plurality of treatmentprotocols for affecting Thrombopoiesis and treating Thrombocytopeniausing at least one drug; modifying the model based on parametersspecific to the individual; and predicting the progression of thedisease or the natural biological process under said plurality oftreatment protocols based on the modified system model.
 351. The methodof claim 350 wherein the model incorporates a realistic progression ofcells involved in diseased Thrombopoiesis.
 352. The method of claim 351wherein diseased Thrombopoiesis includes Thrombocytopenia.
 353. Themethod of claim 351 wherein the model incorporates effects of at leastone drug in the realistic progression of cells involved inThrombocytopenia.
 354. The method of claim 353 wherein said at least onedrug is Thrombopoietin (TPO).
 355. The method of claim 351 wherein themodel imitates a course of the individual's bone marrow progression,peripheral platelet counts and TPO concentration changes.
 356. Themethod of claim 351, wherein the model incorporates cell-suppressivetreatment effects and administration of TPO to the patient.
 357. Themethod of claim 356, wherein said cell-suppressive treatment ischemotherapy.
 358. The method of claim 351 wherein said process modelfurther comprises a plurality of compartments.
 359. The method of claim358 wherein said compartments include: a stem cell (SC) compartment thatcomprises bone marrow hemopoietic progenitors that have an ability todifferentiate into more than one cell line wherein cells in the stemcell compartment proliferate and differentiate into one of megakaryocyteprogenitors; a colony forming units—megakaryocytes (CFU-Meg)compartment, wherein the megakaryocyte progenitors get committed as amegakaryocyte line and spend some time multiplying and maturing; amegakaryoblast (MKB) compartment, which receives the cells from CFU-Meg,wherein the cells in the MKB compartment have lost their ability toproliferate but are not mature to release platelets; a MK16 compartment,which receives cells from the MKB compartment, wherein a subset of cellsin the MK16 compartment release platelets at a constant rate until theyexhaust their capacity and are disintegrated and a second subset ofcells do not release platelets but continue with endomitosis; a MK32compartment that receives cells from the MK16 compartment, wherein asubset of cells in this compartment release platelets and a secondsubset of cells do not release platelets but continue with endomitosis;a MK64 compartment that receives cells from the MK32 compartment whereina subset of cells in this compartment release platelets and a secondsubset of cells do not release platelets but continue with endomitosis;a MK128 compartment that receives cells from the MK64 compartmentwherein a subset of cells in this compartment release platelets; aplatelets (PL) compartment.
 360. The method of claim 359 wherein aneffect of apoptosis are included with an overall effect of cellproliferation in giving rise to an amplification of cell numbers in acorresponding compartment.
 361. The method of claim 359 wherein themodel further incorporates the effects of TPO on the SC, CFU-Meg and MKBcompartments.
 362. The method of claim 361 wherein the effects areexpressed in terms of effects of TPO concentration on amplificationrate, rate of cell maturation and a fraction of cells that undergoendomotisis.
 363. The method of claim 362 wherein when the TPOconcentration is above a predetermined threshold level, theamplification rate of cells in the SC compartment are affected and belowthe threshold the amplification rate is dependent only on a currentnumber of cells.
 364. The method of claim 361 wherein in the CFU-Megcompartment the cells are sensitive to TPO concentration regardless ofthe concentration of TPO.
 365. The method of claim 361, wherein thetransit time is same in all platelet releasing compartments and thetransit time of the SC, CFU-Meg and MKB compartments are functions ofmicro-environmental conditions.
 366. The method of claim 365 wherein inthe SC compartment when the TPO concentration is above the threshold,the transit time is shortened based the dose.
 367. The method of claim365 wherein in the CFU-Meg and MKB, the transit time is solely based onTPO concentration.
 368. The method of claim 361 wherein a fraction ofcells in the SC compartment that commits to megakaryocytic lineage isconstant.
 369. The method of claim 361 wherein in the CFU-Meg and MKBcompartments, every mature cell passes on to the next compartment. 370.The method of claim 361 wherein in the MK16, MK32 and MK64 compartments,a fraction of cells pass on to the next compartment, said fraction beingdependent on the TPO concentration.
 371. The method of claim 361 whereincells from MK128 compartment do not flow into any other compartment.372. The method of claim 358, wherein each of said compartments isfurther divided into sub-compartments, each of said sub-compartmentscontaining cells of a specific age in hours.
 373. The method of claim372 wherein cells that spend all their corresponding transit time in agiven compartment pass on to the next compartment, wherein cells thathave left a corresponding compartment each hour fill the firstsub-compartment of the next compartment.
 374. The method of claim 373,wherein the platelet releasing cells contribute platelets to the firstsub-compartment of the PL compartment.
 375. A method for predictingprogression of Thrombopoiesis and Thrombocytopenia for a general patientunder a plurality of treatment protocols, said plurality of protocolsincluding no treatment, said method comprising: creating a realisticmodel Thrombopoiesis and Thrombocytopenia; generating a plurality oftreatment protocols for affecting Thrombopoiesis and treatingThrombocytopenia using at least one drug; and predicting the progressionof the disease or the natural biological process under said plurality oftreatment protocols based on the modified system model.
 376. The methodof claim 375 wherein the model incorporates a realistic progression ofcells involved in diseased Thrombopoiesis.
 377. The method of claim 376wherein diseased Thrombopoiesis includes Thrombocytopenia.
 378. Themethod of claim 376 wherein the model incorporates effects of at leastone drug in the realistic progression of cells involved inThrombocytopenia.
 379. The method of claim 378 wherein said at least onedrug is Thrombopoietin (TPO).
 380. The method of claim 376 wherein themodel imitates a course of the individual's bone marrow progression,peripheral platelet counts and TPO concentration changes.
 381. Themethod of claim 376, wherein the model incorporates cell-suppressivetreatment effects and administration of TPO to the patient.
 382. Themethod of claim 381, wherein said cell-suppressive treatment ischemotherapy.
 383. The method of claim 376 wherein said process modelfurther comprises a plurality of compartments.
 384. The method of claim383 wherein said compartments include: a stem cell (SC) compartment thatcomprises bone marrow hemopoietic progenitors that have an ability todifferentiate into more than one cell line wherein cells in the stemcell compartment proliferate and differentiate into one of megakaryocyteprogenitors; a colony forming units—megakaryocytes (CFU-Meg)compartment, wherein the megakaryocyte progenitors get committed as amegakaryocyte line and spend some time multiplying and maturing; amegakaryoblast (MKB) compartment, which receives the cells from CFU-Meg,wherein the cells in the MKB compartment have lost their ability toproliferate but are not mature to release platelets; a MK16 compartment,which receives cells from the MKB compartment, wherein a subset of cellsin the MK16 compartment release platelets at a constant rate until theyexhaust their capacity and are disintegrated and a second subset ofcells do not release platelets but continue with endomitosis; a MK32compartment that receives cells from the MK16 compartment, wherein asubset of cells in this compartment release platelets and a secondsubset of cells do not release platelets but continue with endomitosis;a MK64 compartment that receives cells from the MK32 compartment whereina subset of cells in this compartment release platelets and a secondsubset of cells do not release platelets but continue with endomitosis;a MK128 compartment that receives cells from the MK64 compartmentwherein a subset of cells in this compartment release platelets; aplatelets (PL) compartment.
 385. The method of claim 384 wherein aneffect of apoptosis are included with an overall effect of cellproliferation in giving rise to an amplification of cell numbers in acorresponding compartment.
 386. The method of claim 384 wherein themodel further incorporates the effects of TPO on the SC, CFU-Meg and MKBcompartments.
 387. The method of claim 386 wherein the effects areexpressed in terms of effects of TPO concentration on amplificationrate, rate of cell maturation and a fraction of cells that undergoendomotisis.
 388. The method of claim 387 wherein when the TPOconcentration is above a predetermined threshold level, theamplification rate of cells in the SC compartment are affected and belowthe threshold the amplification rate is dependent only on a currentnumber of cells.
 389. The method of claim 386 wherein in the CFU-Megcompartment the cells are sensitive to TPO concentration regardless ofthe concentration of TPO.
 390. The method of claim 386, wherein thetransit time is same in all platelet releasing compartments and thetransit time of the SC, CFU-Meg and MKB compartments are functions ofmicro-environmental conditions.
 391. The method of claim 390 wherein inthe SC compartment when the TPO concentration is above the threshold,the transit time is shortened based the dose.
 392. The method of claim390 wherein in the CFU-Meg and MKB, the transit time is solely based onTPO concentration.
 393. The method of claim 386 wherein a fraction ofcells in the SC compartment that commits to megakaryocytic lineage isconstant.
 394. The method of claim 386 wherein in the CFU-Meg and MKBcompartments, every mature cell passes on to the next compartment. 395.The method of claim 386 wherein in the MK16, MK32 and MK64 compartments,a fraction of cells pass on to the next compartment, said fraction beingdependent on the TPO concentration.
 396. The method of claim 386 whereincells from MK128 compartment do not flow into any other compartment.397. The method of claim 383, wherein each of said compartments isfurther divided into sub-compartments, each of said sub-compartmentscontaining cells of a specific age in hours.
 398. The method of claim397 wherein cells that spend all their corresponding transit time in agiven compartment pass on to the next compartment, wherein cells thathave left a corresponding compartment each hour fill the firstsub-compartment of the next compartment.
 399. The method of claim 398,wherein the platelet releasing cells contribute platelets to the firstsub-compartment of the PL compartment.
 400. A method for modellingNeutrophil lineage for an individual, said method comprising: creating arealistic a Neutrophil system model including a realistic process modelfor cells involved in Neutrophil lineage; and modifying the system modelbased on parameters specific to the individual.
 401. The method of claim400 wherein the system model incorporates a realistic progression ofcells involved in Granulopoietic disorders, including Neutropenia. 402.The method of claim 401 wherein the system model incorporates effects ofat least one drug in the realistic progression of cells involved inGranulopoiesis and Neutropenia.
 403. The method of claim 402 whereinsaid at least one drug is Granulocyte Colony Stimulating Factor (G-CSF).404. The method of claim 403 wherein said system model comprises atleast three stages, a first stage related to an administered amount ofcytokine; a second stage representing a pharmacokinetic behavior ofG-CSF; and a third stage representing a phrmacodynamic effect of G-CSFon kinetic parameters of the system.
 405. The method of claim 400wherein said model comprises a mitotic compartment, and a post mitoticcompartment, said mitotic compartment being divided into subcompartmentswherein a kth sub-compartment contains cells of age between k−1 and khours relative to a time of entry into the mitotic compartment.
 406. Themethod of claim 405, wherein effects of toxic drugs, includingchemotherapy are incorporated by mapping various cell-cycle phases tothe sub-compartments and formulating a function of cytotoxic effects oftoxic drugs, including chemotherapy on the cell-cycle phases.
 407. Themethod of claim 405 wherein the effects of G-CSF on the mitoticcompartment are modeled as an increase in a rate of cells entering themyeloblasts compartment from an uncommitted stem cell pool.
 408. Themethod of claim 405 wherein the post-mitotic compartment is modeled as asingle pool of cells wherein cells in a last sub-compartment of themitotic compartment enters the post-mitotic compartment and a proportionof cells within the post-mitotic compartment enters a Neutrophil poolevery hour.
 409. The method of claim 405 wherein effects of G-CSF on theNeutrophil lineage are modeled as a decrease in the cells in thepost-mitotic compartment which is subsequently compensated by anincreased production in the mitotic compartment, said compensationsustaining an increase in mature Neutrophil count.
 410. The method ofclaim 405, wherein an elimination of Neutrophils in the post-mitoticcompartment is represented by a Poisson distribution.
 411. The method ofclaim 405, wherein the cytotoxic effects of toxic drugs, includingchemotherapy in the post-mitotic compartment is modeled as an effect ona single pool of cells.
 412. The method of claim 405, wherein kinetic ofG-CSF is modeled as an exponential distribution.
 413. The method ofclaim 401, wherein a selection of an optimal treatment uses an objectivefunction that aims at minimizing G-CSF administration and returningNeutrophil lineage to normal levels.
 414. The method of claim 413,wherein said selection is performed using linear programming.
 415. Themethod of claim 414, wherein phrmacokinetics and pharmacodynamics ofG-CSF are defined using piecewise linear functions.
 416. The method ofclaim 400, wherein said method is used for recommending an optimumtreatment protocol, and wherein said method further comprises:enumerating a plurality of treatment protocols; and selecting an optimaltreatment protocol from said plurality of treatment protocols based onthe modified system model.
 417. A method for modelling Neutrophillineage for a general patient, said method comprising: creating arealistic a Granulopoiesis system model including a realistic processmodel for cells involved in Granulopoiesis lineage.
 418. The method ofclaim 417 wherein the system model incorporates a realistic progressionof cells involved in Granulopoietic disorders, including Neutropenia.419. The method of claim 418 wherein the system model incorporateseffects of at least one drug in the realistic progression of cellsinvolved Granulopoiesis and in Neutropenia.
 420. The method of claim 419wherein said at least one drug is Granulocyte Colony Stimulating Factor(G-CSF).
 421. The method of claim 420 wherein said system modelcomprises at least three stages, a first stage related to anadministered amount of cytokine; a second stage representing apharmacokinetic behavior of G-CSF; and a third stage representing aphrmacodynamic effect of G-CSF on kinetic parameters.
 422. The method ofclaim 417 wherein said model comprises a mitotic compartment, and a postmitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.
 423. The method of claim 422, wherein effects of toxicdrugs, including chemotherapy are incorporated by mapping variouscell-cycle phases to the sub-compartments and formulating a function ofcytotoxic effects of toxic drugs, including chemotherapy on thecell-cycle phases.
 424. The method of claim 422 wherein the effects ofG-CSF on the mitotic compartment are modeled as an increase in a rate ofcells entering the myeloblasts compartment from an uncommitted stem cellpool.
 425. The method of claim 422 wherein the post-mitotic compartmentis modeled as a single pool of cells wherein cells in a lastsub-compartment of the mitotic compartment enters the post-mitoticcompartment and a proportion of cells within the post-mitoticcompartment enters a Neutrophil pool every hour.
 426. The method ofclaim 422 wherein effects of G-CSF on the Neutrophil lineage are modeledas a decrease in the cells in the post-mitotic compartment which issubsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in matureNeutrophil count.
 427. The method of claim 422, wherein an eliminationof Neutrophils in the post-mitotic compartment is represented by aPoisson distribution.
 428. The method of claim 422, wherein thecytotoxic effects of toxic drugs, including chemotherapy in thepost-mitotic compartment is modeled as an effect on a single pool ofcells.
 429. The method of claim 422 wherein kinetic of G-CSF is modeledas an exponential distribution.
 430. The method of claim 418, wherein aselection of an optimal treatment uses an objective function that aimsat minimizing G-CSF administration and returning Neutrophil lineage tonormal levels.
 431. The method of claim 430, wherein said selection isperformed using linear programming.
 432. The method of claim 431,wherein phrmacokinetics and pharmacodynamics of G-CSF are defined usingpiecewise linear functions.
 433. The method of claim 417 wherein saidmethod is used for recommending an optimum treatment protocol, andwherein said method further comprises: enumerating a plurality oftreatment protocols; and selecting an optimal treatment protocol fromsaid plurality of treatment protocols based on the modified systemmodel.
 434. A method for predicting progression of Granulopoiesis for anindividual under a plurality of treatment protocols, said plurality ofprotocols including no treatment, said system comprising: creating aNeutrophil system model including a realistic process model for cellsinvolved in Neutrophil production; generating a plurality of treatmentprotocols; and modifying the system model modifier, wherein saidNeutrophil system model is modified by the system model modifier basedon parameters specific to the individual; and predicting the progressionunder the plurality of treatment protocols based on the modified systemmodel.
 435. The method of claim 434 wherein the system modelincorporates a realistic progression of cells involved in Granulopoieticdisorders, including Neutropenia.
 436. The method of claim 435 whereinthe system incorporates effects of at least one drug in the realisticprogression of cells involved in Granulopoiesis and Neutropenia. 437.The system of claim 436 wherein said at least one drug is GranulocyteColony Stimulating Factor (G-CSF).
 438. The method of claim 437 whereinsaid model comprises at least three stages, a first stage related to anadministered amount of cytokine; a second stage representing apharmacokinetic behavior of G-CSF; and a third stage representing aphrmacodynamic effect of G-CSF on kinetic parameters.
 439. The method ofclaim 434 wherein said model comprises a mitotic compartment, and a postmitotic compartment, said mitotic compartment being divided intosubcompartments wherein a kth sub-compartment contains cells of agebetween k−1 and k hours relative to a time of entry into the mitoticcompartment.
 440. The method of claim 439, wherein effects of toxicdrugs, including chemotherapy are incorporated by mapping variouscell-cycle phases to the sub-compartments and formulating a function ofcytotoxic effects of toxic drugs, including chemotherapy on thecell-cycle phases.
 441. The method of claim 439 wherein the effects ofG-CSF on the mitotic compartment are modeled as an increase in a rate ofcells entering the myeloblasts compartment from an uncommitted stem cellpool.
 442. The method of claim 439 wherein the post-mitotic compartmentis modeled as a single pool of cells wherein cells in a lastsub-compartment of the mitotic compartment enters the post-mitoticcompartment and a proportion of cells within the post-mitoticcompartment enters a Neutrophil pool every hour.
 443. The method ofclaim 439 wherein effects of G-CSF on the Neutrophil lineage are modeledas a decrease in the cells in the post-mitotic compartment which issubsequently compensated by an increased production in the mitoticcompartment, said compensation sustaining an increase in matureNeutrophil count.
 444. The method of claim 439, wherein an eliminationof Neutrophils in the post-mitotic compartment is represented by aPoisson distribution.
 445. The method of claim 439, wherein thecytotoxic effects of toxic drugs, including chemotherapy in thepost-mitotic compartment is modeled as an effect on a single pool ofcells.
 446. The method of claim 439, wherein kinetic of G-CSF is modeledas an exponential distribution.
 447. The method of claim 435, wherein aselection of an optimal treatment uses an objective function that aimsat minimizing G-CSF administration and returning Neutrophil lineage tonormal levels.
 448. The method of claim 447, wherein said selection isperformed using linear programming.
 449. The method of claim 448,wherein phrmacokinetics and pharmacodynamics of G-CSF are defined usingpiecewise linear functions.
 450. A method for predicting progression ofGranulopoiesis for a general patient under a plurality of treatmentprotocols, said plurality of protocols including no treatment, saidsystem comprising: creating a Neutrophil system model including arealistic process model for cells involved in Neutrophil production;generating a plurality of treatment protocols; and predicting theprogression under the plurality of treatment protocols based on themodified system model.
 451. The method of claim 450 wherein the systemmodel incorporates a realistic progression of cells involved inGranulopoietic disorders, including Neutropenia.
 452. The method ofclaim 451 wherein the system incorporates effects of at least one drugin the realistic progression of cells involved in Granulopoiesis andNeutropenia.
 453. The system of claim 452 wherein said at least one drugis Granulocyte Colony Stimulating Factor (G-CSF).
 454. The method ofclaim 453 wherein said model comprises at least three stages, a firststage related to an administered amount of cytokine; a second stagerepresenting a pharmacokinetic behavior of G-CSF; and a third stagerepresenting a phrmacodynamic effect of G-CSF on kinetic parameters.455. The method of claim 450 wherein said model comprises a mitoticcompartment, and a post mitotic compartment, said mitotic compartmentbeing divided into subcompartments wherein a kth sub-compartmentcontains cells of age between k−1 and k hours relative to a time ofentry into the mitotic compartment.
 456. The method of claim 455,wherein effects of toxic drugs, including chemotherapy are incorporatedby mapping various cell-cycle phases to the sub-compartments andformulating a function of cytotoxic effects of toxic drugs, includingchemotherapy on the cell-cycle phases.
 457. The method of claim 455wherein the effects of G-CSF on the mitotic compartment are modeled asan increase in a rate of cells entering the myeloblasts compartment froman uncommitted stem cell pool.
 458. The method of claim 455 wherein thepost-mitotic compartment is modeled as a single pool of cells whereincells in a last sub-compartment of the mitotic compartment enters thepost-mitotic compartment and a proportion of cells within thepost-mitotic compartment enters a Neutrophil pool every hour.
 459. Themethod of claim 455 wherein effects of G-CSF on the Neutrophil lineageare modeled as a decrease in the cells in the post-mitotic compartmentwhich is subsequently compensated by an increased production in themitotic compartment, said compensation sustaining an increase in matureNeutrophil count.
 460. The method of claim 455, wherein an eliminationof Neutrophils in the post-mitotic compartment is represented by aPoisson distribution.
 461. The method of claim 455, wherein thecytotoxic effects of toxic drugs, including chemotherapy in thepost-mitotic compartment is modeled as an effect on a single pool ofcells.
 462. The method of claim 455, wherein kinetic of G-CSF is modeledas an exponential distribution.
 463. The method of claim 451, wherein aselection of an optimal treatment uses an objective function that aimsat minimizing G-CSF administration and returning Neutrophil lineage tonormal levels.
 464. The method of claim 463, wherein said selection isperformed using linear programming.
 465. The method of claim 464,wherein phrmacokinetics and pharmacodynamics of G-CSF are defined usingpiecewise linear functions.
 466. A method for recommending an optimaltreatment protocol for treating cancer using drugs, includingchemotherapy, for an individual, said method comprising: creating acancer system model; enumerating a plurality of treatment protocols fortreating cancer using drugs, including chemotherapy; modifying thesystem model based on parameters specific to the individual; andselecting an optimal treatment protocol from said plurality of treatmentprotocols based on the modified system model.
 467. The method of claim466 wherein the system model further comprises: a realistic processmodel of cancer development; and a realistic treatment model that modelsthe effects of treating cancer with drugs, including chemotherapy. 468.The method of claim 467 wherein said process model incorporates adistribution of cycling cells and quiescent cells.
 469. The method ofclaim 467 where a tumor cell cycle is divided into at least fourcompartments G1, S, G2 and M and a quiescent stage is denoted by G0,wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age Iin the corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.
 470. The methodof claim 469 wherein the model traces development of cancer cells usinga predetermined set of parameters by calculating a number of cells ineach subcompartment using stepwise equations.
 471. The method of claim470 wherein a probability vector is used to determine a fraction ofcells that leaves any subcompartment in a compartment to move to a firstsubcompartment of the next compartment.
 472. The method of claim 470where a set control functions uniquely determine an outcome of everysingle step, wherein said control functions depend on age of cells,state of a current population and associated environment.
 473. Themethod of claim 470 wherein a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.
 474. The method of claim 473,wherein in each step, a number of cells in each sub-compartment of eachcompartment of each group is calculated according to factors including aprevious state, parameters of tumor, tumor current microenvironment anddrug concentration.
 475. The method of claim 474 where spatial structureof the tumor is included in the model.
 476. The method of claim 475,wherein PK and PD, cytotoxic effects, cytostatic effects and othereffects on cell disintegration of anticancer drugs are incorporated intothe model.
 477. The method of claim 476 wherein a dose-limiting toxicityis incorporated into the model.
 478. The method of claim 466 wherein,said parameters specific to the individual comprise parameters relatedto tumor dynamics, patient specific drug PK, and dynamics ofdose-limiting host tissues.
 479. The method of claim 478, wherein saidparameters related to tumor dynamics comprise age, weight, gender,percentage of limiting healthy cells, desired length of treatmentprotocol, previous reaction to treatment, molecular markers, geneticmarkers, pathologic specifics and cytologic specifics.
 480. A method ofpredicting a progression of cancer in an individual, said methodcomprising: creating a cancer system model; enumerating a plurality oftreatment protocols for treating cancer using drugs, includingchemotherapy; modifying the system model based on parameters specific tothe individual; and selecting an optimal treatment protocol from saidplurality of treatment protocols based on the modified system model.481. The method of claim 480 wherein the system model further comprises:a realistic process model of cancer development; and a realistictreatment model that models the effects of treating cancer with drugs,including chemotherapy.
 482. The method of claim 481 wherein saidprocess model incorporates a distribution of cycling cells and quiescentcells.
 483. The method of claim 481 where a tumor cell cycle is dividedinto at least four compartments G1, S, G2 and M and a quiescent stage isdenoted by G0, wherein each of said four compartments is furthersubdivided into sub-compartments and an ith sub-compartment representingcells of age I in the corresponding compartment, wherein cells enteringa compartment always enter a first sub-compartment of the compartment.484. The method of claim 483 wherein the model traces development ofcancer cells using a predetermined set of parameters by calculating anumber of cells in each subcompartment using stepwise equations. 485.The method of claim 484 wherein a probability vector is used todetermine a fraction of cells that leaves any subcompartment in acompartment to move to a first subcompartment of the next compartment.486. The method of claim 484 where a set control functions uniquelydetermine an outcome of every single step, wherein said controlfunctions depend on age of cells, state of a current population andassociated environment.
 487. The method of claim 484 wherein a tumor ismodelled as a combination of a plurality of homogeneous group of cells,each of said homogeneous group of cells representing a similarlybehaving group of cells distributed between all the cell-cyclecompartments.
 488. The method of claim 487, wherein in each step, anumber of cells in each sub-compartment of each compartment of eachgroup is calculated according to factors including a previous state,parameters of tumor, tumor current microenvironment and drugconcentration.
 489. The method of claim 488 where spatial structure ofthe tumor is included in the model.
 490. The method of claim 489,wherein PK and PD, cytotoxic and other cell disintegration effects, andcytostatic effects of anticancer drugs are incorporated into the model.491. The method of claim 490 wherein a dose-limiting toxicity isincorporated into the model.
 492. The method of claim 480 wherein, saidparameters specific to the individual comprise parameters related totumor dynamics, patient specific drug PK, and dynamics of dose-limitinghost tissues.
 493. The method of claim 492, wherein said parametersrelated to tumor dynamics comprise age, weight, gender, percentage oflimiting healthy cells, desired length of treatment protocol, previousreaction to treatment, molecular markers, genetic markers, pathologicspecifics and cytologic specifics.
 494. A method of predicting aprogression of cancer in a general patient, said method comprising:creating a cancer system model; enumerating a plurality of treatmentprotocols for treating cancer using drugs, including chemotherapy; andselecting an optimal treatment protocol from said plurality of treatmentprotocols based on the modified system model.
 495. The method of claim494 wherein the system model further comprises: a realistic processmodel of cancer development; and a realistic treatment model that modelsthe effects of treating cancer with drugs, including chemotherapy. 496.The method of claim 495 wherein said process model incorporates adistribution of cycling cells and quiescent cells.
 497. The method ofclaim 495 where a tumor cell cycle is divided into at least fourcompartments G1, S, G2 and M and a quiescent stage is denoted by G0,wherein each of said four compartments is further subdivided intosub-compartments and an ith sub-compartment representing cells of age Iin the corresponding compartment, wherein cells entering a compartmentalways enter a first sub-compartment of the compartment.
 498. The methodof claim 497 wherein the model traces development of cancer cells usinga predetermined set of parameters by calculating a number of cells ineach subcompartment using stepwise equations.
 499. The method of claim498 wherein a probability vector is used to determine a fraction ofcells that leaves any subcompartment in a compartment to move to a firstsubcompartment of the next compartment.
 500. The method of claim 498where a set control functions uniquely determine an outcome of everysingle step, wherein said control functions depend on age of cells,state of a current population and associated environment.
 501. Themethod of claim 498 wherein a tumor is modelled as a combination of aplurality of homogeneous group of cells, each of said homogeneous groupof cells representing a similarly behaving group of cells distributedbetween all the cell-cycle compartments.
 502. The method of claim 501,wherein in each step, a number of cells in each sub-compartment of eachcompartment of each group is calculated according to factors including aprevious state, parameters of tumor, tumor current microenvironment anddrug concentration.
 503. The method of claim 502 where spatial structureof the tumor is included in the model.
 504. The method of claim 503,wherein PK and PD, cytotoxic effects and cytostatic effects ofanticancer drugs are incorporated into the model.
 505. The method ofclaim 504 wherein a dose-limiting toxicity is incorporated into themodel.
 506. A computer program product, including a computer readablemedium, said program product comprising a set of instruction to enable acomputer system to aid in recommending an optimal treatment protocol foran individual comprising: a system model code; treatment protocol codefor a plurality of treatment protocols; a system model modifier code,wherein said system model is modified by the system model modifier basedon parameters specific to the individual; and a selector code to selectan optimal treatment protocol from said plurality of treatment protocolsbased on the modified system model.
 507. The computer program product ofclaim 506 wherein the system model code further comprises: a realisticbiological process model code; and a realistic treatment model code thatenables a computer to model the effects of a treatment on the biologicalprocess.
 508. A computer program product, including a computer readablemedium, said program product comprising a set of instructions to enablea computer system to aid in recommending an optimal treatment protocolfor a general patient comprising: a system model code; treatmentprotocol code for a plurality of treatment protocols; and a selectorcode to select an optimal treatment protocol from said plurality oftreatment protocols based on the modified system model.
 509. Thecomputer program product of claim 508 wherein the system model codefurther comprises: a realistic biological process model code; and arealistic treatment model code that enables a computer to model theeffects of a treatment on the biological process.